

Risk Factors for Stroke and Efficacy of Antithrombotic 7

Archives of Internal Medicine

154, 1449

DOI: 10.1001/archinte.1994.00420130036007

Citation Report

#	ARTICLE	IF	CITATIONS
2	Warfarin or aspirin for non-rheumatic atrial fibrillation?. Drug and Therapeutics Bulletin, 1994, 32, 57-60.	0.3	3
3	Warfarin or Aspirin as Secondary Prevention of Ischaemic Stroke?. CNS Drugs, 1994, 2, 341-346.	5.9	0
4	Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. , 1995, , CD000185.		4
5	Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. , 1995, , CD000186.		3
6	Antithrombotic Therapy in Atrial Fibrillation. Chest, 1995, 108, 352S-359S.	0.8	210
7	Hemorrhagic Complications of Anticoagulant Treatment. Chest, 1995, 108, 276S-290S.	0.8	145
8	Making Decisions About Antithrombotic Therapy in Heart Disease. Chest, 1995, 108, 457S-470S.	0.8	25
9	Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. The Cochrane Library, 2008, 2008, .	2.8	0
10	Contemporary management of atrial fibrillation. Medical Clinics of North America, 1995, 79, 1135-1152.	2.5	8
11	Clinical course of lone atrial fibrillation since first symptomatic arrhythmic episode. American Journal of Cardiology, 1995, 76, 837-839.	1.6	48
12	Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulant Therapy Study (AFASAK 2): Methods and design. Journal of Thrombosis and Thrombolysis, 1995, 2, 125-130.	2.1	7
13	Designing a cost-effective clinical trial. Statistics in Medicine, 1995, 14, 2249-2259.	1.6	44
14	Transient ischaemic attacks. Medical Journal of Australia, 1995, 162, 260-263.	1.7	5
15	Value of transoesophageal echocardiography before DC cardioversion in patients with atrial fibrillation: assessment of embolic risk.. Heart, 1995, 73, 306-309.	2.9	1
16	Oral Anticoagulants. Chest, 1995, 108, 231S-246S.	0.8	260
17	Antithrombotic Agents in Coronary Artery Disease. Chest, 1995, 108, 380S-400S.	0.8	47
18	Is aspirin safe for patients with heart failure?. Heart, 1995, 74, 215-219.	2.9	126
19	Risk factors and primary prevention of stroke. Australian and New Zealand Journal of Medicine, 1995, 25, 191-194.	0.5	1

#	ARTICLE	IF	CITATIONS
20	Acute Cerebral Infarction. Drugs and Aging, 1995, 6, 445-455.	2.7	6
21	Research by collaboration. Lancet, The, 1995, 345, 938.	13.7	5
22	Does atrial fibrillation confer a hypercoagulable state?. Lancet, The, 1995, 346, 1313-1314.	13.7	231
23	Drug therapy. Lancet, The, 1995, 346, 32-36.	13.7	108
24	Inpatient general medicine is evidence based. Lancet, The, 1995, 346, 407-410.	13.7	374
25	Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The stroke prevention in atrial fibrillation study. Journal of Stroke and Cerebrovascular Diseases, 1995, 5, 147-157.	1.6	131
26	OUTPATIENT ANTICOAGULATION ISSUES FOR THE PRIMARY CARE PHYSICIAN. Medical Clinics of North America, 1996, 80, 475-491.	2.5	10
27	Management of Atrial Fibrillation in Adults: Prevention of Thromboembolism and Symptomatic Treatment. Mayo Clinic Proceedings, 1996, 71, 150-160.	3.0	57
28	Secular trends in the prevalence of atrial fibrillation: The Framingham study. American Heart Journal, 1996, 131, 790-795.	2.7	386
29	The management of atrial fibrillation. American Journal of Medicine, 1996, 101, 413-421.	1.5	43
30	Thoroscopic obliteration of the left atrial appendage: Potential for stroke reduction?. Annals of Thoracic Surgery, 1996, 61, 565-569.	1.3	123
31	Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Annals of Thoracic Surgery, 1996, 61, 755-759.	1.3	1,419
32	Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet, The, 1996, 348, 633-638.	13.7	1,045
33	PREVENTION OF THROMBOEMBOLISM IN PATIENTS WITH ATRIAL FIBRILLATION. Cardiology Clinics, 1996, 14, 537-542.	2.2	3
34	CLINICAL RESEARCH IN NEUROLOGY. Neurologic Clinics, 1996, 14, 451-466.	1.8	11
35	THERAPEUTIC STRATEGIES FOR ATRIAL FIBRILLATION. Cardiology Clinics, 1996, 14, 623-640.	2.2	8
36	The risks and benefits of antithrombotic therapy in chronic atrial fibrillation. Medical Journal of Australia, 1996, 164, 624-626.	1.7	4
37	The Utilization of Antithrombotic Prophylaxis for Atrial Fibrillation in a Geriatric Rehabilitation Hospital. Journal of the American Geriatrics Society, 1996, 44, 708-711.	2.6	17

#	ARTICLE	IF	CITATIONS
38	Paroxysmal Atrial Fibrillation: Is Anticoagulation Justified?. Hospital Practice (1995), 1996, 31, 11-19.	1.0	0
39	Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. Journal of General Internal Medicine, 1996, 11, 713-720.	2.6	114
40	Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation?. Journal of General Internal Medicine, 1996, 11, 721-728.	2.6	128
41	Should physicians participate in affirming the best approach to atrial fibrillation management?. American Journal of Cardiology, 1996, 78, 1152-1153.	1.6	8
42	Atrial fibrillation, anticoagulation, and stroke. American Journal of Cardiology, 1996, 77, 38A-44A.	1.6	73
43	Maintaining Sinus Rhythm with Antifibrillatory Drugs in Atrial Fibrillation. American Journal of Cardiology, 1996, 78, 67-72.	1.6	5
44	Atrial Defibrillation: Can Modifications in Current Implantable Cardioverter-Defibrillators Achieve This?. American Journal of Cardiology, 1996, 78, 119-127.	1.6	16
45	Cardioversion of atrial fibrillation in the elderly. American Journal of Cardiology, 1996, 78, 1380-1384.	1.6	63
46	Antithrombotic therapy in atrial fibrillation: A review of randomized trials with special reference to the stroke prevention in atrial fibrillation II (SPAF II) trial. Progress in Cardiovascular Diseases, 1996, 38, 337-342.	3.1	29
47	Current recommendations for the anticoagulation of patients with atrial fibrillation. Progress in Cardiovascular Diseases, 1996, 39, 1-20.	3.1	12
48	Stratification of thromboembolic risk of atrial fibrillation by transthoracic echocardiography and transesophageal echocardiography: The relative role of left atrial appendage function, mitral valve disease, and spontaneous echocardiographic contrast. Progress in Cardiovascular Diseases, 1996, 39, 57-68.	3.1	29
49	Non-rheumatic atrial fibrillation and anticoagulation—update. ACC Current Journal Review, 1996, 5, 66-67.	0.1	0
50	Congestive heart failure in the elderly requiring hospital admission. Archives of Gerontology and Geriatrics, 1996, 23, 225-238.	3.0	18
51	Highlights of the fourth ACCP Task Force on Antithrombotic Therapy. Journal of Thrombosis and Thrombolysis, 1996, 2, 261-264.	2.1	0
52	Workshop: Special problems in anticoagulation therapy: Cancer and venous thromboembolism-temporary discontinuation of warfarin for surgery and invasive procedures. Journal of Thrombosis and Thrombolysis, 1996, 2, 289-293.	2.1	0
53	Workshop: Reimbursement for anticoagulation services. Journal of Thrombosis and Thrombolysis, 1996, 2, 301-304.	2.1	2
54	Cardioversion of atrial fibrillation. Postgraduate Medical Journal, 1996, 72, 126-126.	1.8	0
55	Physician variation in the management of patients with atrial fibrillation.. Heart, 1996, 75, 200-205.	2.9	94

#	ARTICLE	IF	CITATIONS
57	The use of antithrombotic drugs for primary and secondary prevention of ischaemic stroke. Reviews in Clinical Gerontology, 1996, 6, 315-323.	0.5	1
58	Cardioversion of atrial fibrillation.. Postgraduate Medical Journal, 1996, 72, 126-126.	1.8	0
59	Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy. Postgraduate Medical Journal, 1996, 72, 731-738.	1.8	38
60	The management of congestive heart failure.. Postgraduate Medical Journal, 1997, 73, 194-200.	1.8	10
61	Therapeutic Options in Atrial Flutter and Fibrillation. Hospital Practice (1995), 1997, 32, 143-164.	1.0	0
62	Meeting the Challenge of Stroke. Scottish Medical Journal, 1997, 42, 145-147.	1.3	5
63	Physician Attitudes Concerning Warfarin for Stroke Prevention in Atrial Fibrillation: Results of a Survey of Long-Term Care Practitioners. Journal of the American Geriatrics Society, 1997, 45, 1060-1065.	2.6	136
64	Atrial Fibrillation: Understanding the Serious Consequences and Learning About the Causes. Journal of the American Geriatrics Society, 1997, 45, 1404-1405.	2.6	0
66	Primary Stroke Prevention in Nonvalvular Atrial Fibrillation: Implementing the Clinical Trial Findings. Annals of Pharmacotherapy, 1997, 31, 1187-1196.	1.9	16
67	Cost Considerations in the Pharmacological Prevention and Treatment of Stroke. Pharmacoeconomics, 1997, 11, 408-418.	3.3	6
68	THE MEDICAL MANAGEMENT OF ATRIAL FIBRILLATION. Cardiology Clinics, 1997, 15, 689-719.	2.2	14
69	Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk?. Lancet, The, 1997, 349, 1565-1566.	13.7	24
70	Successors to heparin: New antithrombotic agents. American Heart Journal, 1997, 134, s71-s77.	2.7	12
71	Stroke prevention in patients with non-valvular atrial fibrillation: a current community perspective. Journal of Clinical Neuroscience, 1997, 4, 320-325.	1.5	7
72	Atrial fibrillation and stroke. Journal of Stroke and Cerebrovascular Diseases, 1997, 6, 165-166.	1.6	2
73	Management of the patient in atrial fibrillation. Evidence-based Cardiovascular Medicine, 1997, 1, 59-60.	0.0	0
74	Interpretation of IST and CAST stroke trials. Lancet, The, 1997, 350, 442-443.	13.7	4
75	Atrial fibrillation. Lancet, The, 1997, 350, 943-950.	13.7	78

#	ARTICLE	IF	CITATIONS
76	Ejection Fraction and Risk of Thromboembolic Events in Patients With Systolic Dysfunction and Sinus Rhythm: Evidence for Gender Differences in the Studies of Left Ventricular Dysfunction Trials. Journal of the American College of Cardiology, 1997, 29, 1074-1080.	2.8	273
77	Atrial Fibrillation in the Setting of Acute Myocardial Infarction: The GUSTO-I Experience. In this study was funded by grants from Genentech, South San Francisco, California; Bayer Corporation, New York, New York; CIBA-Corning, Medfield, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology, 1997, 30, 406-413.	2.8	384
78	Prevention of Primary Event. Neurosurgery Clinics of North America, 1997, 8, 165-178.	1.7	4
79	Major haemorrhagic complications during oral anticoagulant therapy in a Danish Population-based cohort. Journal of Internal Medicine, 1997, 242, 497-502.	6.0	89
80	Anticoagulation in Atrial Fibrillation: Have the Megatrials Answered All the Questions?. ACC Current Journal Review, 1997, 6, 26-27.	0.1	0
81	Pharmacological Therapy of Atrial Fibrillation—An Individualized Approach. ACC Current Journal Review, 1997, 6, 28-32.	0.1	1
82	Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease. Progress in Cardiovascular Diseases, 1997, 40, 205-238.	3.1	22
83	Risk of Thromboembolism in Chronic Atrial Flutter. American Journal of Cardiology, 1997, 79, 1043-1047.	1.6	102
84	Atrial Fibrillation and Stroke. American Journal of Cardiology, 1997, 80, 11D-18D.	1.6	15
85	Atrial Fibrillation: Antiarrhythmic Therapy Versus Rate Control With Antithrombotic Therapy. American Journal of Cardiology, 1997, 80, 74G-81G.	1.6	5
86	The treatment of atrial fibrillation: Pharmacologic and nonpharmacologic strategies. Current Problems in Cardiology, 1997, 22, 37-108.	2.4	19
87	Long-term management of atrial fibrillation. Clinical Cardiology, 1997, 20, 381-390.	1.8	5
88	Atrial fibrillation: A review of mechanism, etiology, and therapy. Clinical Cardiology, 1997, 20, 640-650.	1.8	55
91	Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease. Annals of Behavioral Medicine, 1997, 19, 230-238.	2.9	17
92	Is there a role for warfarin or aspirin therapy in heart failure?. Heart Failure Reviews, 1997, 1, 271-276.	3.9	3
93	Atrial tachyarrhythmia after cardiac surgery. Intensive Care Medicine, 1998, 24, 654-662.	8.2	6
94	Unexpected instant death following successful coronary artery bypass graft surgery (and other) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 10 Cardiology, 1998, 21, 711-718.	1.8	9
95	Congestive cardiac failure (CCF) as a cause of fatal stroke and all cause death. Australian and New Zealand Journal of Medicine, 1998, 28, 799-804.	0.5	11

#	ARTICLE	IF	CITATIONS
96	Impact of Managed Care on the Treatment of Atrial Fibrillation. American Journal of Cardiology, 1998, 81, 30C-34C.	1.6	4
97	Risk factors for new thromboembolic stroke in patients ≥62 years of age with chronic atrial fibrillation. American Journal of Cardiology, 1998, 82, 119-A9.	1.6	68
98	Risk of thromboembolic events in patients with atrial flutter. American Journal of Cardiology, 1998, 82, 580-583.	1.6	120
99	The canadian registry of atrial fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation. American Journal of Cardiology, 1998, 82, 82N-85N.	1.6	66
100	Relation between aging and circadian variation of paroxysmal atrial fibrillation. American Journal of Cardiology, 1998, 82, 1364-1367.	1.6	54
101	Long-term antithrombotic treatment for atrial fibrillation. American Journal of Cardiology, 1998, 82, 37N-42N.	1.6	19
102	Atrial fibrillation trials: will they teach us what we need to know?. American Journal of Cardiology, 1998, 82, 86N-91N.	1.6	13
103	Reply to Bellivier et al.. American Journal of Medical Genetics Part A, 1998, 81, 351-352.	2.4	0
104	Role of routine transthoracic echocardiography in evaluation and management of stroke. Journal of Internal Medicine, 1998, 243, 281-291.	6.0	21
105	Guidelines on oral anticoagulation: third edition. British Journal of Haematology, 1998, 101, 374-387.	2.5	381
106	Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet, The, 1998, 352, 1167-1171.	13.7	374
107	Prevention of stroke. Lancet, The, 1998, 352, S15-S18.	13.7	39
108	A 69-year-old man with atrial fibrillation, previous duodenal ulcer and peripheral arterial disease. Coronary Health Care, 1998, 2, 91-98.	0.4	0
109	Warfarin Anticoagulation and Survival: A Cohort Analysis From the Studies of Left Ventricular Dysfunction 11This study was supported by Grant MO1-RR00054 from the General Clinical Research Center, funded by the Division of Research Resources, National Institutes of Health, Bethesda, Maryland. The Studies of Left Ventricular Dysfunction (SOLVD) were funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, with a contribution from Merck, Sharpe and Dohme Phar. Journal of the American College of Cardiology, 1998, 31, 749-753.	2.8	216
110	Transesophageal Echocardiographic Correlates of Clinical Risk of Thromboembolism in Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology, 1998, 31, 1622-1626.	2.8	527
111	EVALUATION AND MANAGEMENT OF ATRIAL FIBRILLATION IN THE EMERGENCY DEPARTMENT. Emergency Medicine Clinics of North America, 1998, 16, 389-403.	1.2	31
112	Role of Echocardiography in Systemic Arterial Embolism: A Review with Recommendations. Scandinavian Cardiovascular Journal, 1998, 32, 323-342.	1.2	26
113	Impact of Atrial Fibrillation on the Risk of Death. Circulation, 1998, 98, 946-952.	1.6	4,149

#	ARTICLE	IF	CITATIONS
114	Hypofibrinolysis in atrial fibrillation. American Heart Journal, 1998, 136, 956-960.	2.7	59
115	Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: A transesophageal echocardiographic study. American Heart Journal, 1998, 136, 965-971.	2.7	32
116	Treatment Strategies for Atrial Fibrillation. American Journal of Medicine, 1998, 104, 272-286.	1.5	68
117	Epidemiological and Mechanistic Studies of Atrial Fibrillation as a Basis for Treatment Strategies. Circulation, 1998, 98, 943-945.	1.6	12
118	Thrombosis and Hemostasis in Cardiology: Review of Pathophysiology and Clinical Practice (Part I). Clinical and Applied Thrombosis/Hemostasis, 1998, 4, 51-75.	1.7	1
119	The Fontan procedure: lessons from the past. Heart, 1998, 79, 213-214.	2.9	30
120	Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?. Journal of Cardiovascular Pharmacology and Therapeutics, 1998, 3, 185-194.	2.0	1
121	Significance of Paroxysmal Atrial Fibrillation Complicating Acute Myocardial Infarction in the Thrombolytic Era. Circulation, 1998, 97, 965-970.	1.6	168
122	Risk Factors for Ischemic Stroke. Stroke, 1998, 29, 1341-1346.	2.0	209
123	Cost-Effectiveness of Preference-Based Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation. Stroke, 1998, 29, 1083-1091.	2.0	96
124	Asymptomatic Embolization in Subjects With Atrial Fibrillation Not Taking Anticoagulants. Stroke, 1998, 29, 1810-1815.	2.0	67
125	Hemorrhagic Complications of Anticoagulant Treatment. Chest, 1998, 114, 511S-523S.	0.8	136
126	Antithrombotic Therapy in Atrial Fibrillation. Chest, 1998, 114, 579S-589S.	0.8	282
127	Antithrombotic Agents in Coronary Artery Disease. Chest, 1998, 114, 611S-633S.	0.8	66
128	Making Decisions About Antithrombotic Therapy in Heart Disease: Decision Analytic and Costeffectiveness Issues. Chest, 1998, 114, 699S-714S.	0.8	56
129	Performance indicators for primary care groups: an evidence based approach. BMJ: British Medical Journal, 1998, 317, 1354-1360.	2.3	106
130	Atrial Fibrillation and Thromboembolism. Anesthesia and Analgesia, 1998, 87, 217-223.	2.2	3
131	Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. Chest, 1998, 114, 683S-698S.	0.8	271

#	ARTICLE	IF	CITATIONS
132	Controversies Surrounding Long-term Anticoagulation of Very Elderly Patients in Atrial Fibrillation. Chest, 1998, 113, 1115-1118.	0.8	25
133	Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment. BMJ: British Medical Journal, 1998, 316, 509-513.	2.3	109
134	Recent National Patterns of Warfarin Use in Atrial Fibrillation. Circulation, 1998, 97, 1231-1233.	1.6	214
135	Atrial fibrillation as a risk factor for stroke: a retrospective cohort study of hospitalized Medicare beneficiaries.. American Journal of Public Health, 1998, 88, 395-400.	2.7	42
136	Cost-Effectiveness of Anticoagulation in Nonrheumatic Atrial Fibrillation in the Primary Prevention of Ischemic Stroke. Stroke, 1998, 29, 1827-1832.	2.0	67
137	Atrial Fibrillation and Thromboembolism. Anesthesia and Analgesia, 1998, 87, 217-223.	2.2	2
138	Oral Anticoagulants. Chest, 1998, 114, 445S-469S.	0.8	856
139	Generic Warfarin. Chest, 1998, 113, 261-263.	0.8	18
140	Effectiveness of anticoagulation among patients discharged from hospital on warfarin. Medical Journal of Australia, 1998, 169, 243-246.	1.7	21
142	Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention. Annals of Internal Medicine, 1999, 131, 688.	3.9	228
143	10. Warfarin or aspirin: both or others?. Medical Journal of Australia, 1999, 171, 321-326.	1.7	10
144	Antithrombotic Management of Atrial Fibrillation for Stroke Prevention in Older People. Clinics in Geriatric Medicine, 1999, 15, 645-662.	2.6	2
145	4. Atrial fibrillation. Medical Journal of Australia, 1999, 170, 498-504.	1.7	2
146	Oral anticoagulation in the community. Practice Nursing, 1999, 10, 26-28.	0.1	1
147	Ensure Safety By Careful Warfarin Monitoring. Practice Nursing, 1999, 10, 19-22.	0.1	1
148	Aortic Plaque in Atrial Fibrillation. Stroke, 1999, 30, 834-840.	2.0	131
149	Arterial thromboembolism in patients with sick sinus syndrome: prediction from pacing mode, atrial fibrillation, and echocardiographic findings. Heart, 1999, 81, 412-418.	2.9	23
150	Use of antithrombotic measures for stroke prevention in atrial fibrillation. Heart, 1999, 82, 570-574.	2.9	37

#	ARTICLE	IF	CITATIONS
151	Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring. Journal of Cardiovascular Pharmacology and Therapeutics, 1999, 4, 3-8.	2.0	28
152	Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand?. Heart, 1999, 82, 563-569.	2.9	40
153	Atrial Fibrillation and Ethnicity. Circulation, 1999, 100, e153.	1.6	10
154	Contemporary Utilization of Digoxin in Patients with Atrial Fibrillation. Annals of Pharmacotherapy, 1999, 33, 289-293.	1.9	11
155	Identification and treatment of patients with atrial fibrillation in primary care. Heart, 1999, 81, 333-334.	2.9	6
156	Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young. Heart, 1999, 82, 539-540.	2.9	29
157	Identification of Risk Factors in Hypertensive Patients. Circulation, 1999, 100, e88-94.	1.6	38
158	Thromboembolism after atrioventricular node ablation and pacing: long term follow up. Heart, 1999, 82, 494-498.	2.9	13
159	Left atrial appendage: structure, function, and role in thromboembolism. Heart, 1999, 82, 547-554.	2.9	549
160	Oral anticoagulation in nonvalvular atrial fibrillation. Journal of Internal Medicine, 1999, 245, 375-381.	6.0	11
161	Stroke risk in an elderly population with atrial fibrillation. Journal of General Internal Medicine, 1999, 14, 56-59.	2.6	36
162	Nonrheumatic atrial fibrillation and stroke. Australian and New Zealand Journal of Medicine, 1999, 29, 467-472.	0.5	4
163	Atrial fibrillation – prevalence and management. Australian and New Zealand Journal of Medicine, 1999, 29, 568-568.	0.5	0
164	Atrial fibrillation: prevalence and management in an acute general medical unit. Australian and New Zealand Journal of Medicine, 1999, 29, 51-58.	0.5	31
166	Ischemic stroke prevention. Current Treatment Options in Neurology, 1999, 1, 113-125.	1.8	4
167	Outcome of valve repair and the cox maze procedure for mitral regurgitation and associated atrial fibrillation. Journal of Thoracic and Cardiovascular Surgery, 1999, 118, 628-635.	0.8	156
168	Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. Journal of Thoracic and Cardiovascular Surgery, 1999, 118, 833-840.	0.8	321
169	Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation. Contemporary Clinical Trials, 1999, 20, 386-393.	1.9	9

#	ARTICLE	IF	CITATIONS
170	Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care. American Journal of Cardiology, 1999, 83, 788-790.	1.6	84
171	Association of extracranial carotid arterial disease and chronic atrial fibrillation with the incidence of new thromboembolic stroke in 1,846 older persons. American Journal of Cardiology, 1999, 83, 1403-1404.	1.6	21
172	Influence of warfarin therapy on left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. American Journal of Cardiology, 1999, 84, 857-859.	1.6	20
173	Epidemiology and significance of atrial fibrillation. American Journal of Cardiology, 1999, 84, 131-138.	1.6	218
174	Management of Acute Ischaemic Stroke. Disease Management and Health Outcomes, 1999, 5, 311-327.	0.4	1
175	Antiplatelet Agents in the Prevention of Cardiovascular Morbidity and Mortality in Older Patients With Vascular Disease. Drugs and Aging, 1999, 15, 91-101.	2.7	15
176	Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation. Annals of Internal Medicine, 1999, 131, 492.	3.9	1,442
177	Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. American Heart Journal, 1999, 137, 307-312.	2.7	82
178	Applying evidence-based cardiology to the individual patient. Evidence-based Cardiovascular Medicine, 1999, 3, 85-86.	0.0	1
179	Screening for atrial fibrillation in the community: A multicenter validation trial. Journal of Stroke and Cerebrovascular Diseases, 1999, 8, 99-103.	1.6	8
180	Thromboprophylaxis for atrial fibrillation. Lancet, The, 1999, 353, 4-6.	13.7	71
181	Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, The, 1999, 353, 717-719.	13.7	1,181
183	ATRIAL FIBRILLATION IN THE ELDERLY. Cardiology Clinics, 1999, 17, 173-188.	2.2	19
186	Guidelines for Stroke Prevention in Patients with Atrial Fibrillation. Drugs, 1999, 58, 997-1009.	10.9	18
187	Variations in family physicians'™ and cardiologists'™ care for patients with heart failure. American Heart Journal, 1999, 138, 826-834.	2.7	53
189	Lone atrial fibrillation: Prognostic differences between paroxysmal and chronic forms after 10 years of follow-up. American Heart Journal, 1999, 137, 686-691.	2.7	94
190	Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. American Journal of Medicine, 1999, 106, 165-171.	1.5	98
191	Cardiac Arrhythmia: Current Therapy. Hospital Practice (1995), 1999, 34, 27-42.	1.0	0

#	ARTICLE	IF	CITATIONS
192	A Practical Approach to Atrial Fibrillation. Hospital Practice (1995), 1999, 34, 61-78.	1.0	2
193	Preventing Ischemic Stroke in Patients With Prior Stroke and Transient Ischemic Attack. Stroke, 1999, 30, 1991-1994.	2.0	325
194	Treatment for the Secondary Prevention of Stroke in Older Patients: The Influence of Dementia Status. Journal of the American Geriatrics Society, 1999, 47, 824-829.	2.6	61
195	Underutilization of Cardiac Medications in the Pacemaker Selection in the Elderly Study. Journal of the American Geriatrics Society, 1999, 47, 252-255.	2.6	2
196	MANAGEMENT OF ATRIAL FIBRILLATION, VENTRICULAR ARRHYTHMIAS AND PACEMAKERS IN OLDER PERSONS: Series Editor: Wilbert S. Aronow, MD: Management of the Older Person With Atrial Fibrillation. Journal of the American Geriatrics Society, 1999, 47, 740-748.	2.6	25
197	Clinical Prediction Rules as Guides to Treatment. Hospital Practice (1995), 1999, 34, 17-20.	1.0	1
198	Risk Assessment and Anticoagulation for Primary Stroke Prevention in Atrial Fibrillation. Stroke, 1999, 30, 1218-1222.	2.0	31
199	Incidence of New Thromboembolic Stroke in Persons 62 Years and Older with Chronic Atrial Fibrillation Treated with Warfarin Versus Aspirin. Journal of the American Geriatrics Society, 1999, 47, 366-368.	2.6	36
200	Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Annals of Internal Medicine, 1999, 131, 927.	3.9	522
201	Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ: British Medical Journal, 1999, 319, 958-964.	2.3	200
202	Safety and Cost of Low-Molecular-Weight Heparin as Bridging Anticoagulant Therapy in Subacute Cerebral Ischemia. Stroke, 2000, 31, 2563-2568.	2.0	26
203	Improving Management of Atrial Fibrillation and Anticoagulation in a Community Hospital. The Joint Commission Journal on Quality Improvement, 2000, 26, 18-28.	1.5	20
204	Warfarin-associated hemorrhage and cerebral amyloid angiopathy. Neurology, 2000, 55, 947-951.	1.1	303
205	Anticoagulation for patients with atrial fibrillation and risk factors for stroke. BMJ: British Medical Journal, 2000, 320, 1219-1220.	2.3	23
206	Use of Ambulatory Electrocardiography for the Detection of Paroxysmal Atrial Fibrillation in Patients with Stroke. Canadian Journal of Neurological Sciences, 2000, 27, 25-31.	0.5	39
207	Preventing ischemic stroke. Postgraduate Medicine, 2000, 107, 34-50.	2.0	18
208	Management of Stroke in Older People; A Pharmacological Perspective. Journal of Pharmacy Practice and Research, 2000, 30, 60-65.	0.2	2
209	Implementation of antithrombotic management in atrial fibrillation. Postgraduate Medical Journal, 2000, 76, 783-786.	1.8	9

#	ARTICLE	IF	CITATIONS
210	Anticoagulant use in nonvalvular atrial fibrillation. Postgraduate Medicine, 2000, 108, 113-126.	2.0	5
211	The Use of Oral Anticoagulants (warfarin) in Older People. Journal of the American Geriatrics Society, 2000, 48, 224-227.	2.6	38
212	Adverse Outcomes and Predictors of Underuse of Antithrombotic Therapy in Medicare Beneficiaries With Chronic Atrial Fibrillation. Stroke, 2000, 31, 822-827.	2.0	280
213	Underuse of Antithrombotic Therapy in Stroke Patients With Chronic Atrial Fibrillation. Stroke, 2000, 31, 2266-2278.	2.0	8
214	Warfarin for Stroke Prevention Still Underused in Atrial Fibrillation. Stroke, 2000, 31, 1217-1222.	2.0	121
215	Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation. Stroke, 2000, 31, 817-821.	2.0	278
216	Doubts, Fears and Misconceptions. What is the Future of Thrombolysis in Acute Stroke?. Canadian Journal of Neurological Sciences, 2000, 27, 283-287.	0.5	4
217	Significance of thromboembolism in heart failure. European Journal of Heart Failure, 2000, 2, 3-4.	7.1	1
218	Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ: British Medical Journal, 2000, 320, 1236-1239.	2.3	131
219	Second Line Pharmacological Management of Paroxysmal and Persistent Atrial Fibrillation in France: A Cost Analysis. Value in Health, 2000, 3, 407-416.	0.3	20
220	Prevention of thromboembolism in atrial fibrillation. Journal of General Internal Medicine, 2000, 15, 56-67.	2.6	108
221	Development of a decision aid for patients with atrial fibrillation who are considering antithrombotic therapy. Journal of General Internal Medicine, 2000, 15, 723-730.	2.6	32
222	Treating individuals according to evidence: why do primary care practitioners do what they do?. Journal of Evaluation in Clinical Practice, 2000, 6, 139-148.	1.8	28
223	Atrial fibrillation: Epidemiology, mechanisms, and management. Current Problems in Cardiology, 2000, 25, 413-524.	2.4	16
224	Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a veterans affairs medical center. American Journal of Cardiology, 2000, 85, 568-572.	1.6	76
225	Effect of Valsalva maneuver on surface electrocardiographic P-wave dispersion in paroxysmal atrial fibrillation. American Journal of Cardiology, 2000, 85, 896-899.	1.6	84
226	Effect of degree of blood pressure on the hypercoagulable state in chronic atrial fibrillation. American Journal of Cardiology, 2000, 86, 795-797.	1.6	13
227	Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation. American Journal of Cardiology, 2000, 86, 852-855.	1.6	48

#	ARTICLE	IF	CITATIONS
228	Transient ischemic attack and secondary stroke. Current Treatment Options in Neurology, 2000, 2, 329-341.	1.8	0
229	Consensus guidelines for warfarin therapy: Recommendations from the Australasian Society of Thrombosis and Haemostasis. Medical Journal of Australia, 2000, 172, 600-605.	1.7	93
230	Underutilization of antithrombotic therapy in atrial fibrillation. Journal of the Royal Society of Medicine, 2000, 93, 138-140.	2.0	24
231	Stroke Risk Factors. CNS Spectrums, 2000, 5, 70-74.	1.2	10
232	The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis Commentary: patients, preferences, and evidence. BMJ: British Medical Journal, 2000, 320, 1380-1384.	2.3	217
233	Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology, 2000, 54, 288-288.	1.1	187
234	Thromboembolism in heart failure: who should be treated?. European Journal of Heart Failure, 2000, 2, 355-363.	7.1	15
235	Left Atrial Appendage Myopathy. Chest, 2000, 117, 297-298.	0.8	10
236	A European View on the North American Fifth Consensus on Antithrombotic Therapy. Chest, 2000, 117, 1755-1770.	0.8	36
237	GENERAL CARDIOLOGY: Evaluation of large scale clinical trials and their application to usual practice. British Heart Journal, 2000, 84, 679-684.	2.1	7
238	Implications of Stroke Risk Criteria on the Anticoagulation Decision in Nonvalvular Atrial Fibrillation. Circulation, 2000, 102, 11-13.	1.6	223
239	Review: antithrombotic agents prevent stroke in non-valvular atrial fibrillation. Evidence-Based Medicine, 2000, 5, 82-82.	0.6	1
240	Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. American Heart Journal, 2000, 139, 752-760.	2.7	13
241	Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. American Heart Journal, 2000, 139, 814-819.	2.7	159
242	Patent foramen ovale diameter and embolic stroke: a part of the puzzle?. American Journal of Medicine, 2000, 109, 506-507.	1.5	10
243	Residual atrial fibrillation and clinical consequences following postoperative supraventricular arrhythmias. International Journal of Cardiology, 2000, 74, 125-132.	1.7	41
244	Mild mitral regurgitation was associated with increased prevalence of thromboembolic events in patients with nonrheumatic atrial fibrillation. International Journal of Cardiology, 2000, 72, 229-233.	1.7	23
245	Recent advances in stroke management. Journal of Stroke and Cerebrovascular Diseases, 2000, 9, 95-105.	1.6	3

#	ARTICLE	IF	CITATIONS
246	Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: A transesophageal echocardiographic study. American Heart Journal, 2000, 140, 150-156.	2.7	113
247	Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. American Heart Journal, 2000, 140, 886-890.	2.7	150
248	Long-Term Prevention of Ischaemic Stroke and Stroke Recurrence. Thrombosis Research, 2000, 98, 83-96.	1.7	12
249	Use of Oral Anticoagulants in Older Patients. Drugs and Aging, 2000, 16, 409-435.	2.7	35
250	Thrombolytic Therapy for Stroke. Drugs and Aging, 2000, 16, 41-54.	2.7	9
251	Transesophageal Echocardiography (TEE) in Atrial Fibrillation. Cardiology Clinics, 2000, 18, 819-831.	2.2	9
252	Effects of Fixed Low-Dose Warfarin, Aspirin-Warfarin Combination Therapy, and Dose-Adjusted Warfarin on Thrombogenesis in Chronic Atrial Fibrillation. Stroke, 2000, 31, 828-833.	2.0	93
253	Cost Effectiveness of Therapies for Atrial Fibrillation. Pharmacoeconomics, 2000, 18, 317-333.	3.3	8
254	Integrated Backscatter Assessment of Left Atrial Spontaneous Echo Contrast in Chronic Nonvalvular Atrial Fibrillation: Relation with Clinical and Echocardiographic Parameters. Journal of the American Society of Echocardiography, 2000, 13, 666-673.	2.8	10
255	MANAGEMENT OF ARRHYTHMIAS. Clinics in Geriatric Medicine, 2000, 16, 593-618.	2.6	7
257	Cuando y cómo cardiovertir la fibrilación auricular al inicio del año 2000. Revista Española De Cardiología, 2000, 53, 560-567.	1.2	7
258	A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. Journal of the American College of Cardiology, 2000, 35, 1926-1931.	2.8	88
259	A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. Journal of the American College of Cardiology, 2000, 35, 1915-1918.	2.8	123
260	Treatment of underlying atrial fibrillation: paced rhythm obscures recognition. Journal of the American College of Cardiology, 2000, 36, 784-787.	2.8	33
261	Epidemiology and natural history of atrial fibrillation: clinical implications. Journal of the American College of Cardiology, 2001, 37, 371-378.	2.8	685
262	Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. Journal of the American College of Cardiology, 2001, 37, 691-704.	2.8	141
263	Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. Journal of the American College of Cardiology, 2001, 37, 1436-1442.	2.8	131
265	Prevalence of left atrial chamber and appendage thrombi in patients with atrial flutter and its clinical significance. Journal of the American College of Cardiology, 2001, 38, 778-784.	2.8	46

#	ARTICLE	IF	CITATIONS
266	ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. This document was approved by the American College of Cardiology Board of Trustees in August 2001, the American Heart Association Science Advisory and Coordinating Committee in August 2001, and the European Society of Cardiology Board and Committee for Practice Guidelines and Policy Conferences in August 2001. ³² When citing this document, the American College of Cardiology, the American Heart Association, and the European Society. Journal of the American College of Cardiology, 2001, 38, 1266.	2.8	62
267	ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. Journal of the American College of Cardiology, 2001, 38, 1231-1265.	2.8	944
269	Oral anticoagulants. Clinics in Geriatric Medicine, 2001, 17, 1-13.	2.6	71
270	Indobufen. Drugs and Aging, 2001, 18, 369-388.	2.7	26
271	Care for stroke patients. Lancet, The, 2001, 357, 147.	13.7	0
272	Decision analysis and its application in clinical medicine. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2001, 94, 172-179.	1.1	12
275	Association of Atrial Fibrillation and Aortic Atherosclerosis: A Population-Based Study. Mayo Clinic Proceedings, 2001, 76, 252-259.	3.0	24
277	Antithrombotic therapy in atrial fibrillation. Clinics in Geriatric Medicine, 2001, 17, 131-147.	2.6	15
278	Differential atrial stunning after electrical cardioversion: An echo tissue doppler case study. Journal of the American Society of Echocardiography, 2001, 14, 834-837.	2.8	7
279	Fibrilaci?n auricular. EMC - Tratado De Medicina, 2001, 5, 1-7.	0.0	1
280	Perioperative management and reversal of antithrombotic therapy. Clinics in Geriatric Medicine, 2001, 17, 189-202.	2.6	10
282	ANTICOAGULATE OR NOT TO ANTICOAGULATE PATIENTS WITH CARDIOMYOPATHY. Cardiology Clinics, 2001, 19, 605-615.	2.2	8
283	Management of Patients with Syncope and Cardiac Arrhythmias in an Emergency Department Observation Unit. Emergency Medicine Clinics of North America, 2001, 19, 105-121.	1.2	13
284	Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation. CNS Drugs, 2001, 15, 623-631.	5.9	15
285	Current Management of Symptomatic Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2001, 1, 127-139.	2.2	5
286	Nonâ€œvalvular atrial fibrillation and stroke prevention. Medical Journal of Australia, 2001, 174, 234-239.	1.7	48
287	Preinjury Warfarin Does Not Impact Outcome in Trauma Patients. Journal of Trauma, 2001, 51, 1147-1152.	2.3	53
288	The Ten Most Commonly Asked Questions about Stroke Prevention in Atrial Fibrillation. Cardiology in Review, 2001, 9, 187-192.	1.4	1

#	ARTICLE	IF	CITATIONS
289	Anticoagulation in the Ambulatory Patient: Basic Principles and Current Concepts in Warfarin Therapy. Topics in Geriatric Rehabilitation, 2001, 17, 18-37.	0.4	3
290	Characteristics, Outcome, and Care of Stroke Associated With Atrial Fibrillation in Europe. Stroke, 2001, 32, 392-398.	2.0	383
291	Grades of Recommendation for Antithrombotic Agents. Chest, 2001, 119, 3S-7S.	0.8	89
292	Antithrombotic Therapy in Atrial Fibrillation. Chest, 2001, 119, 194S-206S.	0.8	406
293	Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. Chest, 2001, 119, 300S-320S.	0.8	204
294	Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study Commentary: Varied preferences reflect the reality of clinical practice. BMJ: British Medical Journal, 2001, 323, 1218-1218.	2.3	363
295	A Survey of Long-Term Antiarrhythmic Therapy in Elderly Patients with Atrial Fibrillation. Journal of Pharmacy Practice and Research, 2001, 31, 93-97.	0.2	3
296	Primary Prevention of Ischemic Stroke. Stroke, 2001, 32, 280-299.	2.0	512
297	A Transesophageal Echocardiographic Study on Risk Factors for Stroke in Elderly Patients With Atrial Fibrillation. Chest, 2001, 120, 840-846.	0.8	31
298	Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ: British Medical Journal, 2001, 322, 321-326.	2.3	110
299	Towards a National System for Monitoring the Quality of Hospital-Based Stroke Services. Stroke, 2001, 32, 1415-1421.	2.0	38
300	Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial Fibrillation. Stroke, 2001, 32, 2246-2252.	2.0	62
301	Management of anticoagulation for gastrointestinal endoscopic procedures. Current Treatment Options in Gastroenterology, 2001, 4, 459-466.	0.8	0
302	Oral anticoagulant treatment in very elderly patients with atrial fibrillation. Comprehensive Therapy, 2001, 27, 7-10.	0.2	4
303	Choices in medical management for prevention of acute ischemic stroke. Current Neurology and Neuroscience Reports, 2001, 1, 33-38.	4.2	3
304	Stroke prevention in atrial fibrillation: physicians' attitudes to anticoagulation in older people. Archives of Gerontology and Geriatrics, 2001, 33, 219-226.	3.0	30
305	The Sin of Omission: A Systematic Review of Antithrombotic Therapy to Prevent Stroke in Atrial Fibrillation. Journal of the American Geriatrics Society, 2001, 49, 91-94.	2.6	10
306	Management of the first-time transient ischaemic attack. Emergency Medicine (Fremantle, W A), 2001, 13, 70-81.	0.0	5

#	ARTICLE	IF	CITATIONS
307	Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice. Internal Medicine Journal, 2001, 31, 329-336.	0.8	56
308	Clinical trends in atrial fibrillation at the turn of the millenium. Journal of Internal Medicine, 2001, 250, 369-372.	6.0	29
309	Influence of age on left atrial appendage function in patients with nonvalvular atrial fibrillation. Clinical Cardiology, 2001, 24, 39-44.	1.8	10
310	Adequacy of anticoagulation in patients with atrial fibrillation: Effect of various parameters. Clinical Cardiology, 2001, 24, 380-384.	1.8	5
311	Effect of left atrial size and function on Pâ€wave dispersion: A study in patients with paroxysmal atrial fibrillation. Clinical Cardiology, 2001, 24, 676-680.	1.8	50
312	Right atrial function in hypertension. Journal of Human Hypertension, 2001, 15, 439-441.	2.2	2
314	Is warfarin really underused in patients with atrial fibrillation?. Journal of General Internal Medicine, 2001, 16, 743-749.	2.6	30
315	Hemostatic state and atrial fibrillation (The Framingham Offspring Study). American Journal of Cardiology, 2001, 87, 168-171.	1.6	78
316	Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. British Heart Journal, 2001, 86, 284-288.	2.1	226
317	A survey of subjects with present or previous atrial fibrillation in a Swedish community. Scandinavian Journal of Primary Health Care, 2001, 19, 20-24.	1.5	11
318	Antithrombotic Agents in Coronary Artery Disease. Chest, 2001, 119, 228S-252S.	0.8	106
319	Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. Chest, 2001, 119, 8S-21S.	0.8	862
320	Hemorrhagic Complications of Anticoagulant Treatment. Chest, 2001, 119, 108S-121S.	0.8	672
321	Atrial Fibrillation in the Elderlyâ€an Increasing Problem That Mandates Aggressive Management. The American Journal of Geriatric Cardiology, 2001, 10, 289-292.	0.6	2
322	New-Onset Atrial Fibrillation. Circulation, 2001, 103, 2365-2370.	1.6	344
323	Five-year mortality in men and women with atrial fibrillation. Scandinavian Journal of Primary Health Care, 2001, 19, 112-116.	1.5	10
324	Oral anticoagulation for cerebral ischemia of arterial origin. Neurology, 2001, 57, 1993-1999.	1.1	43
325	The efficacy of the Cox/maze procedure combined with mitral valve surgery: a matched control study. European Journal of Cardio-thoracic Surgery, 2001, 19, 438-442.	1.4	158

#	ARTICLE	IF	CITATIONS
326	Primary Prevention of Ischemic Stroke. <i>Circulation</i> , 2001, 103, 163-182.	1.6	340
327	Clinical treatment regimens for chronic heart failure: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1569-1576.	1.8	5
328	Atrial Fibrillation in the Elderly: Anticoagulation Strategies and Indications in the Very Elderly. <i>The American Journal of Geriatric Cardiology</i> , 2002, 11, 357-362.	0.6	14
329	Development and description of a decision analysis based decision support tool for stroke prevention in atrial fibrillation. <i>Quality and Safety in Health Care</i> , 2002, 11, 25-31.	2.5	39
330	Ischemic Stroke Therapy. <i>Annual Review of Medicine</i> , 2002, 53, 453-475.	12.2	76
331	Management of the Older Person With Atrial Fibrillation. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2002, 57, M352-M363.	3.6	43
332	Effects of Anticoagulation on Infarct Size and Clinical Outcome in Acute Cardioembolic Stroke. <i>Angiology</i> , 2002, 53, 551-556.	1.8	25
333	Evaluation of clinical treatment of atrial fibrillation associated with rheumatic mitral valve disease by radiofrequency ablation. <i>European Journal of Cardio-thoracic Surgery</i> , 2002, 21, 249-254.	1.4	31
334	Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. <i>Neurology</i> , 2002, 59, 193-197.	1.1	189
335	Individualizing Treatment Decisions. <i>Evaluation and the Health Professions</i> , 2002, 25, 210-224.	1.9	59
336	Transoesophageal echocardiography in selecting patients for anticoagulation after ischaemic stroke or transient ischaemic attack. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 73, 29-33.	1.9	59
337	Percutaneous Left Atrial Appendage Occlusion (PLAATO) for Preventing Cardioembolism. <i>Circulation</i> , 2002, 105, 2217-2222.	1.6	134
338	Warfarin Therapy for Atrial Fibrillation in the Elderly. <i>Annals of Pharmacotherapy</i> , 2002, 36, 200-204.	1.9	27
339	Effect of Soy Milk on Warfarin Efficacy. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1893-1896.	1.9	52
340	Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 1321 Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2002, 106, 1962-1967.	1.6	186
341	Medical Management of Intracerebral Hemorrhage. <i>Neurosurgery Quarterly</i> , 2002, 12, 261-278.	0.1	4
342	Cognitive impairment after stroke. <i>Current Opinion in Neurology</i> , 2002, 15, 79-84.	3.6	45
343	Direct Current Cardioversion of Atrial Fibrillation—The Next 40 Years. <i>Mayo Clinic Proceedings</i> , 2002, 77, 895-896.	3.0	1

#	ARTICLE	IF	CITATIONS
344	Pulmonary Embolism: What Have We Learned Since Virchow?. Chest, 2002, 122, 1801-1817.	0.8	85
345	Prevalence of Atrial Fibrillation and Antithrombotic Prophylaxis in Emergency Department Patients. Stroke, 2002, 33, 2664-2669.	2.0	58
346	Atrial Mechanical Performance Following Internal and External Cardioversion of Atrial Fibrillation. Chest, 2002, 121, 1-3.	0.8	44
347	Atrial Fibrillation. Heart Disease (Hagerstown, Md), 2002, 4, 91-101.	1.3	12
348	Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. American Journal of Medicine, 2002, 113, 42-51.	1.5	131
349	Atrial Fibrillation in the Elderly. Drugs and Aging, 2002, 19, 819-846.	2.7	58
350	Transient ischemic attacks: an emergency medicine approach. Emergency Medicine Clinics of North America, 2002, 20, 597-608.	1.2	2
351	Direct Current Cardioversion of Atrial Fibrillation—The Next 40 Years. Mayo Clinic Proceedings, 2002, 77, 895-896.	3.0	2
352	Use of ??-Blockers in Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2002, 2, 37-42.	2.2	16
354	Atrial fibrillation: strategies to control, combat, and cure. Lancet, The, 2002, 359, 593-603.	13.7	124
355	The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. Journal of Clinical Neuroscience, 2002, 9, 268-272.	1.5	26
356	Baseline characteristics of patients with atrial fibrillation: The AFFIRM Study. American Heart Journal, 2002, 143, 991-1001.	2.7	157
359	Prevention of cardiovascular diseases. Clinics in Geriatric Medicine, 2002, 18, 463-483.	2.6	13
361	Atrial fibrillation and falls in the elderly. Clinics in Geriatric Medicine, 2002, 18, 323-337.	2.6	11
362	Stroke:Recognizing risk and advising prevention. Practice Nursing, 2002, 13, 534-540.	0.1	0
363	Secondary Prevention of Occlusive Cerebrovascular Diseases : Medical Treatment. Japanese Journal of Neurosurgery, 2002, 11, 402-409.	0.0	0
364	Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial Fibrillation. Stroke, 2002, 33, 2150-2152.	2.0	1
365	Automatic Voice Mail for Delivering Computer-Generated Anticoagulant Dose Advice to Patients. Journal of Telemedicine and Telecare, 2002, 8, 259-263.	2.7	3

#	ARTICLE	IF	CITATIONS
366	Preventing stroke with ramipril. BMJ: British Medical Journal, 2002, 325, 439-439.	2.3	5
367	Evidence-based drug therapy for chronic heart failure. European Heart Journal Supplements, 2002, 4, D66-D72.	0.1	2
368	Aging has a complex effect on a rat model of ischemic stroke. Brain Research, 2002, 925, 148-158.	2.2	90
369	Mechanisms of cardioembolic stroke. Current Cardiology Reports, 2002, 4, 141-148.	2.9	59
370	Prevention of ischemic stroke. Current Cardiology Reports, 2002, 4, 164-171.	2.9	4
371	Prevention of ischemic stroke. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 393-403.	0.9	5
372	Asymptomatic embolisation in non-valvular atrial fibrillation and its relationship to anticoagulation therapy. European Journal of Ultrasound: Official Journal of the European Federation of Societies for Ultrasound in Medicine and Biology, 2002, 15, 21-27.	1.3	14
373	Atrial fibrillation or flutter and stroke: a Danish population-based study of the effectiveness of oral anticoagulation in clinical practice. Journal of Internal Medicine, 2002, 252, 64-69.	6.0	35
374	Determination of the clinical importance of study results. Journal of General Internal Medicine, 2002, 17, 469-476.	2.6	132
375	Deciding on Anticoagulating the Oldest Old with Atrial Fibrillation: Insights from Cost-Effectiveness Analysis. Journal of the American Geriatrics Society, 2002, 50, 863-869.	2.6	36
376	The Use of Oral Anticoagulants (Warfarin) in Older People. Journal of the American Geriatrics Society, 2002, 50, 1439-1445.	2.6	43
377	The effect of qualitative vs. quantitative presentation of probability estimates on patient decision-making: a randomized trial. Health Expectations, 2002, 5, 246-255.	2.6	55
378	What happens after a lung scan? Management and outcome of patients in a regional hospital. Journal of Medical Imaging and Radiation Oncology, 2002, 46, 375-380.	0.6	4
379	The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiology and Drug Safety, 2002, 11, 569-576.	1.9	42
380	The impact of age on antithrombotic use in elderly patients with non-valvular atrial fibrillation. Australasian Journal on Ageing, 2002, 21, 36-41.	0.9	28
381	Clinical Expertise in the Era of Evidence-Based Medicine and Patient Choice (editorial). Vox Sanguinis, 2002, 83, 383-386.	1.5	41
382	Anticoagulants for atrial fibrillation: Why is the treatment rate so low?. Clinical Cardiology, 2002, 25, 447-454.	1.8	66
383	Swazi Concepts of intelligence: The Universal versus the Local. Ethos, 2002, 30, 376-400.	0.2	6

#	ARTICLE	IF	CITATIONS
384	Anticoagulation or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. <i>Annals of Emergency Medicine</i> , 2003, 41, 141-143.	0.6	3
385	Secondary prognosis after cardioembolic stroke of atrial origin: The role of left atrial and left atrial appendage dysfunction. <i>Clinical Cardiology</i> , 2003, 26, 269-274.	1.8	11
386	Pharmacologic management of atrial fibrillation in the elderly: Rate control, rhythm control, and anticoagulation. <i>Current Cardiology Reports</i> , 2003, 5, 380-386.	2.9	1
387	Quality of Blood Pressure Control and Risk of Cerebral Bleeding in Patients with Oral Anticoagulation. <i>Vienna Clinical Weekly</i> , 2003, 30, 6-9.	0.9	4
388	Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. <i>BMC Cardiovascular Disorders</i> , 2003, 3, 9.	1.7	34
390	Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. <i>American Journal of Cardiology</i> , 2003, 91, 9-14.	1.6	206
391	Bleeding complications in patients with atrial fibrillation undergoing cardioversion randomized to transesophageal echocardiographically guided and conventional anticoagulation therapies. <i>American Journal of Cardiology</i> , 2003, 92, 161-165.	1.6	18
392	Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. <i>American Journal of Cardiology</i> , 2003, 92, 868-871.	1.6	116
393	The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 126, 1822-1827.	0.8	542
394	Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. <i>Diabetes/Metabolism Research and Reviews</i> , 2003, 19, 320-328.	4.0	36
395	Arterial hypertension and ischaemic stroke. <i>Acta Neurologica Scandinavica</i> , 2003, 107, 241-251.	2.1	41
396	Duration of warfarin sodium therapy prior to electrical cardioversion of atrial fibrillation. <i>Journal of Internal Medicine</i> , 2003, 253, 76-80.	6.0	14
397	Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France. <i>Journal of General Internal Medicine</i> , 2003, 18, 903-907.	2.6	8
398	Unresolved issues in anticoagulant therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1464-1470.	3.8	37
399	Implantation of Pacemakers and Implantable Cardioverter Defibrillators in Orally Anticoagulated Patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 511-514.	1.2	71
400	An Endovascular Approach to Cardioembolic Stroke Prevention in Atrial Fibrillation Patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 1604-1606.	1.2	10
401	Atrial Fibrillation in Patients with Congestive Heart Failure. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 1620-1623.	1.2	13
402	Managing the warfarinized urological patient. <i>BJU International</i> , 2003, 92, 351-354.	2.5	8

#	ARTICLE	IF	CITATIONS
403	Oral anticoagulation in surgical procedures: risks and recommendations. British Journal of Haematology, 2003, 123, 676-682.	2.5	110
404	EFFICACY OF ANTITHROMBOTIC THERAPY FOR ATRIAL FIBRILLATION IN THE OLDEST OLD. Journal of the American Geriatrics Society, 2003, 51, 887-889.	2.6	0
406	Patología vascular-cerebral: concepto, clasificación, actitud diagnóstica y terapéutica. Medicine, 2003, 8, 5795-5803.	0.0	0
412	Left atrial appendectomy and maze. Journal of the American College of Cardiology, 2003, 41, 170.	2.8	1
413	American Heart Association/American College of Cardiology Foundation guide to warfarin therapy11The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real. Journal of the American College of Cardiology, 2003, 41, 1633-1652.	2.8	314
414	Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. Journal of the American College of Cardiology, 2003, 42, 1249-1252.	2.8	147
415	Blood Coagulation in Patients with Chronic Heart Failure. Drugs, 2003, 63, 565-576.	10.9	32
416	Is left atrial appendage occlusion during routine coronary artery bypass graft surgery useful for stroke prevention?. American Heart Journal, 2003, 146, E3.	2.7	2
417	Can Patients Be Anticoagulated After Intracerebral Hemorrhage?. Stroke, 2003, 34, 1710-1716.	2.0	303
418	Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation. American Journal of Geriatric Pharmacotherapy, 2003, 1, 53-60.	3.0	26
419	Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?. International Journal of Cardiology, 2003, 87, 135-139.	1.7	76
420	Admissions with atrial fibrillation in a multiracial population in Kuala Lumpur, Malaysia. International Journal of Cardiology, 2003, 91, 233-238.	1.7	29
421	Stroke prevention in patients with atrial fibrillation. Journal of Clinical Neuroscience, 2003, 10, 71-73.	1.5	7
422	Current intracerebral haemorrhage management. Journal of Clinical Neuroscience, 2003, 10, 158-167.	1.5	58
423	Common cardiovascular issues encountered in geriatric critical care. Critical Care Clinics, 2003, 19, 677-691.	2.6	13
424	Review of the current management of atrial fibrillation. Expert Opinion on Pharmacotherapy, 2003, 4, 1889-1899.	1.8	0
425	Use of Regression Modeling to Simulate Patient-Specific Decision Analysis for Patients with Nonvalvular Atrial Fibrillation. Medical Decision Making, 2003, 23, 361-368.	2.4	5
426	Atrial fibrillation: relation between clinical risk factors and transoesophageal echocardiographic risk factors for thromboembolism. British Heart Journal, 2003, 89, 165-168.	2.1	32

#	ARTICLE	IF	CITATIONS
427	Present treatment options for atrial fibrillation. Postgraduate Medical Journal, 2003, 79, 67-73.	1.8	10
428	The role of echocardiography in atrial fibrillation and cardioversion. British Heart Journal, 2003, 89, 1447-1454.	2.1	47
429	American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation, 2003, 107, 1692-1711.	1.6	593
430	A systematic review of outcome measures reported for the therapeutic effectiveness of oral anticoagulation. Journal of Clinical Pathology, 2003, 56, 48-51.	2.0	21
431	Heart Failure Complicated by Atrial Fibrillation: Mechanistic, Prognostic, and Therapeutic Implications. Journal of Cardiovascular Pharmacology and Therapeutics, 2003, 8, 107-113.	2.0	32
432	Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1?. Stroke, 2003, 34, 1181-1186.	2.0	93
433	Atrial High Rate Episodes Detected by Pacemaker Diagnostics Predict Death and Stroke. Circulation, 2003, 107, 1614-1619.	1.6	690
434	Antithrombotic Therapy After Cerebral Hemorrhages. Stroke, 2003, 34, e217-8; author reply e217-8.	2.0	1
435	Elimination of the Left Atrial Appendage To Prevent Stroke or Embolism?. Chest, 2003, 124, 2356-2362.	0.8	110
436	Rhythm or Rate Control in Atrial Fibrillation: Insights from the Randomized Controlled Trials. Journal of Cardiovascular Pharmacology and Therapeutics, 2003, 8, S39-S44.	2.0	9
437	Patients with paroxysmal atrial fibrillation but not paroxysmal supraventricular tachycardia display evidence of platelet activation during arrhythmia. Platelets, 2003, 14, 407-411.	2.3	25
438	Thrombotic Disorders: Diagnosis and Treatment. Hematology American Society of Hematology Education Program, 2003, 2003, 520-539.	2.5	53
439	Medical Management of Patients with an Acute Stroke: Treatment and Prevention. Topics in Stroke Rehabilitation, 2003, 10, 34-45.	1.9	54
440	Anticoagulation Management Strategies in Patients with Atrial Fibrillation. Critical Pathways in Cardiology, 2003, 2, 178-187.	0.5	0
441	Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. , 2003, , CD000248.		22
442	Outpatient Management of the Chronically Anticoagulated Patient for Elective Surgery. Anaesthesia and Intensive Care, 2003, 31, 145-154.	0.7	13
443	Managing atrial fibrillation â€” redrawing a line in the sand. Medical Journal of Australia, 2003, 178, 480-481.	1.7	4
444	Will oral antithrombin agents replace warfarin?. Heart, 2004, 90, 827-828.	2.9	7

#	ARTICLE	IF	CITATIONS
445	Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. <i>Circulation</i> , 2004, 109, 1509-1513.	1.6	1,105
446	Analysis of Cause-Specific Mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. <i>Circulation</i> , 2004, 109, 1973-1980.	1.6	215
447	Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. <i>Heart</i> , 2004, 90, 1162-1166.	2.9	80
448	The Pharmacology and Management of the Vitamin K Antagonists. <i>Chest</i> , 2004, 126, 204S-233S.	0.8	1,092
449	Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. <i>Chest</i> , 2004, 126, 483S-512S.	0.8	456
450	Management of Anticoagulant Therapy for Patients with Prosthetic Heart Valves or Atrial Fibrillation. <i>Hematology</i> , 2004, 9, 1-9.	1.5	6
451	Selecting Patients With Atrial Fibrillation for Anticoagulation. <i>Circulation</i> , 2004, 110, 2287-2292.	1.6	728
452	Guidelines on the management of secondary prophylaxis of vascular events in stable patients in primary care. <i>International Journal of Clinical Practice</i> , 2004, 58, 153-168.	1.7	4
453	Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 798-806.	2.4	90
454	The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. <i>British Journal of Haematology</i> , 2004, 126, 557-564.	2.5	134
455	Point of care testing for INR monitoring: where are we now?. <i>British Journal of Haematology</i> , 2004, 127, 373-378.	2.5	38
456	Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1637-1644.	3.8	64
457	Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1873-1878.	3.8	102
458	Inadequate management of cerebrovascular risk factors in participants of a public stroke prevention program in Austria. <i>European Journal of Neurology</i> , 2004, 11, 679-685.	3.3	2
459	Should aspirin be continued in patients started on warfarin?. <i>Journal of General Internal Medicine</i> , 2004, 19, 879-886.	2.6	39
460	A Six-Year Experience with the Omnicarbon Valve in North American Patients. <i>Journal of Cardiac Surgery</i> , 2004, 19, 432-437.	0.7	2
461	Spinal subdural haematoma: how relevant is the INR?. <i>Spinal Cord</i> , 2004, 42, 477-480.	1.9	27
462	Cardioversion of atrial tachyarrhythmias: anticoagulation to reduce thromboembolic complications. <i>Progress in Cardiovascular Diseases</i> , 2004, 46, 487-505.	3.1	3

#	ARTICLE	IF	CITATIONS
463	A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]. BMC Cardiovascular Disorders, 2004, 4, 5.	1.7	11
464	Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). American Journal of Cardiology, 2004, 94, 889-894.	1.6	227
465	Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (The Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	66
466	Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. Clinical Cardiology, 2004, 27, 40-46.	1.8	54
467	The decision to anticoagulate: Assessing whether benefits outweigh the risks for patients with atrial fibrillation. Clinical Cardiology, 2004, 27, 313-320.	1.8	5
468	Secondary stroke prevention: Review of clinical trials. Clinical Cardiology, 2004, 27, 25-35.	1.8	4
469	New approaches to anticoagulation in atrial fibrillation. Current Cardiology Reports, 2004, 6, 354-364.	2.9	5
470	Oral anticoagulants and the risk of osteoporotic fractures among elderly. Pharmacoepidemiology and Drug Safety, 2004, 13, 289-294.	1.9	48
471	Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clinical Pharmacology and Therapeutics, 2004, 75, 204-212.	4.7	183
472	Risk factors for stroke and thromboprophylaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-1 study. Annals of Emergency Medicine, 2004, 44, 3-11.	0.6	42
473	Novel therapies for the prevention of stroke. Expert Opinion on Investigational Drugs, 2004, 13, 1615-1630.	4.1	7
474	Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. The Cochrane Library, 2004, , CD000185.	2.8	61
475	Lifetime Risk for Development of Atrial Fibrillation. Circulation, 2004, 110, 1042-1046.	1.6	1,819
476	Combined Anticoagulantâ€“Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation Patients. Stroke, 2004, 35, 2362-2367.	2.0	206
477	The Increasing Need for Anticoagulant Therapy to Prevent Stroke in Patients With Atrial Fibrillation. Mayo Clinic Proceedings, 2004, 79, 904-913.	3.0	41
480	Anticoagulation for atrial fibrillation. Cardiology Clinics, 2004, 22, 47-62.	2.2	11
483	Surgical Treatment of Atrial Fibrillation. Heart Lung and Circulation, 2004, 13, 280-287.	0.4	11
484	Atrial Fibrillation, Stroke and Anticoagulant Use. Heart Lung and Circulation, 2004, 13, 252-255.	0.4	1

#	ARTICLE	IF	CITATIONS
485	Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device. Journal of the American College of Cardiology, 2004, 43, 47-52.	2.8	462
486	Predictors of stroke in patients paced for sick sinus syndrome. Journal of the American College of Cardiology, 2004, 43, 1617-1622.	2.8	54
487	Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. Journal of the American College of Cardiology, 2004, 43, 929-935.	2.8	109
488	Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation. Journal of the American College of Cardiology, 2004, 44, 1557-1566.	2.8	217
490	Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke. American Journal of Geriatric Pharmacotherapy, 2004, 2, 265-273.	3.0	7
491	Socioeconomic Implications of Long-Term Warfarin Use. Disease Management and Health Outcomes, 2004, 12, 385-392.	0.4	0
492	Effect of Intravenous Heparin Administration on Duration of Hospitalization. Mayo Clinic Proceedings, 2004, 79, 159-163.	3.0	13
493	Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. Expert Review of Cardiovascular Therapy, 2004, 2, 163-174.	1.5	6
494	Thromboembolic prophylaxis in nonrheumatic atrial fibrillation: utilization patterns, efficacy, and complications in a long-term follow-up of community patients. International Journal of Cardiology, 2004, 96, 89-95.	1.7	12
495	Detection of atrial fibrillation in patients with acute stroke. Journal of Stroke and Cerebrovascular Diseases, 2004, 13, 12-15.	1.6	20
496	A community education program on atrial fibrillation: Implications of pulse self-examination on awareness and behavior. Journal of Stroke and Cerebrovascular Diseases, 2004, 13, 208-213.	1.6	24
497	Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) Pilot Study. American Heart Journal, 2004, 148, 180.	2.7	30
498	The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. American Journal of Medicine, 2004, 116, 451-459.	1.5	28
499	Non-valvular atrial fibrillation and stroke: Implications for nursing practice and therapeutics. Australian Critical Care, 2004, 17, 65-73.	1.3	3
501	Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology, 2004, 63, 1059-1064.	1.1	572
502	ACST: which subgroups will benefit most from carotid endarterectomy?. Lancet, The, 2004, 364, 1124.	13.7	1
503	Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. The Cochrane Library, 2004, , CD000187.	2.8	68
504	Current and future concepts in stroke prevention. Cmaj, 2004, 170, 1123-1133.	2.0	32

#	ARTICLE	IF	CITATIONS
505	A Pharmacokinetic Study of the Combined Administration of Amiodarone and Ximelagatran, an Oral Direct Thrombin Inhibitor. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1063-1071.	2.0	16
506	Pocket Hematoma After Pacemaker or Implantable Cardioverter Defibrillator Surgery. <i>Chest</i> , 2004, 126, 1177-1186.	0.8	210
507	Implications for Nursing Care of Patients With Atrial Fibrillation. <i>Journal of Cardiovascular Nursing</i> , 2004, 19, 128-137.	1.1	7
508	Antithrombotic Therapy in Atrial Fibrillation. <i>Chest</i> , 2004, 126, 429S-456S.	0.8	519
509	Hemorrhagic Complications of Anticoagulant Treatment. <i>Chest</i> , 2004, 126, 287S-310S.	0.8	452
510	Further Insights Into the Prothrombotic State in Mitral Stenosis and Atrial Flutter. <i>Chest</i> , 2004, 125, 2363.	0.8	0
511	Prothrombotic Activity Is Increased in Patients With Nonvalvular Atrial Fibrillation and Risk Factors for Embolism. <i>Chest</i> , 2004, 126, 687-692.	0.8	74
513	Stroke in the Very Elderly. <i>Stroke</i> , 2005, 36, 705-706.	2.0	4
514	Are Atrial Fibrillation Guidelines Altering Management? A Community Based Study. <i>Scottish Medical Journal</i> , 2005, 50, 166-169.	1.3	8
515	Minimising Medication Mishap: Introducing a Warfarin Safety Strategy. <i>Journal of Pharmacy Practice and Research</i> , 2005, 35, 266-270.	0.8	3
516	Anticoagulation as thromboprophylaxis for atrial fibrillation: implications in the "real world" and the need for risk stratification. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 461-464.	1.0	5
517	Is Stroke a Paradoxical Embolism in Patients with Patent Foramen Ovale?. <i>Internal Medicine</i> , 2005, 44, 434-438.	0.7	52
518	Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. <i>Country Review Ukraine</i> , 2005, 7, C41-C54.	0.8	7
519	Warfarin Maintenance Dosing Patterns in Clinical Practice. <i>Chest</i> , 2005, 127, 2049-2056.	0.8	197
520	Left Atrial Dysfunction in Patients With Atrial Fibrillation After Successful Rhythm Control for > 3 Months. <i>Chest</i> , 2005, 128, 2551-2556.	0.8	23
521	Differences among Clinical Classification Schemes for Predicting Stroke in Atrial Fibrillation: Implications for Therapy in Daily Practice. <i>Academic Emergency Medicine</i> , 2005, 12, 828-834.	1.8	9
522	With what to treat which patient with recently symptomatic carotid stenosis?. <i>Practical Neurology</i> , 2005, 5, 68-83.	1.1	2
523	Antithrombotic strategies for atrial fibrillation: on the threshold of changes? No. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 433-435.	3.8	1

#	ARTICLE	IF	CITATIONS
524	Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1218-1223.	3.8	57
525	Preventable stroke and stroke prevention. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1638-1645.	3.8	47
526	People Aged Over 75 in Atrial Fibrillation on Warfarin: The Rate of Major Hemorrhage and Stroke in More Than 500 Patient-Years of Follow-Up. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 655-659.	2.6	33
527	Antithrombotic therapy for congestive heart failure. <i>International Journal of Clinical Practice</i> , 2005, 60, 36-47.	1.7	9
528	Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation. <i>Journal of Internal Medicine</i> , 2005, 258, 133-144.	6.0	61
529	Utility of Transesophageal Echocardiography in Identification of Thrombogenic Milieu in Patients With Atrial Fibrillation (an ACUTE Ancillary Study). <i>American Journal of Cardiology</i> , 2005, 96, 935-941.	1.6	97
530	Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation. <i>Progress in Cardiovascular Diseases</i> , 2005, 48, 108-124.	3.1	11
531	An evidence-based causative classification system for acute ischemic stroke. <i>Annals of Neurology</i> , 2005, 58, 688-697.	5.3	573
534	Self-Management of oral Anticoagulation in nonvalvular Atrial Fibrillation (SMAAF study). <i>Clinical Research in Cardiology</i> , 2005, 94, 182-186.	1.1	37
535	New treatment options for stroke prevention in atrial fibrillation. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 341-349.	0.9	0
536	Transesophageal echocardiography and stroke. <i>Current Atherosclerosis Reports</i> , 2005, 7, 255-262.	4.8	4
537	Drug Interaction Exposure in Chronic Atrial Fibrillation Patients Maintained on Warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 123-124.	2.1	2
538	The Impact of Patient Self-Testing of Prothrombin Time for Managing Anticoagulation: Rationale and Design of VA Cooperative Study #481â€”The Home INR Study (THINRS). <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 163-172.	2.1	25
539	Post Mortem Analysis of a Left Atrial Appendage Occlusion Device (PLAATO) in a Patient with Permanent Atrial Fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2005, 14, 17-20.	1.3	15
540	Ximelagatran Compared with Warfarin for the Prevention of Systemic Embolism and Stroke. An Imputed Placebo Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 149-151.	2.6	2
541	Secondary prevention of stroke. <i>British Journal of Neuroscience Nursing</i> , 2005, 1, 32-37.	0.2	2
542	Zerebrale Durchblutungsstörungen. , 2005, , 1347-1361.		0
543	Antithrombotic Therapy in Atrial Fibrillation. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2005, 1, 129-134.	0.0	0

#	ARTICLE	IF	CITATIONS
544	Editorial Commentâ€™ Time to Burn the TOAST. Stroke, 2005, 36, 902-904.	2.0	40
545	Activation of coagulation and hyperfibrinolysis in patients with aortic arch atheromatosis (Aortic) Tj ETQq1 1 0.784314 rgBT 6 Overloc	3.4	6
546	Long-Term Therapy to Prevent Stroke. Journal of the American Board of Family Medicine, 2005, 18, 528-540.	1.5	12
547	Preference-Based Antithrombotic Therapy in Atrial Fibrillation: Implications for Clinical Decision Making. Medical Decision Making, 2005, 25, 548-559.	2.4	67
548	Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation. Postgraduate Medical Journal, 2005, 81, 370-375.	1.8	3
549	Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart, 2005, 91, 472-477.	2.9	287
550	Can recent-onset atrial fibrillation be safely and successfully treated with self-administered antiarrhythmic drugs?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 132-133.	3.3	0
551	Do Different Atrial Flutter Types Carry the Same Thromboembolic Risk?. Angiology, 2005, 56, 593-599.	1.8	2
552	Acute anticoagulation adjustment in patients with atrial fibrillation at risk for stroke: approaches, strategies, risks and benefits. Expert Review of Cardiovascular Therapy, 2005, 3, 571-590.	1.5	2
553	Socioeconomic relevance of selected treatment strategies in patients with chronic heart failure. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 277-286.	1.4	0
554	Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population. Current Medical Research and Opinion, 2005, 21, 1905-1913.	1.9	21
555	The Epidemiology of Atrial Fibrillation in Elderly Persons: The Tip of the Iceberg. The American Journal of Geriatric Cardiology, 2005, 14, 56-61.	0.6	107
556	Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation. Heart, 2005, 91, 759-763.	2.9	37
557	Atrial fibrillation as a predictive factor for severe stroke and early death in 15 831 patients with acute ischaemic stroke. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 679-683.	1.9	265
558	Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation. Circulation, 2005, 112, 1687-1691.	1.6	413
559	Perioperative Management of Patients on Oral Anticoagulants: A Decision Analysis. Medical Decision Making, 2005, 25, 387-397.	2.4	33
560	Risk modeling to identify patients with symptomatic carotid stenosis most at risk of stroke. Neurological Research, 2005, 27, 18-28.	1.3	15
561	Should a patient with primary intracerebral haemorrhage receive antiplatelet or anticoagulant therapy?. BMJ: British Medical Journal, 2005, 331, 439-442.	2.3	23

#	ARTICLE	IF	CITATIONS
562	Evidence for Age and Sex Differences in the Secondary Prevention of Stroke in Scottish Primary Care. Stroke, 2005, 36, 1771-1775.	2.0	80
563	Culprit Factors for the Failure of Well-Conducted Warfarin Therapy to Prevent Ischemic Events in Patients With Atrial Fibrillation. Stroke, 2005, 36, 2159-2163.	2.0	65
564	Time Trends of Ischemic Stroke Incidence and Mortality in Patients Diagnosed With First Atrial Fibrillation in 1980 to 2000. Stroke, 2005, 36, 2362-2366.	2.0	98
565	Anticoagulants for stroke prevention in atrial fibrillation: what is the right rate and where do we go from here?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 226-227.	3.3	0
566	Prevalence and risk of pulmonary embolism in patients with intracardiac thrombosis: a population-based study of 23â€¦796 consecutive autopsies. European Heart Journal, 2005, 26, 1108-1114.	2.2	95
567	Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Current Medical Research and Opinion, 2005, 21, 1583-1594.	1.9	56
568	Nonpharmacologic stroke prevention in atrial fibrillation. Expert Review of Cardiovascular Therapy, 2005, 3, 619-633.	1.5	48
569	Current status of stroke prevention in patients with atrial fibrillation. Country Review Ukraine, 2005, 7, C12-C18.	0.8	6
570	Emerging therapies for stroke prevention in atrial fibrillation. Country Review Ukraine, 2005, 7, C19-C27.	0.8	6
571	Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. Country Review Ukraine, 2005, 7, C28-C33.	0.8	11
572	The changing epidemiology of non-valvular atrial fibrillation: the role of novel risk factors. Country Review Ukraine, 2005, 7, C5-C11.	0.8	25
573	Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet, The, 2005, 365, 176-186.	13.7	776
575	How many patients in atrial fibrillation admitted to an acute medical unit will benefit from oral anticoagulation?. European Journal of Internal Medicine, 2005, 16, 97-104.	2.2	1
576	Atrial Fibrillation: Modern Concepts and Management. Annual Review of Medicine, 2005, 56, 475-494.	12.2	15
579	Management of Atrial Fibrillation in the Emergency Department. Emergency Medicine Clinics of North America, 2005, 23, 1127-1139.	1.2	28
580	Anticoagulation during Cardioversion in Patients??with Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2005, 5, 155-162.	2.2	3
581	Low-intensity anticoagulation for stroke prevention in elderly patients with atrial fibrillation: efficacy and safety in actual clinical practice. Journal of Clinical Neuroscience, 2005, 12, 891-894.	1.5	7
582	Changes in left atrial size in patients with persistent atrial fibrillation: a prospective echocardiographic study with a 5-year follow-up period. International Journal of Cardiology, 2005, 101, 47-52.	1.7	55

#	ARTICLE	IF	CITATIONS
583	Ximelagatran: A clinical perspective. <i>European Journal of Internal Medicine</i> , 2005, 16, 267-278.	2.2	9
584	Prediction Rule for Atrial Fibrillation After Major Noncardiac Thoracic Surgery. <i>Annals of Thoracic Surgery</i> , 2005, 79, 1698-1703.	1.3	139
585	Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. <i>American Heart Journal</i> , 2005, 149, 650-656.	2.7	190
586	Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril. <i>American Heart Journal</i> , 2005, 150, 985.e1-985.e8.	2.7	3
587	Atrial flutter and the risk of thromboembolism: A systematic review and meta-analysis. <i>American Journal of Medicine</i> , 2005, 118, 101-107.	1.5	81
588	The safety of levofloxacin in elderly patients on warfarin. <i>American Journal of Medicine</i> , 2005, 118, 1417.e7-1417.e12.	1.5	27
593	Ximelagatran: Oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1-9.	2.8	42
594	Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO System) to Prevent Stroke in High-Risk Patients With Non-Rheumatic Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2005, 46, 9-14.	2.8	446
595	Hospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate Anticoagulation. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1729-1736.	2.8	360
596	Functional Status in Rate- Versus Rhythm-Control Strategies for Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1891-1899.	2.8	158
597	Monitored Atrial Fibrillation Duration Predicts Arterial Embolic Events in Patients Suffering From Bradycardia and Atrial Fibrillation Implanted With Antitachycardia Pacemakers. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1913-1920.	2.8	375
598	Trials and Tribulations of Non-Inferiority. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1986-1995.	2.8	104
600	Prevention of Cardiovascular Events in Elderly People. <i>Drugs and Aging</i> , 2005, 22, 859-876.	2.7	65
601	Ximelagatran for stroke prevention in atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 551-563.	1.5	6
602	Perioperative Management of Oral Anticoagulation. <i>Clinics in Geriatric Medicine</i> , 2006, 22, 199-213.	2.6	11
603	Stroke prevention in diabetes and obesity. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 487-502.	1.5	20
604	The mid-term outcome of the Cox maze III procedure and complex concomitant cardiac surgery. <i>Scandinavian Cardiovascular Journal</i> , 2006, 40, 205-208.	1.2	0
605	Pharmacological Prevention of Thromboembolism in Patients with Left Ventricular Dysfunction. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 41-49.	2.2	10

#	ARTICLE	IF	CITATIONS
606	The risks of warfarin use in the elderly. Expert Opinion on Drug Safety, 2006, 5, 417-431.	2.4	14
607	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke, 2006, 37, 577-617.	2.0	1,510
608	Prediction and prevention of stroke after transient ischemic attack in the short and long term. Expert Review of Neurotherapeutics, 2006, 6, 381-395.	2.8	9
609	Atrial fibrillation: Challenges and opportunities. Canadian Journal of Cardiology, 2006, 22, 21C-26C.	1.7	3
610	Controversies in atrial fibrillation. Lancet, The, 2006, 367, 262-272.	13.7	169
611	Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, The, 2006, 367, 1903-1912.	13.7	1,820
612	Antithrombotic Therapy in Atrial Fibrillation. Clinics in Geriatric Medicine, 2006, 22, 155-166.	2.6	6
613	Warfarin Pharmacology, Clinical Management, and Evaluation of Hemorrhagic Risk for the Elderly. Clinics in Geriatric Medicine, 2006, 22, 17-32.	2.6	34
614	Update on Anticoagulant Medications for the Interventional Radiologist. Journal of Vascular and Interventional Radiology, 2006, 17, 597-612.	0.5	16
615	ACC/AHA/ESC: Guías de Práctica Clínica 2006 para el manejo de pacientes con fibrilación auricular. Versión resumida. Revista Espanola De Cardiología, 2006, 59, 1329.e1-1329.e64.	1.2	15
616	Cost-Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation. Journal of the American College of Cardiology, 2006, 47, 2513-2520.	2.8	95
617	Cardiovascular Imaging in the Management of Atrial Fibrillation. Journal of the American College of Cardiology, 2006, 48, 2077-2084.	2.8	99
618	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary. Journal of the American College of Cardiology, 2006, 48, 854-906.	2.8	1,044
619	Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: The Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. American Heart Journal, 2006, 152, 1097-1103.	2.7	166
620	Warfarin Prescribing in Atrial Fibrillation: The Impact of Physician, Patient, and Hospital Characteristics. American Journal of Medicine, 2006, 119, 607-615.	1.5	75
621	Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). American Heart Journal, 2006, 151, 713-719.	2.7	890
622	A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: There remains an unmet need. American Heart Journal, 2006, 151, 771-778.	2.7	56
623	Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. American Heart Journal, 2006, 151, 1187-1193.	2.7	94

#	ARTICLE	IF	CITATIONS
624	Benefits of left atrial appendage occlusion for stroke prevention. American Heart Journal, 2006, 151, e1.	2.7	79
625	Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Clinical Neurology and Neurosurgery, 2006, 108, 135-142.	1.4	30
626	D-dimer level influences thromboembolic events in patients with atrial fibrillation. International Journal of Cardiology, 2006, 109, 59-65.	1.7	92
627	Stroke: epidemiology, classification, risk factors, complications, diagnosis, prevention, and medical and dental management. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2006, 102, 180-191.	1.4	58
628	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Circulation, 2006, 113, .	1.6	416
629	Development of a Contemporary Bleeding Risk Model for Elderly Warfarin Recipients. Chest, 2006, 130, 1390-1396.	0.8	244
630	Bleeding Risk Stratification Models in Deciding on Anticoagulation in Patients With Atrial Fibrillation. Chest, 2006, 130, 1296-1299.	0.8	18
631	Fibrillation auriculaire. EMC - Traitement De Maladie AKOS, 2006, 1, 1-7.	0.0	0
633	Additive Role of Plasma von Willebrand Factor Levels to Clinical Factors for Risk Stratification of Patients With Atrial Fibrillation. Stroke, 2006, 37, 2294-2300.	2.0	140
634	Atrial Fibrillation and Stroke in the General Medicare Population. Stroke, 2006, 37, 1969-1974.	2.0	226
635	Perceived Effects on Patients' Health of Participation in the Atrial Fibrillation Follow-up Investigation of Rhythm Management Study. Journal of Cardiovascular Nursing, 2006, 21, 388-396.	1.1	0
636	Stroke Management in Women. Women's Health, 2006, 2, 597-603.	1.5	0
637	Antithrombotic therapy in atrial fibrillation: beyond the AFFIRM study. Journal of Cardiovascular Medicine, 2006, 7, 505-513.	1.5	2
638	Rapid achievement of therapeutic anticoagulation positively affects outcome in patients undergoing cardioversion for persistent atrial fibrillation. Clinical Cardiology, 2006, 29, 78-82.	1.8	4
639	The Emergency Department: First Line of Defense in Preventing Secondary Stroke. Academic Emergency Medicine, 2006, 13, 215-222.	1.8	16
640	Monitoring anticoagulation in atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2006, 21, 191-198.	2.1	33
641	Worldwide Management of Oral Anticoagulant Therapy: the ISAM Study. Journal of Thrombosis and Thrombolysis, 2006, 21, 73-77.	2.1	111
643	Cardioembolic stroke. Current Atherosclerosis Reports, 2006, 8, 310-316.	4.8	74

#	ARTICLE	IF	CITATIONS
644	Medical management of atrial fibrillation. Current Cardiology Reports, 2006, 8, 323-329.	2.9	6
645	Atrial fibrillation: Choosing an antiarrhythmic drug. Current Cardiology Reports, 2006, 8, 370-376.	2.9	8
646	Transthoracic Echocardiographic Predictors of Left Atrial Appendage Thrombus. American Journal of Cardiology, 2006, 97, 421-425.	1.6	55
647	Patterns and Predictors of Warfarin Use in Patients With New-Onset Atrial Fibrillation from the FRACTAL Registry. American Journal of Cardiology, 2006, 97, 538-543.	1.6	102
649	Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurology, The, 2006, 5, 749-754.	10.2	141
650	Translating the Results of Randomized Trials into Clinical Practice. Stroke, 2006, 37, 1075-1080.	2.0	249
651	Optimising stroke prevention in non-valvular atrial fibrillation. Expert Opinion on Pharmacotherapy, 2006, 7, 2079-2094.	1.8	4
652	Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. European Heart Journal, 2006, 27, 1947-1953.	2.2	88
653	Stroke prophylaxis in atrial fibrillation: who gets it and who does not?. European Heart Journal, 2006, 27, 1954-1964.	2.2	173
654	Post-operative use of heparin increases morbidity of pacemaker implantation. Europace, 2006, 8, 283-287.	1.7	62
655	Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy. Stroke, 2006, 37, 256-262.	2.0	286
656	Percutaneous left atrial appendage closure in a patient with atrial fibrillation. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 456-459.	3.3	2
657	Timing of Fresh Frozen Plasma Administration and Rapid Correction of Coagulopathy in Warfarin-Related Intracerebral Hemorrhage. Stroke, 2006, 37, 151-155.	2.0	227
658	Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. Heart, 2006, 92, 196-200.	2.9	39
659	Rapid High-Volume Population Screening for Three Major Risk Factors of Future Stroke: Phase I Results. Vascular and Endovascular Surgery, 2006, 40, 177-187.	0.7	13
660	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillationâ€”Executive Summary. Circulation, 2006, 114, 700-752.	1.6	294
661	Bringing the Benefits of Anticoagulation Management Services to the Community. Canadian Pharmacists Journal, 2006, 139, 58-64.	0.8	9
662	A Pharmacotherapy Clinic in a Neurologic Practice. Journal of Pharmacy Technology, 2006, 22, 254-260.	1.0	0

#	ARTICLE	IF	CITATIONS
663	Risk of Thromboembolic Events After Percutaneous Left Atrial Radiofrequency Ablation of Atrial Fibrillation. <i>Circulation</i> , 2006, 114, 759-765.	1.6	395
664	Warfarin Exposure and the Risk of Thromboembolic and Major Bleeding Events Among Medicaid Patients with Atrial Fibrillation. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1024-1029.	1.9	35
665	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. <i>Circulation</i> , 2006, 114, e257-354.	1.6	2,120
666	Stroke Prevention in Atrial Fibrillation. <i>Stroke</i> , 2007, 38, 615-617.	2.0	31
667	Left atrial appendage closure for stroke prevention in atrial fibrillation: state of the art and current challenges. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 428-435.	3.3	31
668	Ventricular-assist devices for the treatment of chronic heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 571-584.	1.5	19
669	ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 2281-2291.	1.0	4
670	Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial. <i>Cmaj</i> , 2007, 176, 1583-1587.	2.0	62
671	Cardioembolism. , 2007, , 235-240.		1
672	Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation. <i>Stroke</i> , 2007, 38, 874-880.	2.0	71
673	Prevalence and Determinants of Subdiaphragmatic Visceral Infarction in Patients With Fatal Stroke. <i>Stroke</i> , 2007, 38, 1442-1446.	2.0	18
674	Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified?. <i>Stroke</i> , 2007, 38, 2459-2463.	2.0	68
675	Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation. <i>Stroke</i> , 2007, 38, 2965-2971.	2.0	21
676	Use of Long-Term Anticoagulation is Associated With Traumatic Intracranial Hemorrhage and Subsequent Mortality in Elderly Patients Hospitalized After Falls: Analysis of the New York State Administrative Database. <i>Journal of Trauma</i> , 2007, 63, 519-524.	2.3	66
677	Perindopril and prevention of atrial fibrillation. <i>Country Review Ukraine</i> , 2007, 9, E25-E29.	0.8	5
678	Coronary Artery Disease and Ischemic Stroke in Atrial Fibrillation. <i>Chest</i> , 2007, 132, 8-10.	0.8	22
679	Noninvasive Cardiac Monitoring for Detecting Paroxysmal Atrial Fibrillation or Flutter After Acute Ischemic Stroke. <i>Stroke</i> , 2007, 38, 2935-2940.	2.0	309
680	Anticoagulation in Women with Nonvalvular Atrial Fibrillation: Insights from Clinical Trials. <i>Women's Health</i> , 2007, 3, 673-678.	1.5	1

#	ARTICLE	IF	CITATIONS
681	Effect of On-Admission Antiplatelet Treatment on Patients with Cerebral Hemorrhage. Cerebrovascular Diseases, 2007, 24, 215-218.	1.7	43
682	Intracardiac Thrombosis and Embolism in Patients With Cardiac Amyloidosis. Circulation, 2007, 116, 2420-2426.	1.6	217
683	A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart, 2007, 93, 606-612.	2.9	154
684	A Cautionary Note on Data Sources for Evidence-Based Clinical Decisions: Warfarin and Stroke Prevention. Medical Decision Making, 2007, 27, 438-447.	2.4	2
685	Long-Term Progression and Outcomes With Aging in Patients With Lone Atrial Fibrillation. Circulation, 2007, 115, 3050-3056.	1.6	347
686	Bleeding While Starting Anticoagulation for Thromboembolism Prophylaxis in Elderly Patients With Atrial Fibrillation. Circulation, 2007, 115, 2684-2686.	1.6	16
687	Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation. Circulation, 2007, 115, 2689-2696.	1.6	962
688	A comprehensive view of sex-specific issues related to cardiovascular disease. Cmaj, 2007, 176, S1-S44.	2.0	348
689	National survey of anticoagulation policy in endoscopy. European Journal of Gastroenterology and Hepatology, 2007, 19, 51-56.	1.6	15
690	Cost-effectiveness of catheter ablation for atrial fibrillation. Current Opinion in Cardiology, 2007, 22, 11-17.	1.8	18
691	Left Atrial Appendage Exclusion for Stroke Prevention in Patients With Nonrheumatic Atrial Fibrillation. Stroke, 2007, 38, 624-630.	2.0	119
692	Degree of Anticoagulation, but Not Warfarin Use Itself, Predicts Adverse Outcomes After Traumatic Brain Injury in Elderly Trauma Patients. Journal of Trauma, 2007, 63, 525-530.	2.3	115
693	Alcohol consumption and risk and prognosis of atrial fibrillation among older adults: The Cardiovascular Health Study. American Heart Journal, 2007, 153, 260-266.	2.7	81
694	Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. American Heart Journal, 2007, 154, 899-907.	2.7	25
695	Death and Disability from Warfarin-Associated Intracranial and Extracranial Hemorrhages. American Journal of Medicine, 2007, 120, 700-705.	1.5	457
696	Health Care Consumption Due to Atrial Fibrillation is Markedly Reduced by Maze III Surgery. Annals of Thoracic Surgery, 2007, 83, 1713-1716.	1.3	8
697	Stroke prevention in elderly patients with atrial fibrillation. Lancet, The, 2007, 370, 460-461.	13.7	25
698	Management of atrial fibrillation. Lancet, The, 2007, 370, 604-618.	13.7	205

#	ARTICLE	IF	CITATIONS
699	Atrial Fibrillation in the Elderly. American Journal of Medicine, 2007, 120, 481-487.	1.5	83
700	Gender differences in dementia risk factors. Gender Medicine, 2007, 4, 120-129.	1.4	156
701	Therapeutic management of acute intracerebral haemorrhage. Expert Opinion on Pharmacotherapy, 2007, 8, 3097-3116.	1.8	16
702	Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults. Stroke, 2007, 38, 2001-2023.	2.0	1,543
703	Long-term Efficacy of Combination Therapy with Antiarrhythmic Agents and Pravastatin in Patients with Paroxysmal Atrial Fibrillation. Journal of Arrhythmia, 2007, 23, 124-130.	1.2	3
704	Clinical Predictors of Left Atrial Thrombus and Spontaneous Echocardiographic Contrast in Patients with Atrial Fibrillation. Journal of the American Society of Echocardiography, 2007, 20, 1181-1185.	2.8	49
705	REPRINT. Circulation, 2007, 116, e391-413.	1.6	314
706	Approaches to Prevention of Cardiovascular Complications and Events in Diabetes Mellitus. Drugs, 2007, 67, 997-1026.	10.9	117
707	Impact of Implementing Common Guidelines at Different Care Levels in a Healthcare Area on the Improvement of Atrial Fibrillation Treatment. Revista Espanola De Cardiologia (English Ed), 2007, 60, 392-403.	0.6	3
708	Trends in Anticoagulation for Atrial Fibrillation in the U.S.. Journal of the American College of Cardiology, 2007, 49, 1561-1565.	2.8	69
709	Racial/Ethnic Differences in the Risk of Intracranial Hemorrhage Among Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2007, 50, 309-315.	2.8	567
710	Platelet Surface CD62P and CD63, Mean Platelet Volume, and Soluble/Platelet P-Selectin as Indexes of Platelet Function in Atrial Fibrillation. Journal of the American College of Cardiology, 2007, 49, 1957-1964.	2.8	101
711	Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. Journal of the American College of Cardiology, 2007, 50, 2156-2161.	2.8	422
712	Stroke in atrial fibrillation: Update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Annals of Medicine, 2007, 39, 371-391.	3.8	79
713	Sealing the Left Atrial Appendage: Ready for Prime Time?. American Journal of the Medical Sciences, 2007, 333, 285-289.	1.1	2
714	Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. Medical Journal of Australia, 2007, 186, 175-180.	1.7	46
715	Atrial fibrillation. Medical Journal of Australia, 2007, 186, 197-202.	1.7	30
716	Clinical outcomes three years after PLAATO implantation. Catheterization and Cardiovascular Interventions, 2007, 69, 704-707.	1.7	41

#	ARTICLE	IF	CITATIONS
717	Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 32-38.	1.9	17
718	Antithrombotic therapy in patients with chronic heart failure: rationale, clinical evidence and practical implications. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 224-231.	3.8	15
719	Clinical and Echocardiographic Markers of Mortality Risk in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2007, 99, 1733-1736.	1.6	35
720	Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study). <i>American Journal of Cardiology</i> , 2007, 100, 1419-1426.	1.6	389
721	Atrial fibrillation and stroke prevention. <i>Lancet Neurology</i> , The, 2007, 6, 981-993.	10.2	216
722	Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2007, 335, 383.	2.3	326
723	Independent predictors of stroke in patients with atrial fibrillation. <i>Neurology</i> , 2007, 69, 546-554.	1.1	559
724	Misuse of antithrombotic therapy in atrial fibrillation patients: frequent, pervasive and persistent. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 23, 65-71.	2.1	32
725	The role of pacing in rhythm control and management of atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2007, 18, 159-186.	1.3	9
726	Current strategies for ischemic stroke prevention: role of multimodal combination therapies. <i>Journal of Neurology</i> , 2007, 254, 1414-1426.	3.6	22
727	Intracerebral haemorrhage: an often neglected medical emergency. <i>Internal and Emergency Medicine</i> , 2007, 2, 38-45.	2.0	22
728	A problem for achieving informed choice. <i>Theoretical Medicine and Bioethics</i> , 2008, 29, 255-265.	0.8	0
729	Determinants and measures of quality in oral anticoagulation therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 61-66.	2.1	55
731	Feasibility, cost-effectiveness and patients' acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic. <i>Annals of Hematology</i> , 2008, 87, 905-910.	1.8	26
732	Application of a Decision Support Tool for Anticoagulation in Patients with Non-valvular Atrial Fibrillation. <i>Journal of General Internal Medicine</i> , 2008, 23, 411-417.	2.6	27
734	Inguinal hernia repair in the anticoagulated patient: a retrospective analysis. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2008, 12, 589-592.	2.0	23
738	Risk factors for nonadherence to warfarin: results from the INâ€RANGE study. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 853-860.	1.9	104
739	Complications of needle electromyography: Hematoma risk and correlation with anticoagulation and antiplatelet therapy. <i>Muscle and Nerve</i> , 2008, 38, 1225-1230.	2.2	57

#	ARTICLE	IF	CITATIONS
740	Heart and vessel pathology underlying brain infarction in 142 stroke patients. <i>Annals of Neurology</i> , 2008, 63, 770-781.	5.3	70
741	Update on Atrial Fibrillation: Part I. <i>Clinical Cardiology</i> , 2008, 31, 55-62.	1.8	92
742	Atrial Fibrillation and Mitral Valve Repair. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2008, 31, 1057-1063.	1.2	15
743	Efficacy, Safety, and Outcome of Atrial Fibrillation Ablation in Septuagenarians. <i>Journal of Cardiovascular Electrophysiology</i> , 2008, 19, 807-811.	1.7	104
744	Asymptomatic Atrial Fibrillation on Device Interrogation. <i>Journal of Cardiovascular Electrophysiology</i> , 2008, 19, 891-893.	1.7	25
745	Pharmacotherapy of Atrial Fibrillation. <i>Annals of Noninvasive Electrocardiology</i> , 1998, 3, 153-161.	1.1	0
746	Should patients with hypertension receive antithrombotic therapy?. <i>Journal of Internal Medicine</i> , 2001, 249, 205-214.	6.0	1
747	The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACEIs and ARBS. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 345-351.	2.4	62
748	Echocardiographic and Clinical Risk Factors for Atrial Fibrillation in Hypertensive Patients With Ischemic Stroke. <i>American Journal of Cardiology</i> , 2008, 102, 1348-1351.	1.6	22
749	Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. <i>Lancet Neurology</i> , The, 2008, 7, 915-926.	10.2	982
750	Remote Monitoring for Atrial Fibrillation. <i>Congestive Heart Failure</i> , 2008, 14, 14-18.	2.0	6
751	Isolating the entire posterior left atrium improves surgical outcomes after the Cox maze procedure. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 135, 870-877.	0.8	129
752	Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment. <i>Chest</i> , 2008, 133, 257S-298S.	0.8	655
753	Predicting Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Evaluation of the CHADS2 Score in a Mediterranean Population. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 29-35.	0.6	3
754	Management of atrial fibrillation in heart failure in the elderly. <i>International Journal of Cardiology</i> , 2008, 125, 178-182.	1.7	8
755	Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2008, 51, 810-815.	2.8	308
757	ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter. <i>Journal of the American College of Cardiology</i> , 2008, 51, 865-884.	2.8	130
758	Success of Surgical Left Atrial Appendage Closure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 924-929.	2.8	488

#	ARTICLE	IF	CITATIONS
759	Epidemiology, Risk Factors for Stroke, and Management of Atrial Fibrillation in China. Journal of the American College of Cardiology, 2008, 52, 865-868.	2.8	100
760	The New World of Cardiac Interventions: A Brief Review of the Recent Advances in Non-Coronary Percutaneous Interventions. Heart Lung and Circulation, 2008, 17, 186-199.	0.4	7
761	Chapter 36 Cardioembolic stroke. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 93, 719-749.	1.8	3
762	Review: Stroke prevention: modifying risk factors. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 287-303.	2.1	92
763	The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm, 2008, 5, S12-S17.	0.7	117
765	Intermediate to Long-Term Results of Radiofrequency Modified Maze Procedure as an Adjunct to Open-Heart Surgery. Annals of Thoracic Surgery, 2008, 86, 1409-1414.	1.3	28
766	Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005. American Heart Journal, 2008, 155, 829-840.	2.7	18
767	Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. American Heart Journal, 2008, 156, 57-64.	2.7	198
768	Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. American Heart Journal, 2008, 156, 855-863.e2.	2.7	243
769	Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. American Journal of Geriatric Pharmacotherapy, 2008, 6, 1-11.	3.0	29
770	Chapter 38 Intracerebral hemorrhage. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 93, 767-790.	1.8	14
773	Atrial Fibrillation: Goals of Therapy and Management Strategies to Achieve the Goals. Medical Clinics of North America, 2008, 92, 217-235.	2.5	6
774	Periprocedural Anticoagulation Management of Patients With Nonvalvular Atrial Fibrillation. Mayo Clinic Proceedings, 2008, 83, 639-645.	3.0	49
775	Perioperative Management of Oral Anticoagulation. Cardiology Clinics, 2008, 26, 299-309.	2.2	25
776	Status of the Epidemiology of Atrial Fibrillation. Medical Clinics of North America, 2008, 92, 17-40.	2.5	286
777	Catheter Ablation of Atrial Fibrillation. Medical Clinics of North America, 2008, 92, 179-201.	2.5	15
778	Anticoagulation: Stroke Prevention in Patients with Atrial Fibrillation. Medical Clinics of North America, 2008, 92, 143-159.	2.5	10
779	Effect of Race/Ethnicity on the Efficacy of Warfarin. CNS Drugs, 2008, 22, 815-825.	5.9	40

#	ARTICLE	IF	CITATIONS
780	Major Bleeding in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 105-110.	4.5	158
781	Prognostic models. Practical Neurology, 2008, 8, 242-253.	1.1	11
782	Chapter 5 Neuropathology of ischemic brain injury. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 92, 93-116.	1.8	7
783	Reducing the Risk for Stroke in Patients Who Have Atrial Fibrillation. Cardiology Clinics, 2008, 26, 267-275.	2.2	15
784	Anticoagulation Control in Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2008, 1, 72-73.	2.2	1
785	Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. Circulation, 2008, 118, 2029-2037.	1.6	789
786	Severe Left Atrial Appendage Stunning After Electrical Cardioversion of Atrial Fibrillation. Circulation, 2008, 118, e699-700.	1.6	4
787	Will Warfarin Soon Be Passed? New Approaches to Stroke Prevention in Atrial Fibrillation. Journal of Cardiovascular Pharmacology, 2008, 52, 18-27.	1.9	15
788	Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. Chest, 2008, 133, 630S-669S.	0.8	312
789	Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk. Stroke, 2008, 39, 1482-1486.	2.0	177
790	Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation. Stroke, 2008, 39, 1901-1910.	2.0	247
791	Racial/Ethnic Differences in Ischemic Stroke Rates and the Efficacy of Warfarin Among Patients With Atrial Fibrillation. Stroke, 2008, 39, 2736-2743.	2.0	77
792	Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation. Stroke, 2008, 39, 3009-3014.	2.0	32
793	Antithrombotic Therapy in Atrial Fibrillation. Chest, 2008, 133, 546S-592S.	0.8	706
794	Use of Anticoagulation in Elderly Patients with Atrial Fibrillation Who Are at Risk for Falls. Annals of Pharmacotherapy, 2008, 42, 523-532.	1.9	82
795	Age alone is not a risk factor for left atrial thrombus in atrial fibrillation. Heart, 2008, 94, 197-199.	2.9	9
796	ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter. Circulation, 2008, 117, 1101-1120.	1.6	76
797	Chapter 1 The history of stroke and cerebrovascular disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 92, 3-28.	1.8	8

#	ARTICLE	IF	CITATIONS
798	Influence of <i>CYP2C9</i> and <i>VKORC1</i> on warfarin dose, anticoagulation attainment and maintenance among European-American and African-American. <i>Pharmacogenomics</i> , 2008, 9, 511-526.	1.3	142
799	Atrial Fibrillation and Isolated Systolic Hypertension. <i>Hypertension</i> , 2008, 51, 1552-1556.	2.7	47
800	Patient-Specific Decision-Making for Warfarin Therapy in Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2008, 39, 3308-3315.	2.0	39
801	Hypertension, stroke and the impact of atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1287-1289.	1.5	9
802	Pharmacotherapy of atrial fibrillation: an old option with new possibilities. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 913-925.	1.8	5
803	Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 57-70.	1.5	68
804	Periprocedural Anticoagulation Management of Patients With Nonvalvular Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2008, 83, 639-645.	3.0	74
805	Secondary Stroke Prevention: From Guidelines to Clinical Practice. <i>Journal of the National Medical Association</i> , 2008, 100, 1125-1137.	0.8	20
806	Pharmacology and Management of the Vitamin K Antagonists. <i>Chest</i> , 2008, 133, 160S-198S.	0.8	1,926
807	NT-ProBNP Predicts Rhythm Stability After Cardioversion of Lone Atrial Fibrillation. <i>Circulation Journal</i> , 2008, 72, 921-925.	1.6	40
808	Current Status of Anticoagulation Therapy for Elderly Atrial Fibrillation Patients in Japan From Hokuriku Atrial Fibrillation Trial. <i>Circulation Journal</i> , 2008, 72, 2058-2061.	1.6	16
809	Soluble CD40 Ligand, Platelet Surface CD40 Ligand, and Total Platelet CD40 Ligand in Atrial Fibrillation. <i>Chest</i> , 2008, 134, 574-581.	0.8	39
811	Clinical Applications of Aspirin. , 0, , 223-365.		0
812	Clinical Epidemiology of Atrial Fibrillation and Related Cerebrovascular Events in the United States. <i>Neurologist</i> , 2008, 14, 143-150.	0.7	49
813	Secondary Stroke Prevention. <i>Journal of Cardiovascular Nursing</i> , 2008, 23, 34-41.	1.1	22
814	Etiology, Pathophysiology, and Treatment of Atrial Fibrillation. <i>Cardiology in Review</i> , 2008, 16, 181-188.	1.4	20
815	Treatment of Atrial Fibrillation and Atrial Flutter. <i>Cardiology in Review</i> , 2008, 16, 230-239.	1.4	12
816	Role of anticoagulation therapy after pulmonary vein antrum isolation for atrial fibrillation treatment. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 51-55.	1.5	19

#	ARTICLE	IF	CITATIONS
818	Prevalence of cardiovascular risk factors among elderly Brazilians over eighty with ischemic stroke. Arquivos De Neuro-Psiquiatria, 2008, 66, 454-457.	0.8	5
819	Anticoagulation and the Elderly Head Trauma Patient. American Surgeon, 2008, 74, 802-805.	0.8	22
820	Long-term prognosis after transient ischemic attack and stroke. , 0, , 213-222.		0
821	Brain Embolism. , 2009, , 316-374.		2
822	How Well Does the Target INR Level Maintain in Warfarin-Treated Patients with Non-Valvular Atrial Fibrillation?. Yonsei Medical Journal, 2009, 50, 83.	2.2	14
823	Noninferiority trials: determining whether alternative treatments are good enough. Medical Journal of Australia, 2009, 190, 326-330.	1.7	59
824	Cardioembolic Stroke in Atrial Fibrillation-Rationale for Preventive Closure of the Left Atrial Appendage. Korean Circulation Journal, 2009, 39, 443.	1.9	23
825	Vernakalant hydrochloride for the treatment of atrial fibrillation. Expert Opinion on Investigational Drugs, 2009, 18, 1929-1937.	4.1	15
826	Reducing Stroke Rates in Patients With Atrial Fibrillation. Circulation, 2009, 120, 1169-1170.	1.6	4
827	Thrombosis and Antithrombotic Therapy in Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 284-288.	2.4	51
828	Sex Differences in Stroke Epidemiology. Stroke, 2009, 40, 1082-1090.	2.0	772
829	The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 474-480.	4.8	747
830	Detection of Atrial Fibrillation Using a Modified Microlife Blood Pressure Monitor. American Journal of Hypertension, 2009, 22, 848-852.	2.0	103
831	Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac Amyloidosis. Circulation, 2009, 119, 2490-2497.	1.6	215
832	Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed. Current Medical Research and Opinion, 2009, 25, 2853-2864.	1.9	26
833	Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated. Stroke, 2009, 40, 235-240.	2.0	358
834	Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation. Stroke, 2009, 40, 1410-1416.	2.0	306
835	Current Status of Stroke Risk Stratification in Patients With Atrial Fibrillation. Stroke, 2009, 40, 2607-2610.	2.0	66

#	ARTICLE	IF	CITATIONS
836	Cerebral Microbleeds in Ischemic Stroke Patients on Warfarin Treatment. <i>Stroke</i> , 2009, 40, 3638-3640.	2.0	39
837	Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies. <i>Mayo Clinic Proceedings</i> , 2009, 84, 643-662.	3.0	62
838	Chagas Disease. <i>Stroke</i> , 2009, 40, 3691-3694.	2.0	55
839	Routine screening for detection of atrial fibrillation?. <i>Future Cardiology</i> , 2009, 5, 213-214.	1.2	2
840	Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. <i>Neurology</i> , 2009, 72, 171-176.	1.1	162
841	Anticoagulation in patients with heart failure and normal sinus rhythm. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 134-141.	1.0	6
842	Left Atrial Appendage Thrombi in Stroke Patients: Detection with Two-Phase Cardiac CT Angiography versus Transesophageal Echocardiography. <i>Radiology</i> , 2009, 251, 683-690.	7.3	142
843	Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 297-304.	2.2	96
844	Left atrial appendage-occluding devices for stroke prevention in patients with nonvalvular atrial fibrillation. <i>Expert Review of Medical Devices</i> , 2009, 6, 611-620.	2.8	4
845	Cost of Hospital Admission for Antiarrhythmic Drug Initiation in Atrial Fibrillation. <i>Annals of Pharmacotherapy</i> , 2009, 43, 840-848.	1.9	29
846	Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure. <i>Circulation</i> , 2009, 119, 1616-1624.	1.6	370
847	Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation. <i>Circulation</i> , 2009, 119, 1363-1369.	1.6	397
848	Rivaroxaban “an oral, direct Factor Xa inhibitor” lessons from a broad clinical study programme. <i>European Journal of Haematology</i> , 2009, 82, 339-349.	2.2	52
849	Differential Use of Warfarin for Secondary Stroke Prevention in Patients With Various Types of Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2009, 103, 227-231.	1.6	36
850	Body Mass Index and Risk of Left Atrial Thrombus in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2009, 104, 1699-1703.	1.6	25
851	Is the left atrial appendage more than a simple appendage?. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 234-242.	1.7	36
852	Percutaneous closure of left atrial appendage to prevent embolic events in high-risk patients with chronic atrial fibrillation. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 217-222.	1.7	31
853	Trends in catheter ablation for atrial fibrillation in the United States. <i>Journal of Hospital Medicine</i> , 2009, 4, E1-5.	1.4	88

#	ARTICLE	IF	CITATIONS
854	Antithrombotic therapy for the treatment of atrial fibrillation in the elderly. Journal of Interventional Cardiac Electrophysiology, 2009, 25, 19-23.	1.3	17
855	Epidemiology of atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2009, 25, 3-8.	1.3	89
856	Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio?. Journal of Thrombosis and Thrombolysis, 2009, 27, 293-299.	2.1	44
857	Rational patient selection for catheter ablation of atrial fibrillation. Current Cardiology Reports, 2009, 11, 327-334.	2.9	0
858	Should We Test for CYP2C9 Before Initiating Anticoagulant Therapy in Patients with Atrial Fibrillation?. Journal of General Internal Medicine, 2009, 24, 543-549.	2.6	11
859	Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin. Journal of General Internal Medicine, 2009, 24, 656-664.	2.6	105
860	Cost of atrial fibrillation in United States managed care organizations. Advances in Therapy, 2009, 26, 847-857.	2.9	81
861	Is primary care a neglected piece of the jigsaw in ensuring optimal stroke care? Results of a national study. BMC Family Practice, 2009, 10, 27.	2.9	7
862	Incidence and Predictors of Left Atrial Thrombus Prior to Catheter Ablation of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2009, 20, 379-384.	1.7	168
863	Evaluation of Left Atrial Appendage Functions According to Different Etiologies of Atrial Fibrillation with a Tissue Doppler Imaging Technique by Using Transesophageal Echocardiography. Echocardiography, 2009, 26, 171-181.	0.9	21
864	Neuropsychological deficits in asymptomatic atrial fibrillation. Acta Neurologica Scandinavica, 1997, 96, 310-316.	2.1	54
865	A review on sex differences in stroke treatment and outcome. Acta Neurologica Scandinavica, 2010, 121, 359-369.	2.1	100
866	<i>Reviews</i>: Use of Warfarin in People with Low Glomerular Filtration Rate or on Dialysis. Seminars in Dialysis, 2009, 22, 503-511.	1.3	22
867	Variability of response to antiplatelet therapy: what should we do next?. Fundamental and Clinical Pharmacology, 2009, 23, 19-22.	1.9	1
868	Atrial fibrillation and coagulation: Who and when?. Blood Reviews, 2009, 23, 241-244.	5.7	6
869	Predictors of Stroke Risk in Native Chinese with Nonrheumatic Atrial Fibrillation: Retrospective Investigation of Hospitalized Patients. Clinical Cardiology, 2009, 32, 76-81.	1.8	21
870	Atrial fibrillation: Mechanistic insights and treatment options. European Journal of Internal Medicine, 2009, 20, 672-681.	2.2	62
873	The quality of anticoagulation on functional outcome and mortality for TIA/stroke in atrial fibrillation patients. International Journal of Cardiology, 2009, 132, 109-113.	1.7	15

#	ARTICLE	IF	CITATIONS
874	Relation of left atrial blood stasis to clinical risk factors in atrial fibrillation. International Journal of Cardiology, 2009, 132, 210-215.	1.7	26
875	Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis. International Journal of Cardiology, 2009, 136, 186-192.	1.7	28
876	Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. American Heart Journal, 2009, 157, 805-810.e2.	2.7	298
877	Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: A single-center, retrospective, observational study. American Journal of Geriatric Pharmacotherapy, 2009, 7, 159-166.	3.0	62
878	Quality of Care for Atrial Fibrillation Among Patients Hospitalized for Heart Failure. Journal of the American College of Cardiology, 2009, 54, 1280-1289.	2.8	129
879	Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering) Tj ETQq1 1 0.784314 rgBT /Overlock 2023-2031.	2.8	165
880	Management of antithrombotic agents for endoscopic procedures. Gastrointestinal Endoscopy, 2009, 70, 1060-1070.	1.0	501
881	Pharmacotherapy for the Secondary Prevention of Stroke. Drugs, 2009, 69, 633-647.	10.9	28
882	Management of Anticoagulation Before and After Gastrointestinal Endoscopy. American Journal of Gastroenterology, 2009, 104, 3085-3097.	0.4	53
883	Safety of the Combination of Intensive Cholesterol-Lowering Therapy with Oral Anticoagulation Medication in Elderly Patients with Atrial Fibrillation. Drugs and Aging, 2009, 26, 585-593.	2.7	11
884	Secondary Stroke Prevention Strategies for the Oldest Patients. Drugs and Aging, 2009, 26, 209-230.	2.7	18
885	Catheter Ablation of Atrial Fibrillation. Cardiology Clinics, 2009, 27, 163-178.	2.2	12
886	Perioperative Anticoagulant Management. Anesthesiology Clinics, 2009, 27, 761-777.	1.4	6
887	Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors. Journal of Arrhythmia, 2009, 25, 81-88.	1.2	0
888	Management of bleeding in patients on antithrombotics: maintaining the balance between thrombosis and hemorrhage. Expert Review of Hematology, 2009, 2, 357-360.	2.2	1
889	Anticoagulation for heart failure: selecting the best therapy. Expert Review of Cardiovascular Therapy, 2009, 7, 1209-1217.	1.5	2
890	Bridging of Chronic Oral Anticoagulation with Enoxaparin in Patients with Atrial Fibrillation: Results from the Prospective BRAVE Registry. Cardiovascular Therapeutics, 2009, 27, 230-238.	2.5	27
891	Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies. Mayo Clinic Proceedings, 2009, 84, 643-662.	3.0	57

#	ARTICLE	IF	CITATIONS
892	Current Perceptions of the Epidemiology of Atrial Fibrillation. <i>Cardiology Clinics</i> , 2009, 27, 13-24.	2.2	112
893	Value of implantable cardioverter-defibrillators in managing atrial fibrillation. <i>Heart Rhythm</i> , 2009, 6, 9-10.	0.7	3
894	Milestones in the management of atrial fibrillation. <i>Heart Rhythm</i> , 2009, 6, S62-S67.	0.7	34
895	Atrial Fibrillation: Goals of Therapy and Management Strategies to Achieve the Goals. <i>Cardiology Clinics</i> , 2009, 27, 189-200.	2.2	17
896	Anticoagulation: Stroke Prevention in Patients with Atrial Fibrillation. <i>Cardiology Clinics</i> , 2009, 27, 125-135.	2.2	7
897	Bleeding rates in patients older than 90 years of age on vitamin K antagonist therapy for nonvalvular atrial fibrillation. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 47-51.	1.0	11
898	The current role of anticoagulants in cardiovascular medicine. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 595-604.	1.5	17
899	4. Chronic Phase Antithrombotic Treatment. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2009, 98, 1285-1293.	0.0	0
900	Restarting Anticoagulation Therapy After Warfarin-Associated Intracerebral Hemorrhage. <i>Yearbook of Cardiology</i> , 2009, 2009, 460-461.	0.0	0
901	Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. <i>The Cochrane Library</i> , 2009, , CD000248.	2.8	39
902	The potential yield of ECG screening of hypertensive patients: the Utrecht Health Project. <i>Journal of Hypertension</i> , 2010, 28, 1527-1533.	0.5	18
903	Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. <i>Chest</i> , 2010, 137, 263-272.	0.8	5,657
904	Anticoagulation therapy for cardioembolic stroke prevention in the elderly: defining benefits and risks. <i>Aging Health</i> , 2010, 6, 439-450.	0.3	2
905	Needs assessment analysis for vitamin K antagonist anticoagulation in the resource-constrained setting of Eldoret, Kenya. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2010, 50, 723-725.	1.5	5
906	Sex-Related Differences in the Risk Factor Profile and Medications of Patients With Atrial Fibrillation Recruited in J-TRACE. <i>Circulation Journal</i> , 2010, 74, 650-654.	1.6	22
907	Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA-Like Patients With Atrial Fibrillation/Atrial Flutter in the United States. <i>Clinical Cardiology</i> , 2010, 33, 270-279.	1.8	57
908	Patient Attitudinal and Behavioral Factors Associated with Warfarin Non-adherence at Outpatient Anticoagulation Clinics. <i>International Journal of Behavioral Medicine</i> , 2010, 17, 33-42.	1.7	52
909	Atrial Fibrillation in the Elderly. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 354-360.	2.0	0

#	ARTICLE	IF	CITATIONS
910	Late thromboembolic events after circumferential pulmonary vein ablation of atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2010, 27, 33-39.	1.3	10
911	Unexpected low prevalence of atrial fibrillation in cryptogenic ischemic stroke: a prospective study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2010, 28, 101-107.	1.3	63
912	Advanced age, low left atrial appendage velocity, and Factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 192-199.	2.1	14
913	Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neurology</i> , The, 2010, 9, 1157-1163.	10.2	399
914	Avances en la prevención de la isquemia cerebral por fibrilación auricular. <i>Neurología</i> , 2010, 25, 401-408.	0.7	13
915	Dietary Fish Intake and Incident Atrial Fibrillation (from the Women's Health Initiative). <i>American Journal of Cardiology</i> , 2010, 105, 844-848.	1.6	76
916	Surgical Treatment of Atrial Fibrillation: The Time Is Now. <i>Annals of Thoracic Surgery</i> , 2010, 90, 2079-2086.	1.3	11
917	Gender in atrial fibrillation: Ten years later. <i>Gender Medicine</i> , 2010, 7, 206-217.	1.4	92
918	Meeting the Unmet Needs in Anticoagulant Therapy. <i>European Journal of Haematology</i> , 2010, 85, 1-28.	2.2	87
919	Predictors of anticoagulation in hospice patients with lung cancer. <i>Cancer</i> , 2010, 116, 4817-4824.	4.1	8
920	Medical treatment of patients with atrial fibrillation aged over 80 years in daily clinical practice: Influence of age and CHADS2 score. <i>Archives of Gerontology and Geriatrics</i> , 2010, 50, 36-41.	3.0	10
921	Optimal loading dose for the initiation of warfarin: a systematic review. <i>BMC Cardiovascular Disorders</i> , 2010, 10, 18.	1.7	23
922	Trends in publications regarding evidence-practice gaps: A literature review. <i>Implementation Science</i> , 2010, 5, 11.	6.9	32
923	Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2201-2207.	3.8	40
924	First time and repeat cardioversion of atrial tachyarrhythmias - a comparison of outcomes. <i>International Journal of Clinical Practice</i> , 2010, 64, 1062-1068.	1.7	4
925	Antithrombotic management of ischaemic stroke and transient ischaemic attack in China: A consecutive cross-sectional survey. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2010, 37, 775-781.	1.9	17
929	The evaluation of pulmonary vein isolation and wide-area left atrial ablation to treat atrial fibrillation in patients with implanted permanent pacemakers: the Previously Paced Pulmonary Vein Isolation Study. <i>Heart</i> , 2010, 96, 1037-1042.	2.9	6
930	Warfarin in haemodialysis patients with atrial fibrillation: what benefit?. <i>Europace</i> , 2010, 12, 1666-1672.	1.7	62

#	ARTICLE	IF	CITATIONS
931	Anticoagulation in the Elderly. <i>Pharmaceuticals</i> , 2010, 3, 3543-3569.	3.8	23
932	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , 2010, 31, 2133-2140.	2.2	35
933	Vernakalant: A novel agent for the termination of atrial fibrillation. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 1157-1164.	1.0	10
934	The assessment of stroke and bleeding risk in atrial fibrillation: where are we now?. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1703-1710.	1.5	2
935	Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. <i>European Heart Journal</i> , 2010, 31, 967-975.	2.2	305
936	Recent advances in oral anticoagulation for atrial fibrillation. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 395-407.	2.1	5
937	The Relationship between Sleep Disorders and Stroke. <i>Postgraduate Medicine</i> , 2010, 122, 145-153.	2.0	20
938	Stroke risk in AF: do AF patterns matter?. <i>European Heart Journal</i> , 2010, 31, 908-910.	2.2	11
939	Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation. <i>European Heart Journal</i> , 2010, 31, 1046-1054.	2.2	95
940	Atrial fibrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon. <i>Europace</i> , 2010, 12, 482-487.	1.7	70
941	Incidence of left atrial thrombus prior to atrial fibrillation ablation: is pre-procedural transoesophageal echocardiography mandatory?. <i>Europace</i> , 2010, 12, 927-932.	1.7	101
942	Prevalence and Predictors of Paroxysmal Atrial Fibrillation on Holter Monitor in Patients With Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2010, 41, 2596-2600.	2.0	82
943	Blood Pressure Levels and Bleeding Events During Antithrombotic Therapy. <i>Stroke</i> , 2010, 41, 1440-1444.	2.0	102
944	Stroke Risk and Antithrombotic Strategies in Atrial Fibrillation. <i>Stroke</i> , 2010, 41, 2705-2713.	2.0	70
945	The Evolving Field of Stroke Prevention in Patients With Atrial Fibrillation. <i>Stroke</i> , 2010, 41, S17-S20.	2.0	15
946	Identifying Patients at High Risk for Stroke Despite Anticoagulation. <i>Stroke</i> , 2010, 41, 2731-2738.	2.0	448
947	Stroke prevention in atrial fibrillation patients. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2331-2350.	1.8	5
948	The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. <i>Europace</i> , 2010, 12, 779-784.	1.7	40

#	ARTICLE	IF	CITATIONS
949	Fibrillation atriale et sujet Ã¢gÃ©. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2010, 2010, 12-15.	0.0	1
950	Principles of Anticoagulation and New Therapeutic Agents in Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2010, 2, 479-492.	1.7	1
952	Age as a Risk Factor for Stroke in Atrial Fibrillation Patients. Journal of the American College of Cardiology, 2010, 56, 827-837.	2.8	206
954	Pharmacogenetics of Warfarin. Annual Review of Medicine, 2010, 61, 63-75.	12.2	92
955	The environmental epidemiology of atrial arrhythmogenesis. Journal of Epidemiology and Community Health, 2010, 64, 587-590.	3.7	5
956	Should all patients with non-valvular atrial fibrillation be anticoagulated?. International Journal of Cardiology, 2010, 143, 8-15.	1.7	7
959	Predicting left atrial thrombi in atrial fibrillation. American Heart Journal, 2010, 159, 665-671.	2.7	72
960	Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk?. American Journal of Medicine, 2010, 123, 446-453.	1.5	139
961	A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. Chest, 2010, 138, 1093-1100.	0.8	3,810
962	REVIEW: New Antithrombotics for Atrial Fibrillation. Cardiovascular Therapeutics, 2010, 28, 278-286.	2.5	19
963	REVIEW: Atrial Fibrillation and Dabigatran: Has the Time Come To Use New Anticoagulants?. Cardiovascular Therapeutics, 2010, 28, 295-301.	2.5	13
964	Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation. Thrombosis Research, 2010, 126, e69-e77.	1.7	36
966	Stroke Prevention in Atrial Fibrillation. Drugs and Aging, 2010, 27, 859-870.	2.7	8
967	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Circulation, 2011, 124, 2458-2473.	1.6	1,369
968	The role of echocardiography in percutaneous left atrial appendage occlusion. European Journal of Echocardiography, 2011, 12, i3-i10.	2.3	49
969	Association Between CHADS2 Risk Factors and Anticoagulation-Related Bleeding: A Systematic Literature Review. Mayo Clinic Proceedings, 2011, 86, 509-521.	3.0	15
970	Use of Oral Anticoagulant for Secondary Prevention of Stroke in Very Elderly Patients With Atrial Fibrillation: An Observational Study. International Journal of Gerontology, 2011, 5, 45-48.	0.6	7
971	2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 57, e101-e198.	2.8	756

#	ARTICLE	IF	CITATIONS
972	Association of Left Atrial Fibrosis Detected by Delayed-Enhancement Magnetic Resonance Imaging and the Risk of Stroke in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 57, 831-838.	2.8	349
973	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. Journal of the American College of Cardiology, 2011, 57, 1002-1044.	2.8	346
974	Transcatheter Patch Occlusion of the Left Atrial Appendage Using Surgical Adhesives in High-Risk Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 58, 2236-2240.	2.8	46
975	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Journal of the American College of Cardiology, 2011, 58, 2432-2446.	2.8	700
976	Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ: British Medical Journal, 2011, 342, d124-d124.	2.3	1,143
977	Antithrombotic therapy in nonvalvular atrial fibrillation: A narrative review. Revista Portuguesa De Cardiologia, 2011, 30, 905-924.	0.5	4
978	The epidemiology of atrial fibrillation in adults depends on locale of diagnosis. American Heart Journal, 2011, 161, 986-992.e1.	2.7	38
979	The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: Data from the Heart and Soul Study. American Heart Journal, 2011, 162, 555-561.	2.7	98
980	Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter. Canadian Journal of Cardiology, 2011, 27, 74-90.	1.7	273
981	Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Etiology and Initial Investigations. Canadian Journal of Cardiology, 2011, 27, 31-37.	1.7	65
982	Relation of the severity of mitral regurgitation to thromboembolic risk in patients with atrial fibrillation. International Journal of Cardiology, 2011, 146, 197-201.	1.7	16
983	Quality of coronary arterial 320-slice computed tomography images in subjects with chronic atrial fibrillation compared with normal sinus rhythm. International Journal of Cardiology, 2011, 150, 65-70.	1.7	40
984	Prognostic impact of atrial fibrillation progression in a community study: AFBAR Study (Atrial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 262	1.7	26
985	Obstructive sleep apnea may increase the risk of stroke in AF patients: Refining the CHADS2 score. International Journal of Cardiology, 2011, 146, 131-133.	1.7	32
986	Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. Stroke, 2011, 42, 227-276.	2.0	1,433
988	Neurology and Cardiology: Points of Contact. Revista Espanola De Cardiologia (English Ed), 2011, 64, 319-327.	0.6	4
989	Impact of New Criteria for Anticoagulant Treatment in Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed), 2011, 64, 649-653.	0.6	1
990	Antithrombotic therapy in nonvalvular atrial fibrillation: A narrative review. Revista Portuguesa De Cardiologia (English Edition), 2011, 30, 905-924.	0.2	3

#	ARTICLE	IF	CITATIONS
991	Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillationâ€”A nation wide database analysis. <i>Atherosclerosis</i> , 2011, 217, 292-295.	0.8	108
992	Clinical Profiles, Efficacy of Antiarrhythmic Drug Therapy, and Cardiovascular Prognosis in Patients With First Detected Paroxysmal Atrial Fibrillation. <i>International Heart Journal</i> , 2011, 52, 32-38.	1.0	7
993	Bleeding risk assessment and management in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 997-1011..	3.4	234
994	Bleeding and Stroke Risk in a Real-world Prospective Primary Prevention Cohort of Patients With Atrial Fibrillation. <i>Chest</i> , 2011, 140, 918-924.	0.8	29
995	Current and emerging therapies for stroke prophylaxis in atrial fibrillation. <i>Clinical Investigation</i> , 2011, 1, 1019-1037.	0.0	0
996	Determinants of Warfarin Use and International Normalized Ratio Levels in Atrial Fibrillation Patients in Japan - Subanalysis of the J-RHYTHM Registry -. <i>Circulation Journal</i> , 2011, 75, 2357-2362.	1.6	36
997	Stroke risk assessment for atrial fibrillation: hospital-based stroke risk assessment and intervention program. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 71-79.	1.5	9
998	A comparison of risk stratification schemes for stroke in 79â€”884 atrial fibrillation patients in general practice. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 39-48.	3.8	240
999	Bleeding risk in â€”real worldâ€” patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1460-1467.	3.8	177
1000	Left atrial thrombus and prognosis after anticoagulation therapy in patients with atrial fibrillation. <i>Journal of Cardiology</i> , 2011, 58, 266-277.	1.9	45
1001	Chronic Kidney Disease and CHADS2 Score Independently Predict Cardiovascular Events and Mortality in Patients With Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2011, 107, 912-916.	1.6	89
1002	Comparison of Mortality and Morbidity in Patients With Atrial Fibrillation and Heart Failure With Preserved Versus Decreased Left Ventricular Ejection Fraction. <i>American Journal of Cardiology</i> , 2011, 108, 1283-1288.	1.6	45
1003	The Society of Thoracic Surgeons Practice Guideline on the Prophylaxis and Management of Atrial Fibrillation Associated With General Thoracic Surgery: Executive Summary. <i>Annals of Thoracic Surgery</i> , 2011, 92, 1144-1152.	1.3	109
1004	Feasibility of TEE-guided stroke risk assessment in atrial fibrillationâ€”background, aims, design and baseline data of the TIARA pilot study. <i>Netherlands Heart Journal</i> , 2011, 19, 214-222.	0.8	14
1005	Stroke Prevention in Atrial Fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 561-570.	2.6	4
1006	Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. <i>Advances in Therapy</i> , 2011, 28, 460-472.	2.9	15
1008	Prevention of Cardioembolic Stroke. <i>Neurotherapeutics</i> , 2011, 8, 488-502.	4.4	31
1009	Stroke Prevention in Atrial Fibrillation: Atrial Appendage Closure. <i>Current Cardiology Reports</i> , 2011, 13, 159-166.	2.9	32

#	ARTICLE	IF	CITATIONS
1010	Update on the Management of Atrial Fibrillation: Anticoagulation and Medical Therapy. Current Cardiology Reports, 2011, 13, 387-393.	2.9	0
1011	Major bleeding risk associated with warfarin and co-medications in the elderly population. Pharmacoepidemiology and Drug Safety, 2011, 20, 1057-1063.	1.9	47
1012	Bleeding and electromyography: The needle and the damage (NOT) done. Muscle and Nerve, 2011, 44, 313-315.	2.2	1
1013	Risk of hematoma following needle electromyography of the paraspinal muscles. Muscle and Nerve, 2011, 44, 439-440.	2.2	26
1014	Anticoagulation prescription in atrial fibrillation. Expert Opinion on Pharmacotherapy, 2011, 12, 1473-1479.	1.8	11
1015	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. Stroke, 2011, 42, e420-63.	2.0	132
1016	Moving the Tipping Point. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 14-21.	2.2	234
1017	Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation. Circulation, 2011, 123, 2562-2570.	1.6	299
1018	Usability of an Atrial Fibrillation Anticoagulation Decision-Support Tool. Journal of Primary Care and Community Health, 2011, 2, 100-106.	2.1	9
1019	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Ne. Journal of NeuroInterventional Surgery, 2011, 3, 100-130.	3.3	51
1020	Atrial Fibrillation. Circulation, 2011, 124, 95-99.	1.6	10
1021	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. Circulation, 2011, 124, 489-532.	1.6	499
1022	An Observational, Prospective Survey Assessing the Control of Atrial Fibrillation in Asia Pacific: Rationale and Design of the RecordAF-AP Registry. Clinical Medicine Insights: Cardiology, 2011, 5, CMC.S6289.	1.8	3
1023	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Circulation, 2011, 124, e54-130.	1.6	100
1024	2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2011, 123, e269-367.	1.6	747
1025	An Evaluation of the CHADS 2 Stroke Risk Score in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Revascularization. Chest, 2011, 139, 1402-1409.	0.8	15
1026	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Stroke, 2011, 42, e464-540.	2.0	162
1027	Dual-Enhanced Cardiac CT for Detection of Left Atrial Appendage Thrombus in Patients With Stroke. Stroke, 2011, 42, 2471-2477.	2.0	110

#	ARTICLE	IF	CITATIONS
1028	A Study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation. <i>Europace</i> , 2011, 13, 31-36.	1.7	43
1029	What are the costs of atrial fibrillation?. <i>Europace</i> , 2011, 13, ii9-ii12.	1.7	29
1030	Pacemaker clinic: an opportunity to detect silent atrial fibrillation and improve antithrombotic treatment. <i>Europace</i> , 2011, 13, 1574-1579.	1.7	19
1031	Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism: NICE guidance. <i>Heart</i> , 2011, 97, 762-765.	2.9	14
1032	Acute cardioembolic stroke: an update. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 367-379.	1.5	71
1033	The Link between Atrial Fibrillation and Stroke in Women. <i>Women's Health</i> , 2011, 7, 375-382.	1.5	11
1034	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011, 13, 723-746.	1.7	197
1035	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/ SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. <i>Vascular Medicine</i> , 2011, 16, 35-77.	1.5	81
1036	Fine Particulate Air Pollution is Associated with Higher Vulnerability to Atrial Fibrillation—the Apac Study. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2011, 74, 693-705.	2.3	72
1037	Newer Anticoagulants for Non-Valvular Atrial Fibrillation. <i>Pharmaceuticals</i> , 2012, 5, 469-480.	3.8	3
1038	Management of the Anticoagulated Patient. , 2012, , 203-207.		0
1039	Heart failure and dysrhythmias after maternal placental syndromes: HAD MPS Study. <i>Heart</i> , 2012, 98, 1136-1141.	2.9	75
1040	Oral antithrombotic treatment and postoperative thrombotic complications after head and neck reconstruction using free flaps. <i>Journal of Plastic Surgery and Hand Surgery</i> , 2012, 46, 163-166.	0.8	4
1041	Novel incentive-based approaches to adherence. <i>Clinical Trials</i> , 2012, 9, 689-695.	1.6	16
1042	Minimally Invasive Surgical Implantation of the Percutaneous Left Atrial Appendage Transcatheter Occlusion Device Initial Experience in a Canine Model. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2012, 7, 52-58.	0.9	0
1043	Providing Best Practice in the Management of Atrial Fibrillation in the United States. <i>Journal of Cardiovascular Nursing</i> , 2012, 27, 445-456.	1.1	8
1044	Anticoagulation for atrial fibrillation in patients on dialysis. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 600-606.	2.0	30
1045	Transitions of Care in Anticoagulation Management for Patients with Atrial Fibrillation. <i>Hospital Practice (1995)</i> , 2012, 40, 20-27.	1.0	1

#	ARTICLE	IF	CITATIONS
1046	A Review of Oral Anticoagulants in Patients with Atrial Fibrillation. Postgraduate Medicine, 2012, 124, 7-16.	2.0	74
1047	More light at the end of the tunnel “ apixaban in atrial fibrillation. Expert Opinion on Investigational Drugs, 2012, 21, 1235-1239.	4.1	22
1048	Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. European Journal of Heart Failure, 2012, 14, 295-301.	7.1	96
1049	Risk factors of vitamin K antagonist overcoagulation. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 53-62.	0.5	21
1050	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Review of Cardiovascular Therapy, 2012, 10, 1471-1480.	1.5	42
1051	Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 472-479.	2.2	32
1052	Optimal loading dose of warfarin for the initiation of oral anticoagulation. The Cochrane Library, 2021, 2021, CD008685.	2.8	20
1053	Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ, The, 2012, 344, e3522-e3522.	6.0	215
1054	Percutaneous atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review. Heart, 2012, 98, 900-907.	2.9	22
1055	Stroke Prevention in Atrial Fibrillation: Where are We Now?. Clinical Medicine Insights: Cardiology, 2012, 6, CMC.S8976.	1.8	9
1056	Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation. Stroke, 2012, 43, 3442-3453.	2.0	248
1057	Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. European Heart Journal, 2012, 33, 1886-1892.	2.2	67
1058	Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace, 2012, 14, 666-674.	1.7	114
1059	Coumarins and survival in incident dialysis patients. Nephrology Dialysis Transplantation, 2012, 27, 332-337.	0.7	42
1060	Risk Factors for Stroke and Thromboembolism in Relation to Age Among Patients With Atrial Fibrillation. Chest, 2012, 141, 147-153.	0.8	96
1061	Hypertension and atrial fibrillation. Journal of Hypertension, 2012, 30, 239-252.	0.5	177
1062	Stroke prevention in atrial fibrillation. Journal of Cardiovascular Medicine, 2012, 13, 73-85.	1.5	11
1064	Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace, 2012, 14, 1553-1559.	1.7	156

#	ARTICLE	IF	CITATIONS
1065	Managing anticoagulation in patients receiving implantable cardiac devices. <i>Future Cardiology</i> , 2012, 8, 393-411.	1.2	1
1066	Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1745-1751.	3.8	105
1067	Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. <i>Neurology</i> , 2012, 79, 1428-1434.	1.1	70
1068	Outcomes Associated With Warfarin Use in Older Patients With Heart Failure and Atrial Fibrillation and a Cardiovascular Implantable Electronic Device: Findings From the ADHERE Registry Linked to Medicare Claims. <i>Clinical Cardiology</i> , 2012, 35, 649-657.	1.8	11
1069	Outcome of coumarin-therapy in an outpatient setting over a 10-year period. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 756-762.	1.9	0
1070	Peer education for secondary stroke prevention in inner-city minorities: Design and methods of the prevent recurrence of all inner-city strokes through education randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2012, 33, 1065-1073.	1.8	37
1072	An Approach to Catheter Ablation of Atrial Fibrillation in the Elderly. <i>Cardiac Electrophysiology Clinics</i> , 2012, 4, 119-125.	1.7	4
1073	Prevalence of Atrial Fibrillation in US Nursing Homes: Results from the National Nursing Home Survey, 1985-2004. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 529-534.	2.5	12
1074	Evidencias clínicas del estudio RE-LY en la prevención de ictus y tromboembolia por fibrilación auricular. <i>Revista Española De Cardiología Suplementos</i> , 2012, 12, 25-30.	0.2	2
1075	The Role of Repeat Transesophageal Echocardiography in Patients without Atrial Thrombus Prior to Cardioversion or Ablation. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 1106-1112.	2.8	7
1076	Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2012, 367, 625-635.	27.0	795
1077	Detection of Asymptomatic Paroxysmal Atrial Fibrillation with the Trans-Telephonic Electrocardiograph System. <i>Telemedicine Journal and E-Health</i> , 2012, 18, 193-197.	2.8	1
1078	Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation. <i>Thrombosis Research</i> , 2012, 129, 9-16.	1.7	8
1079	Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: A single-center observational study. <i>Thrombosis Research</i> , 2012, 130, 21-26.	1.7	29
1080	Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. <i>American Heart Journal</i> , 2012, 163, 720-728.	2.7	45
1081	Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2012, 110, 845-851.	1.6	120
1082	Warfarin Use in Nursing Home Residents: Results from the 2004 National Nursing Home Survey. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 25-36.e2.	3.0	21
1083	Prestroke Anticoagulation and Paroxysmal Type Are Correlated With Favorable Outcome in Ischemic Stroke Patients With Atrial Fibrillation. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 11-17.	1.6	5

#	ARTICLE	IF	CITATIONS
1084	Detection of Atrial Fibrillation With Concurrent Holter Monitoring and Continuous Cardiac Telemetry Following Ischemic Stroke and Transient Ischemic Attack. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 89-93.	1.6	67
1085	C-reactive protein and transesophageal echocardiographic markers of thromboembolism in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2012, 159, 40-46.	1.7	32
1086	A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 49.	1.7	17
1087	Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management. <i>Thrombosis Journal</i> , 2012, 10, 24.	2.1	9
1088	Persistent Atrial Fibrillation is Associated with a Poor Prognosis in Patients with Atrioventricular Block and Dual-Chamber Pacemaker. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 695-702.	1.2	6
1089	The Role of Anticoagulation in a Patient with Atrial Fibrillation and a CHADS2 Score of 1. <i>Cardiac Electrophysiology Clinics</i> , 2012, 4, 107-117.	1.7	1
1090	New oral anticoagulants in the ED setting: a review. <i>American Journal of Emergency Medicine</i> , 2012, 30, 2046-2054.	1.6	19
1091	Vascular Disease and Stroke Risk in Atrial Fibrillation: A Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2012, 125, 826.e13-826.e23.	1.5	73
1092	Caregiver Assistance Among Medicare Beneficiaries With Atrial Fibrillation and Factors Associated With Anticoagulant Treatment. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 273-283.	3.0	4
1093	Dabigatran in Clinical Practice. <i>Clinical Therapeutics</i> , 2012, 34, 2051-2060.	2.5	14
1094	Left Atrial Appendage Occlusion for Stroke Prevention. <i>Current Problems in Cardiology</i> , 2012, 37, 405-441.	2.4	18
1095	Self-management of oral anticoagulation in elderly patients - Effects on treatment-related Quality of Life. <i>Thrombosis Research</i> , 2012, 130, e60-e66.	1.7	13
1096	New oral anticoagulants for stroke prevention in atrial fibrillation: Evidence from phase III clinical trials. <i>Journal of Indian College of Cardiology</i> , 2012, 2, 112-116.	0.1	0
1099	Atrial Fibrillation Management in Elderly. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 431-442.	2.0	1
1100	Left Atrial Strain Is Reduced in Patients with Atrial Fibrillation, Stroke or TIA, and Low Risk CHADS2 Scores. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 1327-1332.	2.8	79
1101	¿A qu� pacientes beneficia el uso de dabigatr�n? Uso pr�ctico. <i>Revista Espanola De Cardiologia Suplementos</i> , 2012, 12, 37-43.	0.2	1
1102	The risk stratification in atrial fibrillation. <i>Internal and Emergency Medicine</i> , 2012, 7, 233-240.	2.0	7
1103	Modeling gradually changing seasonal variation in count data using state space models: a cohort study of hospitalization rates of stroke in atrial fibrillation patients in Denmark from 1977 to 2011. <i>BMC Medical Research Methodology</i> , 2012, 12, 174.	3.1	6

#	ARTICLE	IF	CITATIONS
1104	Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. Journal of Medical Economics, 2012, 15, 776-785.	2.1	83
1106	A Review of Current Surgical Treatment of Patients with Atrial Fibrillation. Baylor University Medical Center Proceedings, 2012, 25, 218-223.	0.5	17
1107	Dabigatran: Will it Replace Warfarin for Stroke Prevention in Atrial Fibrillation?. Hospital Pharmacy, 2012, 47, 181-186.	1.0	0
1108	Trends in Oral Anticoagulation Therapy Among Korean Patients With Atrial Fibrillation: The KOREan Atrial Fibrillation Investigation. Korean Circulation Journal, 2012, 42, 113.	1.9	21
1109	Open-access approach for atrial fibrillation. British Journal of Cardiac Nursing, 2012, 7, 282-282.	0.1	0
1111	Factors associated with failure to correct the international normalised ratio following fresh frozen plasma administration among patients treated for warfarin-related major bleeding. Thrombosis and Haemostasis, 2012, 107, 662-672.	3.4	13
1112	Impact of CHADS ₂ Score on Neurological Severity and Long-Term Outcome in Atrial		

#	ARTICLE	IF	CITATIONS
1124	Costa "Effectiveness of Clopidogrel Plus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation in Whom Warfarin Is Unsuitable. American Journal of Cardiology, 2012, 109, 1020-1025.	1.6	16
1125	The Impact of Surgical Ablation for Atrial Fibrillation in High-Risk Patients. Annals of Thoracic Surgery, 2012, 93, 1897-1904.	1.3	35
1126	Prevention of stroke in atrial fibrillation: cautious optimism. Lancet Neurology, The, 2012, 11, 203-205.	10.2	1
1127	Rivaroxaban and recurrent stroke prevention in AF. Lancet Neurology, The, 2012, 11, 295-297.	10.2	2
1128	Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurology, The, 2012, 11, 503-511.	10.2	252
1129	Strikingly Low Prevalence of Atrial Fibrillation in Elderly Tanzanians. Journal of the American Geriatrics Society, 2012, 60, 1135-1140.	2.6	32
1130	Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2012, 10, 512-520.	3.8	38
1131	Failure to correct International Normalized Ratio and mortality among patients with warfarin-related major bleeding: an analysis of electronic health records. Journal of Thrombosis and Haemostasis, 2012, 10, 596-605.	3.8	28
1134	Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Family Practice, 2012, 13, 5.	2.9	79
1135	Hematoma risk after needle electromyography. Muscle and Nerve, 2012, 45, 9-12.	2.2	45
1136	Bridging for an isolated subtherapeutic INR: an evaluation of clinical practice patterns, outcomes, and costs from an anticoagulation clinic. Journal of Thrombosis and Thrombolysis, 2012, 33, 28-37.	2.1	2
1137	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary. Catheterization and Cardiovascular Interventions, 2013, 81, E76-123.	1.7	177
1138	Clinically Significant Thrombosis in Pediatric Heart Transplant Recipients During Their Waiting Period. Pediatric Cardiology, 2013, 34, 334-340.	1.3	6
1139	Supraventricular and Ventricular Arrhythmias. Primary Care - Clinics in Office Practice, 2013, 40, 43-71.	1.6	6
1140	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology, 2013, 62, 1495-1539.	2.8	276
1141	A review of current agents for anticoagulation for the critical care practitioner. Journal of Critical Care, 2013, 28, 763-774.	2.2	3
1142	Novel oral anticoagulants in secondary prevention of stroke. Best Practice and Research in Clinical Haematology, 2013, 26, 131-139.	1.7	9
1143	Bleeding Risk in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Systematic Review and Meta-Analysis. Clinical Pharmacology and Therapeutics, 2013, 94, 367-375.	4.7	25

#	ARTICLE	IF	CITATIONS
1144	Safety and Efficacy of New Anticoagulants in Patients with Heart Failure. Current Heart Failure Reports, 2013, 10, 18-25.	3.3	3
1145	Atrial Fibrillation and Race – A Contemporary Review. Current Cardiovascular Risk Reports, 2013, 7, 336-345.	2.0	44
1146	Mechanical closure of the left atrial appendage: Is it time to be more aggressive?. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 1018-1027.e2.	0.8	28
1147	Guidelines for Performing a Comprehensive Transesophageal Echocardiographic Examination: Recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. Journal of the American Society of Echocardiography, 2013, 26, 921-964.	2.8	966
1148	Transcatheter Left Atrial Appendage Occlusion. Cardiology Clinics, 2013, 31, 363-384.	2.2	1
1149	Gender and the risk of stroke in atrial fibrillation: impact of old and new anticoagulation regimens. Clinical Research in Cardiology Supplements, 2013, 8, 38-45.	2.0	1
1150	Bleeding as an Outcome Among Patients With Nonvalvular Atrial Fibrillation in a Large Managed Care Population. Clinical Therapeutics, 2013, 35, 1536-1545.e1.	2.5	18
1151	Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation. International Journal of Cardiology, 2013, 166, 205-209.	1.7	25
1152	Emergency Management of Palpitations in the Elderly. Clinics in Geriatric Medicine, 2013, 29, 205-230.	2.6	6
1153	2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation, 2013, 128, e240-327.	1.6	2,335
1154	Remote Monitoring for Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2013, 5, 357-364.	1.7	0
1155	Acute Exposure to Air Pollution Triggers Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 62, 816-825.	2.8	168
1156	New cerebral microbleeds in ischemic stroke patients on warfarin treatment: Two-year follow-up. Clinical Neurology and Neurosurgery, 2013, 115, 1682-1685.	1.4	38
1157	Does CHA2DS2-VASc Improve Stroke Risk Stratification in Postmenopausal Women with Atrial Fibrillation?. American Journal of Medicine, 2013, 126, 1143.e1-1143.e8.	1.5	13
1158	Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. Cardiology and Therapy, 2013, 2, 135-149.	2.6	37
1159	Optimal treatment duration of venous thrombosis. Journal of Thrombosis and Haemostasis, 2013, 11, 151-160.	3.8	16
1160	Management of Intracerebral Hemorrhage in the Presence of Anticoagulant Therapy. Topics in Stroke Rehabilitation, 2013, 20, 131-138.	1.9	1
1161	Which Oral Anticoagulant for Which Atrial Fibrillation Patient: Recent Clinical Trials and Evidence-Based Choices. Canadian Journal of Cardiology, 2013, 29, 1165-1172.	1.7	16

#	ARTICLE	IF	CITATIONS
1162	Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Review of Cardiovascular Therapy, 2013, 11, 1029-1049.	1.5	4
1163	Influence of blood pressure on atrial fibrillation. Expert Review of Cardiovascular Therapy, 2013, 11, 657-659.	1.5	0
1164	Impact of restarting warfarin therapy in renal disease anticoagulated patients with gastrointestinal hemorrhage. Renal Failure, 2013, 35, 1228-1235.	2.1	27
1165	Atherosclerosis and thromboembolic risk in atrial fibrillation: Focus on peripheral vascular disease. Annals of Medicine, 2013, 45, 274-290.	3.8	25
1166	New Avenues for Anticoagulation in Atrial Fibrillation. Clinical Pharmacology and Therapeutics, 2013, 93, 68-77.	4.7	21
1167	The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin (CME). Transfusion, 2013, 53, 1451-1458.	1.6	36
1168	Epidemiología de la fibrilación auricular en España. Revista Española De Cardiología Suplementos, 2013, 13, 3-8.	0.2	3
1169	Stroke Prevention in Atrial Fibrillation in Heart Failure. Heart Failure Clinics, 2013, 9, 427-435.	2.1	2
1170	Sex differences in clinical presentation, severity and outcome of stroke: Results from a hospital-based registry. European Journal of Internal Medicine, 2013, 24, 167-171.	2.2	60
1171	The Evolving Role of Stroke Prediction Schemes for Patients With Atrial Fibrillation. Canadian Journal of Cardiology, 2013, 29, 1173-1180.	1.7	11
1172	Electromyography and Anticoagulation. PM and R, 2013, 5, S3-7.	1.6	13
1174	Metabolic syndrome and atrial fibrillation in patients with essential hypertension. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 109-114.	2.6	19
1175	Detection of left atrial thrombus during routine diagnostic work-up prior to pulmonary vein isolation for atrial fibrillation: Role of transesophageal echocardiography and multidetector computed tomography. International Journal of Cardiology, 2013, 163, 26-33.	1.7	73
1177	New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery. Journal of Clinical Neuroscience, 2013, 20, 1350-1356.	1.5	10
1178	Thromboembolism in patients with nonvalvular atrial fibrillation: Comparison between Asian and Western countries. Journal of Cardiology, 2013, 61, 1-7.	1.9	23
1179	Is Emergency Department Cardioversion of Recent-onset Atrial Fibrillation Safe and Effective?. Journal of Emergency Medicine, 2013, 45, 117-127.	0.7	16
1180	The type of atrial fibrillation is associated with long-term outcome in patients with acute ischemic stroke. International Journal of Cardiology, 2013, 167, 1519-1523.	1.7	22
1181	Warfarin Use and Stroke Risk Among Patients With Nonvalvular Atrial Fibrillation in a Large Managed Care Population. Clinical Therapeutics, 2013, 35, 1201-1210.	2.5	38

#	ARTICLE	IF	CITATIONS
1182	Evaluación de riesgo tromboembólico y hemorrágico de los pacientes con fibrilación auricular. Revista Española De Cardiología Suplementos, 2013, 13, 9-13.	0.2	6
1183	Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. Journal of Electrocardiology, 2013, 46, 45-50.	0.9	23
1184	Anticoagulation in heart failure: current status and future direction. Heart Failure Reviews, 2013, 18, 797-813.	3.9	28
1185	The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. Thrombosis and Haemostasis, 2013, 109, 431-439.	3.4	32
1186	Risk versus Benefit of Non-Vitamin K Dependent Anticoagulants Compared to Warfarin for the Management of Atrial Fibrillation in the Elderly. Drugs and Aging, 2013, 30, 513-525.	2.7	16
1187	Efficacy and Safety of Omega-3 Fatty Acids for the Prevention of Atrial Fibrillation: A Meta-analysis. Canadian Journal of Cardiology, 2013, 29, 196-203.	1.7	34
1188	Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. International Journal of Clinical Practice, 2013, 67, 647-655.	1.7	4
1189	2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2013, 62, e147-e239.	2.8	7,017
1190	Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Archives of Cardiovascular Diseases, 2013, 106, 303-323.	1.6	48
1191	Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 724-731.	2.2	71
1192	Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation. Stroke, 2013, 44, 1676-1681.	2.0	233
1193	Gender differences in patients with atrial fibrillation. Herzschrittmachertherapie Und Elektrophysiologie, 2013, 24, 176-183.	0.8	9
1194	The Pharmacology and Therapeutic Use of Dabigatran Etxilate. Journal of Clinical Pharmacology, 2013, 53, 1-13.	2.0	22
1195	Mild elevations of international normalized ratio at hospital Day 1 and risk of expansion in warfarin-associated subdural hematomas. Journal of Neurosurgery, 2013, 119, 1050-1057.	1.6	3
1196	Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart, 2013, 99, 127-132.	2.9	72
1197	Recent Advances in Antithrombotic Therapy for Stroke Prevention in Patients With Atrial Fibrillation. Hospital Practice (1995), 2013, 41, 49-60.	1.0	0
1198	Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 29-42.	1.4	7
1199	New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: More Choices Bring More Challenges. Hospital Pharmacy, 2013, 48, 366-371.	1.0	2

#	ARTICLE	IF	CITATIONS
1200	Novel anticoagulants for stroke prevention in atrial fibrillation among diabetics. British Journal of Diabetes and Vascular Disease, 2013, 13, 51-55.	0.6	1
1201	Risks and Benefits of Anticoagulation in Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 461-469.	2.2	78
1202	Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. Circulation: Heart Failure, 2013, 6, 740-747.	3.9	102
1203	Vascular cognitive impairment. Current Opinion in Neurology, 2013, 26, 29-36.	3.6	61
1204	Dabigatran: A Cause of Hematologic Emergency. American Journal of the Medical Sciences, 2013, 346, 190-193.	1.1	17
1205	Higher Persistence in Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran Versus Warfarin. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 567-574.	2.2	131
1206	Association Between Panic Disorder and Risk of Atrial Fibrillation. Psychosomatic Medicine, 2013, 75, 30-35.	2.0	30
1207	The unappreciated importance of blood pressure in recent and older atrial fibrillation trials. Journal of Hypertension, 2013, 31, 2109-2117.	0.5	19
1208	A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score. Journal of the American Heart Association, 2013, 2, e000250.	3.7	315
1209	Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation. Heart, 2013, 99, 17-21.	2.9	25
1210	Stroke Prevention in Patients With Atrial Fibrillation: Focus on New Oral Anticoagulants. Postgraduate Medicine, 2013, 125, 155-161.	2.0	1
1211	Modeling of the Impact on Health Outcomes of the Use of Dabigatran in Patients with Atrial Fibrillation. Cerebrovascular Diseases, 2013, 35, 320-326.	1.7	2
1212	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Circulation, 2013, 128, 1810-1852.	1.6	2,807
1213	Treatment algorithm for oral anticoagulant and antiplatelet therapy in epistaxis patients. Journal of Laryngology and Otology, 2013, 127, 483-488.	0.8	26
1214	Stroke Prevention in Atrial Fibrillation in Older Adults: Existing Knowledge Gaps and Areas for Innovation: A Summary of an American Federation for Aging Research Seminar. Journal of the American Geriatrics Society, 2013, 61, 1798-1803.	2.6	14
1215	Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2013, 11, 1619-1629.	1.5	15
1216	Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives. Expert Review of Cardiovascular Therapy, 2013, 11, 77-90.	1.5	10
1217	Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?. European Heart Journal, 2013, 34, 1041-1049.	2.2	141

#	ARTICLE	IF	CITATIONS
1218	A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE. Expert Review of Cardiovascular Therapy, 2013, 11, 1105-1114.	1.5	7
1219	Guideline Adherence of Antithrombotic Treatment Initiated by General Practitioners in Patients With Nonvalvular Atrial Fibrillation: A Danish Survey. Clinical Cardiology, 2013, 36, 427-432.	1.8	24
1220	Vitamin K antagonists in patients with nonvalvular atrial fibrillation. Journal of Cardiovascular Medicine, 2013, 14, 534-540.	1.5	7
1221	Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation." Thrombosis and Haemostasis, 2013, 110, 493-495.	3.4	12
1222	Female sex as an independent risk factor for stroke in atrial fibrillation: Possible mechanisms. Thrombosis and Haemostasis, 2014, 111, 385-391.	3.4	90
1223	Location and Characteristics of Warfarin Associated Intracranial Hemorrhage. Journal of Cerebrovascular and Endovascular Neurosurgery, 2014, 16, 184.	0.5	4
1224	Comparison Between CHA ₂ DS ₂ -VASc Score for Risk Stratification of Ischemic Stroke in Japanese Patients With Non-Valvular Paroxysmal Atrial Fibrillation Not Receiving Anticoagulant Therapy. International Heart Journal, 2014, 55, 119-125.	1.0	19
1225	Improving ablation strategies for the treatment of atrial fibrillation. Expert Review of Medical Devices, 2014, 11, 77-88.	2.8	1
1226	Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 955-967.	0.5	124
1227	Is screening for AF worthwhile? Stroke risk in a screened population from the SAFE study. Family Practice, 2014, 31, 298-302.	1.9	19
1229	Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. European Heart Journal, 2014, 35, 1457-1465.	2.2	174
1230	Cryptogenic stroke and diabetes: a probable link between silent atrial fibrillation episodes and cerebrovascular disease. Expert Review of Cardiovascular Therapy, 2014, 12, 323-329.	1.5	4
1231	Use of blood products in patients with anticoagulant-related major bleeding: An analysis of in-hospital outcomes. American Journal of Health-System Pharmacy, 2014, 71, 1635-1645.	1.0	1
1232	Effect of Hyperthyroidism on the Hypercoagulable State and Thromboembolic Events in Patients with Atrial Fibrillation. Cardiology, 2014, 127, 176-182.	1.4	25
1233	Awareness of the Role of Atrial Fibrillation as a Cause of Ischemic Stroke. Stroke, 2014, 45, e19-21.	2.0	7
1234	Stroke and Transient Ischemic Attack. , 2014, , 433-443.		1
1235	Evaluation of the WATCHMAN left atrial appendage closure device. Expert Review of Medical Devices, 2014, 11, 541-551.	2.8	6
1236	Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 628-636.	1.5	9

#	ARTICLE	IF	CITATIONS
1237	Oral anticoagulants for Asian patients with atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2014, 11, 290-303.	13.7	36
1238	Neurologic complications of arrhythmia treatment. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014, 119, 129-150.	1.8	2
1239	Incidence, Mortality, and Risk Factors for Oral Anticoagulant-associated Intracranial Hemorrhage in Patients with Atrial Fibrillation. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 2479-2488.	1.6	22
1240	Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. <i>Digestive Endoscopy</i> , 2014, 26, 1-14.	2.3	341
1241	Intracardiac Thrombosis in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 1359-1362.	1.7	16
1242	Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 575-585.	2.6	24
1243	Physician's Fear of Anticoagulant Therapy in Nonvalvular Atrial Fibrillation. <i>American Journal of the Medical Sciences</i> , 2014, 348, 513-521.	1.1	46
1244	Emergent Reversal of Oral Anticoagulation. <i>AACN Advanced Critical Care</i> , 2014, 25, 5-12.	1.1	1
1245	Patients'™ Preferences in Anticoagulant Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 912-919.	2.2	28
1246	Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making. <i>Therapeutic Advances in Drug Safety</i> , 2014, 5, 21-37.	2.4	13
1248	Vitamin K Antagonist Treatment in Patients With Atrial Fibrillation and Time in Therapeutic Range in Four European Countries. <i>Clinical Therapeutics</i> , 2014, 36, 1160-1168.	2.5	54
1249	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. <i>Europace</i> , 2014, 16, 1397-1416.	1.7	259
1250	Role of video-assisted thoracoscopy in the management of stroke. <i>Asian Cardiovascular and Thoracic Annals</i> , 2014, 22, 155-159.	0.5	3
1251	Evaluation and Prevention of Cardioembolic Stroke. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2014, 20, 309-322.	0.8	3
1252	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 130, e199-267.	1.6	3,471
1253	Profile of CZECH AF 2012. Profile of atrial fibrillation patients receiving antithrombotic therapy. <i>Cor Et Vasa</i> , 2014, 56, e207-e216.	0.1	3
1255	Risk factors and incidence of stroke and MACE in Chinese atrial fibrillation patients presenting to emergency departments: A national wide database analysis. <i>International Journal of Cardiology</i> , 2014, 173, 242-247.	1.7	21
1257	Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation. <i>Heart Failure Reviews</i> , 2014, 19, 305-313.	3.9	24

#	ARTICLE	IF	CITATIONS
1258	Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis. <i>Clinical Drug Investigation</i> , 2014, 34, 9-17.	2.2	53
1259	Incidence and Cost of Stroke and Hemorrhage in Patients Diagnosed with Atrial Fibrillation in France. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, e73-e83.	1.6	32
1260	Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 87-96.	2.1	6
1261	Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use—learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 150-159.	2.1	62
1262	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 64, e1-e76.	2.8	3,332
1263	Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2141-2147.	2.8	308
1264	Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation. <i>Neurology</i> , 2014, 82, 716-724.	1.1	110
1265	Atrial Fibrillation and Stroke. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 31-41.	1.7	2
1266	Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: A special reference to low-intensity warfarin therapy. <i>Journal of Cardiology</i> , 2014, 64, 127-132.	1.9	15
1267	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. <i>Circulation</i> , 2014, 130, 2071-2104.	1.6	1,803
1268	Practical Considerations in the Use of Novel Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation. <i>Cardiovascular Therapeutics</i> , 2014, 32, 74-81.	2.5	8
1269	Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. <i>European Heart Journal</i> , 2014, 35, 1881-1887.	2.2	96
1270	Bleeding complications related to warfarin treatment: a descriptive register study from the anticoagulation clinic at Helsingborg Hospital. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 98-104.	2.1	16
1271	Diagnostic Evaluation and Follow-Up of Patients with Atrial Fibrillation. <i>Cardiology Clinics</i> , 2014, 32, 507-519.	2.2	3
1272	PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease. <i>Canadian Journal of Cardiology</i> , 2014, 30, e1-e63.	1.7	200
1273	Does warfarin-related intracerebral haemorrhage lead to higher costs of management?. <i>Clinical Neurology and Neurosurgery</i> , 2014, 126, 38-42.	1.4	2
1274	Effect of preinjury warfarin use on outcomes after head trauma in Medicare beneficiaries. <i>American Journal of Surgery</i> , 2014, 208, 544-549.e1.	1.8	39
1275	Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 1093-1102.	5.0	10

#	ARTICLE	IF	CITATIONS
1276	Anticoagulation-related reduction of first-ever stroke severity in Chinese patients with atrial fibrillation. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1755-1760.	1.5	9
1277	Mechanical Discordance of the Left Atrium and Appendage. <i>Stroke</i> , 2014, 45, 1481-1484.	2.0	44
1278	Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. <i>Current Problems in Cardiology</i> , 2014, 39, 319-344.	2.4	5
1279	Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update. <i>Open Heart</i> , 2014, 1, e000020.	2.3	52
1280	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, e153-e193.	0.8	236
1281	The Clinical Profile and Pathophysiology of Atrial Fibrillation. <i>Circulation Research</i> , 2014, 114, 1453-1468.	4.5	899
1282	The Impact of Heart Failure and Left Ventricular Dysfunction in Predicting Stroke, Thromboembolism, and Mortality in Atrial Fibrillation Patients: A Systematic Review. <i>Clinical Therapeutics</i> , 2014, 36, 1135-1144.	2.5	57
1283	Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. <i>Thrombosis Journal</i> , 2014, 12, 14.	2.1	86
1284	Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. <i>Stroke</i> , 2014, 45, 2160-2236.	2.0	3,891
1285	Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) Database. <i>Clinical Research in Cardiology</i> , 2014, 103, 887-893.	3.3	21
1286	Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 247-262.	2.6	5
1287	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2246-2280.	2.8	569
1288	Prevalence of Atrial Fibrillation in Spain. OFRECE Study Results. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 259-269.	0.6	98
1289	Left Atrial Appendage Exclusion for Prevention of Stroke in Atrial Fibrillation: Review of Minimally Invasive Approaches. <i>Current Cardiology Reports</i> , 2014, 16, 448.	2.9	15
1290	Use of Novel Oral Anticoagulants in Patients With Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 285.	0.9	4
1291	Statins Improve Survival in Patients With Cardioembolic Stroke. <i>Stroke</i> , 2014, 45, 1849-1852.	2.0	36
1292	The association of asthma and atrial fibrillation – A nationwide population-based nested case-control study. <i>International Journal of Cardiology</i> , 2014, 176, 464-469.	1.7	37
1293	Drug Therapies for Stroke Prevention in Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 61-78.	1.7	0

#	ARTICLE	IF	CITATIONS
1294	Complications of Perioperative Warfarin Therapy in Total Knee Arthroplasty. <i>Journal of Arthroplasty</i> , 2014, 29, 320-324.	3.1	24
1295	Um estudo de qualidade numa unidade de saúde familiar para a melhoria da qualidade da terapêutica profilática antitrombótica prescrita a doentes com fibrilhação auricular. <i>Revista Portuguesa De Cardiologia</i> , 2014, 33, 89-94.	0.5	4
1296	Rationale for Left Atrial Appendage Exclusion. <i>Interventional Cardiology Clinics</i> , 2014, 3, 203-208.	0.4	0
1297	Meta-Analysis of Gender Differences in Residual Stroke Risk and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants. <i>American Journal of Cardiology</i> , 2014, 113, 485-490.	1.6	171
1298	A quality study to improve prophylactic antithrombotic therapy prescribed to patients with atrial fibrillation. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2014, 33, 89-94.	0.2	4
1299	Stroke and Bleeding Risks in Patients with Atrial Fibrillation. <i>Interventional Cardiology Clinics</i> , 2014, 3, 175-190.	0.4	0
1300	PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease. <i>Heart Rhythm</i> , 2014, 11, e102-e165.	0.7	585
1301	Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 381-390.	1.6	16
1302	Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation – Quality and Cost Implications. <i>American Journal of Medicine</i> , 2014, 127, 1075-1082.e1.	1.5	199
1303	Current status of atrial pacing algorithms for the prevention of atrial fibrillation: Should algorithms be used?. <i>Journal of Arrhythmia</i> , 2014, 30, 77-81.	1.2	1
1304	The Impact of Age on the Epidemiology of Atrial Fibrillation Hospitalizations. <i>American Journal of Medicine</i> , 2014, 127, 158.e1-158.e7.	1.5	40
1305	Atrial Fibrillation and Congestive Heart Failure. <i>Heart Failure Clinics</i> , 2014, 10, 305-318.	2.1	19
1306	Transesophageal Echocardiography in Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 43-59.	1.7	4
1307	Atrial fibrillation: Stroke prevention in focus. <i>Australian Critical Care</i> , 2014, 27, 92-98.	1.3	18
1308	PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: Executive Summary. <i>Heart Rhythm</i> , 2014, 11, e81-e101.	0.7	33
1309	Long-term Adherence to National Guidelines for Secondary Prevention of Ischemic Stroke: A Prospective Cohort Study in a Public Hospital in Chile. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 490-495.	1.6	5
1310	Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. <i>Thrombosis and Haemostasis</i> , 2014, 111, 233-239.	3.4	43
1311	Research into practice: management of atrial fibrillation in general practice. <i>British Journal of General Practice</i> , 2014, 64, 540-542.	1.4	4

#	ARTICLE	IF	CITATIONS
1312	Prediction of Congestive Heart Failure in Patients with Non Valvular Atrial Fibrillation. Internal Medicine, 2014, 53, 7-12.	0.7	10
1313	Stroke and Bleeding Risk in Atrial Fibrillation: Navigating the Alphabet Soup of Risk Score Acronyms (CHADS ₂ , CHA ₂ DS ₂ -VASc, R ₂ -CHADS ₂), Tj ETQ ₁ 1 0.784314 rgB	1.1	14
1314	Stroke prevention in atrial fibrillation: An Asian perspective. Thrombosis and Haemostasis, 2014, 112, 789-797.	3.4	231
1315	Long-term Outcomes Following Development of New-Onset Atrial Fibrillation During Sepsis. Chest, 2014, 146, 1187-1195.	0.8	195
1316	The Impact of Smoking on Thromboembolism and Mortality in Patients With Incident Atrial Fibrillation. Chest, 2014, 145, 559-566.	0.8	54
1317	Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method. Therapeutic Drug Monitoring, 2015, 37, 375-380.	2.0	8
1318	A convenient method for semiautomatic atrial body segmentation. , 2015, , .		0
1319	Validation of Risk Scoring System Excluding Female Sex From CHA ₂ DS ₂ -VASc in Japanese Patients With Nonvalvular Atrial Fibrillation—Subanalysis of the J-RHYTHM Registry. Circulation Journal, 2015, 79, 1719-1726.	1.6	44
1320	Methods and characteristics of published network meta-analyses using individual patient data: protocol for a scoping review. BMJ Open, 2015, 5, e007103-e007103.	1.9	22
1321	Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A single-center observational study. Journal of Arrhythmia, 2015, 31, 339-344.	1.2	45
1322	Detecting and Diagnosing Atrial Fibrillation (D2AF): study protocol for a cluster randomised controlled trial. Trials, 2015, 16, 478.	1.6	29
1323	Combined antithrombotic therapy of potential value in acute atrial fibrillation related stroke. European Journal of Neurology, 2015, 22, 1027-1028.	3.3	2
1324	Comparison of the international normalized ratio levels obtained by portable coagulometer and laboratory in a clinic specializing in oral anticoagulation. International Journal of Laboratory Hematology, 2015, 37, 536-543.	1.3	16
1325	Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis. BMC Cardiovascular Disorders, 2015, 15, 104.	1.7	3
1326	A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. Thrombosis Journal, 2015, 13, 29.	2.1	1
1327	Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials, 2015, 16, 393.	1.6	59
1328	Incident atrial fibrillation in the emergency department in Ontario: a population-based retrospective cohort study of follow-up care. CMAJ Open, 2015, 3, E182-E191.	2.4	12
1329	Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence. Thrombosis and Haemostasis, 2015, 114, 1156-1164.	3.4	14

#	ARTICLE	IF	CITATIONS
1330	New Approach to Exclude the Left Atrial Appendage during Minimally Invasive Cryothermic Surgical Ablation. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2015, 10, 323-327.	0.9	16
1331	Factors Associated with Ischemic Stroke on Therapeutic Anticoagulation in Patients with Nonvalvular Atrial Fibrillation. Yonsei Medical Journal, 2015, 56, 410.	2.2	9
1332	Association Between Left Atrial Appendage Morphology Evaluated by Trans-Esophageal Echocardiography and Ischemic Cerebral Stroke in Patients With Atrial Fibrillation. International Heart Journal, 2015, 56, 329-334.	1.0	11
1333	New Approach to Exclude the Left Atrial Appendage during Minimally Invasive Cryothermic Surgical Ablation. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2015, 10, 323-327.	0.9	7
1334	Clinical Characteristics and Impact of Diabetes Mellitus on Outcomes in Patients with Nonvalvular Atrial Fibrillation. Yonsei Medical Journal, 2015, 56, 62.	2.2	12
1335	Atrial Fibrillation: Pathophysiology and Therapeutic Options. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 1333-1340.	1.3	32
1336	Novel oral anticoagulants and reversal agents: Considerations for clinical development. American Heart Journal, 2015, 169, 751-757.	2.7	69
1337	A Unified Framework for Classification of Methods for Benefit-Risk Assessment. Value in Health, 2015, 18, 250-259.	0.3	16
1338	Management and prognosis of atrial fibrillation in the diabetic patient. Expert Review of Cardiovascular Therapy, 2015, 13, 643-651.	1.5	17
1339	Strategies to Incorporate Left Atrial Appendage Occlusion Into Clinical Practice. Journal of the American College of Cardiology, 2015, 65, 2337-2344.	2.8	11
1341	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Journal of the American Heart Association, 2015, 4, .	3.7	68
1342	Real-time physiologic biomarker for prediction of atrial fibrillation recurrence, stroke, and mortality after electrical cardioversion: A prospective observational study. American Heart Journal, 2015, 170, 914-922.	2.7	21
1343	The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology, 2015, 31, 1207-1218.	1.7	43
1344	Stroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation. Medicine (United States), 2015, 94, e2364.	1.0	2
1345	Análisis coste-efectividad de apixabán frente a acenocumarol en la prevención del ictus en pacientes con fibrilación auricular no valvular en España. Revista Espanola De Cardiologia, 2015, 68, 680-690.	1.2	22
1346	Percutaneous Left Atrial Appendage Closure With the Watchman Device. JACC: Cardiovascular Interventions, 2015, 8, 1915-1921.	2.9	44
1347	Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study. Value in Health, 2015, 18, 1057-1062.	0.3	3
1348	The New Canadian Cardiovascular Society Algorithm for Antithrombotic Therapy of Atrial Fibrillation Is Appropriately Based on Current Epidemiologic Data. Canadian Journal of Cardiology, 2015, 31, 20-23.	1.7	8

#	ARTICLE	IF	CITATIONS
1349	A circulating biomarker risk-prediction model correlates with CHADS-2 risk score in chronic atrial fibrillation. <i>IJC Metabolic & Endocrine</i> , 2015, 6, 24-26.	0.5	5
1350	Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. <i>European Heart Journal</i> , 2015, 36, 297-306.	2.2	140
1351	Dementia in patients with atrial fibrillation and the value of the <sc>H</sc>achinski ischemic score. <i>Geriatrics and Gerontology International</i> , 2015, 15, 770-777.	1.5	23
1352	Topical use of antithrombotics: Review of literature. <i>Thrombosis Research</i> , 2015, 135, 575-581.	1.7	10
1353	Probl�me des INR en EHPAD�: un protocole pourquoi�? Un protocole comment�?. <i>NPG Neurologie - Psychiatrie - Geriatrie</i> , 2015, 15, 138-146.	0.2	0
1354	The Association Between Thromboembolic Complications and Blood Group in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2015, 90, 216-223.	3.0	9
1355	Left atrial appendage closure (WATCHMAN�,�) after bleeding complications during oral anticoagulant therapy in high risk patients. <i>Journal of Indian College of Cardiology</i> , 2015, 5, 25-28.	0.1	0
1356	Thromboembolic Prevention in Frail Elderly Patients With Atrial Fibrillation: A Practical Algorithm. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 358-364.	2.5	41
1357	A jumping left atrial thrombus connected to a pulmonary vein thrombus using transthoracic echocardiography and 64-slice multi-detector computed tomography. <i>IJC Heart and Vasculature</i> , 2015, 6, 32-34.	1.1	5
1358	Adding Rigor to Stroke Risk Prediction in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 233-235.	2.8	13
1359	Cost-effectiveness Analysis Comparing Apixaban and Acenocoumarol in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 680-690.	0.6	14
1360	One-Year Outcomes of Emergency Department Patients With Atrial Fibrillation. <i>Angiology</i> , 2015, 66, 745-752.	1.8	12
1361	Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 149-154.	2.1	32
1362	Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. <i>Journal of Internal Medicine</i> , 2015, 278, 1-18.	6.0	64
1363	Left Atrial Appendage Occlusion for Stroke Prevention. <i>Current Problems in Cardiology</i> , 2015, 40, 429-476.	2.4	10
1364	Protocol for Cerebral Microbleeds during the Non��Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients with Nonvalvular Atrial Fibrillation (CMB-NOW) Study: Multisite Pilot Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 2143-2148.	1.6	10
1365	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). <i>American Heart Journal</i> , 2015, 170, 675-682.e8.	2.7	128
1366	Atrial Fibrillation and Heart Failure: Update 2015. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 126-135.	3.1	50

#	ARTICLE	IF	CITATIONS
1367	Patients with atrial fibrillation and CHA2DS2-VASc score 1: ¿To anticoagulate or not to anticoagulate? That is the question! Heart Rhythm, 2015, 12, 2515-2520.	0.7	5
1368	Coagulopathy and Anticoagulation During Thoracic Surgery. Thoracic Surgery Clinics, 2015, 25, 309-323.	1.0	5
1369	Atrial Fibrillation Burden and Short-Term Risk of Stroke. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1040-1047.	4.8	168
1370	New oral anticoagulants in severe trauma patients: Enemy at the gates?. Medicina Intensiva (English) Tj ETQq1 1 0.784314 rgBT /Overlo	0.2	3
1371	Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making. Current Medical Research and Opinion, 2015, 31, 603-614.	1.9	32
1372	Antiplatelet and Anticoagulant Therapy After Intracerebral Hemorrhage. Neurologic Clinics, 2015, 33, 329-345.	1.8	7
1373	Weighing the risks: Thrombotic and bleeding events in adults with atrial arrhythmias and congenital heart disease. International Journal of Cardiology, 2015, 186, 315-320.	1.7	27
1374	Nuevos anticoagulantes orales en el paciente traumatizado grave: ¿enemigo a las puertas?. Medicina Intensiva, 2015, 39, 167-171.	0.7	7
1376	Is diabetes a hypercoagulable state? A critical appraisal. Acta Diabetologica, 2015, 52, 1007-1016.	2.5	44
1377	Fibrotic Atrial Cardiomyopathy, Atrial Fibrillation, and Thromboembolism. Journal of the American College of Cardiology, 2015, 65, 2239-2251.	2.8	173
1378	Holter monitoring to detect silent atrial fibrillation in high-risk subjects: the Perugia General Practitioner Study. Internal and Emergency Medicine, 2015, 10, 595-601.	2.0	12
1379	Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure. Stroke, 2015, 46, 667-672.	2.0	46
1380	Misconceptions and Facts About Atrial Fibrillation. American Journal of Medicine, 2015, 128, 938-942.	1.5	9
1381	Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. Expert Opinion on Drug Safety, 2015, 14, 683-695.	2.4	9
1382	Dabigatran for the prevention and treatment of thromboembolic disorders. Expert Review of Cardiovascular Therapy, 2015, 13, 529-540.	1.5	6
1383	Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting. Clinical Drug Investigation, 2015, 35, 693-705.	2.2	6
1384	The Impact of Uninterrupted Warfarin on Hand and Wrist Surgery. Journal of Hand Surgery, 2015, 40, 2133-2140.	1.6	19
1385	Gaps and Resemblances in Current Heart Failure Guidelines. Heart Failure Clinics, 2015, 11, 529-541.	2.1	1

#	ARTICLE	IF	CITATIONS
1386	Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in nonâ€œvalvular atrial fibrillation patients: a multicenter propensityâ€œmatched analysis. Journal of Thrombosis and Haemostasis, 2015, 13, 182-190.	3.8	28
1387	Underuse of Oral Anticoagulation for Individuals with Atrial Fibrillation in a Nursing Home Setting in France: Comparisons of Resident Characteristics and Physician Attitude. Journal of the American Geriatrics Society, 2015, 63, 71-76.	2.6	79
1388	Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina. Health Economics Review, 2015, 5, 52.	2.0	11
1389	Recommendations for Perioperative Management of Patients on Existing Anticoagulation Therapy. JBJS Reviews, 2015, 3, .	2.0	3
1390	Contour-Driven Atlas-Based Segmentation. IEEE Transactions on Medical Imaging, 2015, 34, 2492-2505.	8.9	34
1391	Left Ventricular Systolic Dysfunction by Longitudinal Strain Is an Independent Predictor of Incident Atrial Fibrillation. Circulation: Cardiovascular Imaging, 2015, 8, e003520.	2.6	39
1392	Republished: Left atrial appendage occlusion. Postgraduate Medical Journal, 2015, 91, 527-534.	1.8	0
1393	Age, Ethnicity, and Stroke Risk in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2015, 66, 1348-1349.	2.8	1
1394	Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF. Journal of the American College of Cardiology, 2015, 66, 2728-2739.	2.8	86
1395	Left atrial appendage occlusion. Heart, 2015, 101, 834-841.	2.9	8
1396	Management of Extracranial Carotid Artery Disease. Cardiology Clinics, 2015, 33, 1-35.	2.2	68
1397	Effect of Obstructive Sleep Apnea on Frequency of Stroke in Patients With Atrial Fibrillation. American Journal of Cardiology, 2015, 115, 461-465.	1.6	82
1398	Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation. Pharmacoeconomics, 2015, 33, 271-283.	3.3	22
1399	Early results with the LARIAT device for left atrial appendage exclusion in patients with atrial fibrillation at high risk for stroke and anticoagulation. Catheterization and Cardiovascular Interventions, 2015, 86, 121-127.	1.7	67
1400	Management of Atrial Fibrillation. Journal of Intensive Care Medicine, 2015, 30, 484-498.	2.8	5
1401	Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States. Journal of Thrombosis and Thrombolysis, 2015, 39, 508-515.	2.1	11
1402	Comparison of Frequency and Outcome of Major Gastrointestinal Hemorrhage in Patients With Atrial Fibrillation on Versus Not Receiving Warfarin Therapy (from the ATRIA and ATRIA-CVRN Cohorts). American Journal of Cardiology, 2015, 115, 40-46.	1.6	15
1403	Perioperative complications in patients on lowâ€œmolecularâ€œweight heparin bridging therapy. ANZ Journal of Surgery, 2016, 86, 167-172.	0.7	7

#	ARTICLE	IF	CITATIONS
1404	Renal Function and Treatment Persistence with Non-Vitamin K Antagonist Oral Anticoagulants in Japanese Patients with Atrial Fibrillation: A Single-Center Experience. Japanese Journal of Clinical Pharmacology and Therapeutics, 2016, 47, 115-122.	0.1	1
1405	Incidence and Risk Factors for Atrial Fibrillation in Korea: the National Health Insurance Service Database (2002â€“2010). Korean Circulation Journal, 2016, 46, 515.	1.9	48
1406	Primary prevention of cardiovascular disease. Tenri Medical Bulletin, 2016, 19, 90-94.	0.1	0
1407	Managing reversal of direct oral anticoagulants in emergency situations. Thrombosis and Haemostasis, 2016, 116, 1003-1010.	3.4	39
1408	Radiofrequency Catheter Ablation Improves the Quality of Life Measured with a Short Form-36 Questionnaire in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0163755.	2.5	30
1409	Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation. Thrombosis and Haemostasis, 2016, 115, 663-677.	3.4	62
1410	Who Were the Early Adopters of Dabigatran?. Medical Care, 2016, 54, 725-732.	2.4	21
1411	Costâ€Effectiveness of Highâ€Dose Edoxaban Compared with Adjustedâ€Dose Warfarin for Stroke Prevention in Nonâ€Valvular Atrial Fibrillation Patients. Pharmacotherapy, 2016, 36, 488-495.	2.6	14
1412	Thoracoscopic Ablation with Appendage Ligation versus Medical Therapy for Stroke Prevention a Proof-of-Concept Randomized Trial. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2016, 11, 99-105.	0.9	10
1413	2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter. Journal of the American College of Cardiology, 2016, 68, 525-568.	2.8	55
1414	2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 443-488.	2.2	32
1416	Effect of vitamin K2 on the anticoagulant activity of warfarin during the perioperative period of catheter ablation: Population analysis of retrospective clinical data. Journal of Pharmaceutical Health Care and Sciences, 2016, 2, 17.	1.0	2
1419	Longitudinal relationships of periodic limb movements during sleep and incident atrial fibrillation. Sleep Medicine, 2016, 25, 78-86.	1.6	20
1420	Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view. Journal of Medical Economics, 2016, 19, 769-776.	2.1	13
1421	Â¿Debemos anticoagular a pacientes en alto riesgo de sufrir fibrilaci3n auricular?. Revista Espanola De Cardiologia, 2016, 69, 374-376.	1.2	28
1422	Reply. Journal of the American College of Cardiology, 2016, 67, 2319.	2.8	0
1423	Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 585-599.	1.6	23
1424	Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA ₂ DS ₂) Tj ETQq1 1,0784314 rgBT /Ove	1.6	15

#	ARTICLE	IF	CITATIONS
1425	Design, synthesis, anticoagulant activity evaluation and molecular docking studies of a class of N-ethyl dabigatran derivatives. European Journal of Medicinal Chemistry, 2016, 120, 148-159.	5.5	12
1426	Prevention and Treatment of Atrial Fibrillation in Patients with Hypertension. , 2016, , 121-136.		0
1427	Risk Stratification in Atrial Fibrillation and Observation Unit Entry. Contemporary Cardiology, 2016, , 125-131.	0.1	0
1428	Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest, 2016, 150, 1302-1312.	0.8	210
1429	Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants. International Journal of Stroke, 2016, 11, 950-967.	5.9	2
1430	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. Stroke, 2016, 47, 2075-2082.	2.0	83
1431	Reversal agents for direct oral anticoagulants: A focused review. International Journal of Cardiology, 2016, 223, 244-250.	1.7	10
1432	The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation. Cardiovascular Therapeutics, 2016, 34, 94-99.	2.5	3
1433	Modelling the cost-effectiveness of pharmacist-managed anticoagulation service for older adults with atrial fibrillation in Singapore. International Journal of Clinical Pharmacy, 2016, 38, 1230-1240.	2.1	8
1434	Relationship between smoking and adverse outcomes in patients with atrial fibrillation: A meta-analysis and systematic review. International Journal of Cardiology, 2016, 222, 289-294.	1.7	14
1435	Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. International Journal of Cardiology, 2016, 223, 543-547.	1.7	71
1436	Update on specificities of stroke in women. Presse Medicale, 2016, 45, e409-e418.	1.9	6
1437	Beneficial Effect of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation—Results of the J-RHYTHM Registry 2. Circulation Journal, 2016, 80, 843-851.	1.6	42
1438	The C of CHADS: Historical perspective and clinical applications for anticoagulation in patients with non valvular atrial fibrillation and congestive heart failure. International Journal of Cardiology, 2016, 224, 431-436.	1.7	4
1439	Ablation of Atrial Fibrillation. Circulation, 2016, 134, 339-352.	1.6	46
1440	The potential role of the left atrial septal pouch in cryptogenic stroke. Expert Review of Cardiovascular Therapy, 2016, 14, 1-3.	1.5	8
1441	Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists. European Journal of Medical Research, 2016, 21, 41.	2.2	11
1442	The safety and efficacy of vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding. Medicine (United States), 2016, 95, e5467.	1.0	10

#	ARTICLE	IF	CITATIONS
1443	Rationale and design of the ODIn-AF Trial: randomized evaluation of the prevention of silent cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2016, 105, 95-105.	3.3	10
1444	Resuming anticoagulant therapy after intracerebral bleeding. <i>Vascular Pharmacology</i> , 2016, 84, 15-24.	2.1	17
1446	Clinical Implications of Leaks Following Left Atrial Appendage Ligation With the LARIAT Device. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1051-1057.	2.9	45
1447	Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults. <i>International Journal of Epidemiology</i> , 2017, 46, dyw053.	1.9	44
1448	Four-factor prothrombin complex concentrates for warfarin reversal: do real-world outcomes differ from controlled clinical trials?. <i>Transfusion</i> , 2016, 56, 784-786.	1.6	2
1449	Individualized approaches to thromboprophylaxis in atrial fibrillation. <i>American Heart Journal</i> , 2016, 173, 143-158.	2.7	12
1450	A Diabetes-Atrial Fibrillation Conundrum. <i>Journal of the American College of Cardiology</i> , 2016, 67, 248-250.	2.8	3
1451	Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients. <i>Journal of the American College of Cardiology</i> , 2016, 67, 239-247.	2.8	71
1452	Cardiac Diseases. , 2016, , 563-575.e5.		0
1453	Frequency of hemorrhagic complications on abdominal CT in patients with warfarin therapy. <i>Clinical Imaging</i> , 2016, 40, 435-439.	1.5	5
1454	Secondary Prevention After Cardioembolic Stroke. , 2016, , 111-135.		1
1455	Cost-Effectiveness of Dabigatran (150mg Twice Daily) and Warfarin in Patients ≥65 Years With Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2016, 117, 54-60.	1.6	15
1456	Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. <i>Europace</i> , 2016, 18, 979-986.	1.7	44
1457	New-onset atrial fibrillation and thromboembolic risk: Cardiovascular synergy?. <i>Heart Rhythm</i> , 2016, 13, 1355-1361.	0.7	16
1458	The search for the ideal atrial fibrillation stroke risk prediction schema: is ATRIA a contender?. <i>European Heart Journal</i> , 2016, 37, 3211-3212.	2.2	1
1459	The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2016, 37, 1591-1602.	2.2	296
1460	Secondary Prevention of Cardioembolic Stroke. , 2016, , 1014-1029.e4.		0
1461	Anticoagulation in Older Adults with Multimorbidity. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 331-346.	2.6	16

#	ARTICLE	IF	CITATIONS
1462	Should We Anticoagulate Patients at High Risk of Atrial Fibrillation?. Revista Espanola De Cardiologia (English Ed), 2016, 69, 374-376.	0.6	24
1463	Diagnostic Evaluation and Follow-Up of Patients with Atrial Fibrillation. Heart Failure Clinics, 2016, 12, 179-191.	2.1	1
1464	â€œReal-worldâ€™ haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand. International Journal of Cardiology, 2016, 203, 746-752.	1.7	38
1465	Preventing Thrombosis to Improve Outcomes in Heart Failure Patients. Progress in Cardiovascular Diseases, 2016, 58, 386-392.	3.1	6
1466	Stroke prevention following modified endoscopic ablation and appendectomy for atrial fibrillation. Heart and Vessels, 2016, 31, 1529-1536.	1.2	4
1467	Decision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2016, 41, 234-240.	2.1	8
1468	Chromosome 4q25 Variants rs2200733, rs10033464, and rs1906591 Contribute to Ischemic Stroke Risk. Molecular Neurobiology, 2016, 53, 3882-3890.	4.0	7
1469	Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace, 2016, 18, 955-964.	1.7	62
1470	Prevalence and Course of Atrial Fibrillation in Critically Ill Trauma Patients. Journal of Intensive Care Medicine, 2017, 32, 140-145.	2.8	12
1471	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	139
1472	Secondary prophylactic treatment and long-term prognosis after <scp>TIA</scp> and different subtypes of stroke. A 25-year follow-up hospital-based observational study. Brain and Behavior, 2017, 7, e00603.	2.2	8
1473	Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2017, 33, 737-746.	1.7	58
1474	CHA2DS2-VASc Score: A Predictor of Thromboembolic Events and Mortality in Patients With an Implantable Monitoring Device Without Atrial Fibrillation. Mayo Clinic Proceedings, 2017, 92, 360-369.	3.0	33
1475	Adherence to treatment guidelines: the association between stroke risk stratified comparing CHADS2 and CHA2DS2-VASc score levels and warfarin prescription for adult patients with atrial fibrillation. BMC Health Services Research, 2017, 17, 127.	2.2	12
1476	Replacing warfarin with a novel oral anticoagulant: Risk of recurrent bleeding and stroke in patients with warfarin ineligible or failure in patients with atrial fibrillation (The ROAR study). Journal of Cardiovascular Electrophysiology, 2017, 28, 853-861.	1.7	7
1477	Anticoagulation Bridge Therapy in Patients with Atrial Fibrillation: Recent Updates Providing a Rebalance of Risk and Benefit. Pharmacotherapy, 2017, 37, 712-724.	2.6	18
1478	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. American Heart Journal, 2017, 189, 137-145.	2.7	258
1479	Atrial Fibrillation. Circulation Research, 2017, 120, 1501-1517.	4.5	740

#	ARTICLE	IF	CITATIONS
1480	Changes in Use of Anticoagulation in Patients With Atrial Fibrillation Within a Primary Care Network Associated With the Introduction of Direct Oral Anticoagulants. American Journal of Cardiology, 2017, 120, 786-791.	1.6	30
1481	Pathway for the Management of Atrial Fibrillation and Atrial Flutter. Critical Pathways in Cardiology, 2017, 16, 47-52.	0.5	5
1482	Prevalence and Clinical Intentions of Antithrombotic Therapy on Discharge to Hospice Care. Journal of Palliative Medicine, 2017, 20, 1225-1230.	1.1	16
1483	Incidence of MRI-detected brain lesions and neurocognitive function after electrical cardioversion in anticoagulated patients with persistent atrial fibrillation. International Journal of Cardiology, 2017, 243, 239-243.	1.7	12
1484	Contemporary medical therapies of atherosclerotic carotid artery disease. Seminars in Vascular Surgery, 2017, 30, 8-16.	2.8	12
1485	Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Current Medical Research and Opinion, 2017, 33, 1745-1754.	1.9	62
1486	Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines. Canadian Journal of Cardiology, 2017, 33, 965-976.	1.7	89
1487	Effectiveness and safety of dabigatran versus warfarin in "real-world" Japanese patients with atrial fibrillation: A single-center observational study. Journal of Arrhythmia, 2017, 33, 107-110.	1.2	8
1488	Study design of GENERAL (general practitioners and embolism prevention in NVAf patients treated with) Tj ETQqO O O rgBT /Overlock 10 investigate the effectiveness and safety of rivaroxaban in Japanese patients with NVAf. Journal of Arrhythmia, 2017, 33, 297-301.	1.2	2
1489	Gender differences in the effects of cardiovascular drugs. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 163-182.	3.0	204
1491	2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack. International Journal of Stroke, 2017, 12, 302-320.	5.9	92
1492	Adherence to medication and characteristics of Japanese patients with non-valvular atrial fibrillation. Journal of Cardiology, 2017, 70, 238-243.	1.9	26
1493	Anticoagulation in patients at high risk of stroke without documented atrial fibrillation. Time for a paradigm shift?. Annals of Noninvasive Electrocardiology, 2017, 22, .	1.1	30
1494	Resumption of Anticoagulation After Intracranial Hemorrhage. Current Treatment Options in Neurology, 2017, 19, 39.	1.8	16
1495	Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions. Atherosclerosis, 2017, 266, 81-86.	0.8	11
1496	Atrial fibrillation decision support tool: Population perspective. American Heart Journal, 2017, 194, 49-60.	2.7	9
1497	Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation. Circulation, 2017, 136, 1784-1794.	1.6	434
1498	Stratifying Stroke Risk in Atrial Fibrillation. Stroke, 2017, 48, 2665-2670.	2.0	46

#	ARTICLE	IF	CITATIONS
1499	Diagnostic accuracy of a new algorithm to detect atrial fibrillation in a home blood pressure monitor. <i>Journal of Clinical Hypertension</i> , 2017, 19, 1143-1147.	2.0	15
1500	Atrial Fibrillation and Hypertension. <i>Hypertension</i> , 2017, 70, 854-861.	2.7	100
1501	2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2017, 33, 345-367.	1.2	141
1502	Characteristics of patients receiving district-nursing assistance for anticoagulant therapy: A descriptive cohort study. <i>European Geriatric Medicine</i> , 2017, 8, 256-259.	2.8	0
1503	Assessment of the efficacy of a novel tailored vitamin K dosing regimen in lowering the International Normalised Ratio in over-anticoagulated patients: a randomised clinical trial. <i>British Journal of Haematology</i> , 2017, 178, 800-809.	2.5	0
1504	Intracranial Hemorrhage in Patients with Durable Mechanical Circulatory Support Devices: Institutional Review and Proposed Treatment Algorithm. <i>World Neurosurgery</i> , 2017, 108, 826-835.	1.3	19
1505	Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1101-1114.	1.8	12
1506	Patients'™ and physicians'™ perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review. <i>BMC Family Practice</i> , 2017, 18, 3.	2.9	55
1507	Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1315-1322.	1.9	14
1508	Prevalence of Bleeding Complications Following Ultrasound-Guided Botulinum Toxin Injections in Patients on Anticoagulation or Antiplatelet Therapy. <i>PM and R</i> , 2017, 9, 1217-1224.	1.6	13
1509	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. <i>Thrombosis Research</i> , 2017, 150, 123-130.	1.7	22
1510	Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 208-219.	1.6	103
1511	Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 35-41.	2.6	13
1512	Benefit of Warfarin in Older Persons with Atrial Fibrillation. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 25-26.	2.6	1
1513	Evaluation of anticoagulation status for atrial fibrillation on early ischaemic stroke outcomes: a registry-based, prospective cohort study of acute stroke care in Surrey, UK. <i>BMJ Open</i> , 2017, 7, e019122.	1.9	13
1514	Laboratory characteristics of ischemic stroke patients with atrial fibrillation on or off therapeutic warfarin. <i>Clinical Cardiology</i> , 2017, 40, 1347-1351.	1.8	4
1515	Relationship of Hypertension and Systolic Blood Pressure With the Risk of Stroke or Bleeding in Patients With Atrial Fibrillation: The Fushimi AF Registry. <i>American Journal of Hypertension</i> , 2017, 30, 1073-1082.	2.0	44
1516	The Sexually Dimorphic Characteristics of the Pathophysiology and Treatment of Atrial Fibrillation. , 2017, , 381-390.		0

#	ARTICLE	IF	CITATIONS
1517	Sex-Related Differences in the Clinical Events of Patients With Atrial Fibrillationâ€”The Fushimi AF Registry â€•. Circulation Journal, 2017, 81, 1403-1410.	1.6	17
1518	Comparison of the Feasibility and Safety of First- versus Second-Generation AMPLATZERâ„¢ Occluders for Left Atrial Appendage Closure. BioMed Research International, 2017, 2017, 1-7.	1.9	4
1519	Risk of Ischemic Stroke in Patients With Non-Valvular Atrial Fibrillation Not Receiving Oral Anticoagulantsâ€”Korean Nationwide Population-Based Study â€•. Circulation Journal, 2017, 81, 1158-1164.	1.6	38
1520	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circulation Journal, 2017, 47, 555.	1.9	56
1521	Diabetes mellitus and stroke: A clinical update. World Journal of Diabetes, 2017, 8, 235.	3.5	105
1522	The CHA 2 DS 2 -VASc score: Not as simple as it seems. International Journal of Cardiology, 2018, 257, 92-96.	1.7	8
1523	Is anticoagulating haemodialysis patients with nonâ€•valvular atrial fibrillation too risky?. British Journal of Haematology, 2018, 181, 725-736.	2.5	9
1524	New-onset atrial fibrillation: an update. Journal of Anesthesia, 2018, 32, 414-424.	1.7	8
1525	Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices. Cardiology and Therapy, 2018, 7, 15-24.	2.6	21
1526	Anticoagulation Reversal. , 2018, , 105-131.		0
1527	Cardiovascular Drugs and Hemostasis. , 2018, , 561-589.		0
1528	An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1). Drug Metabolism and Pharmacokinetics, 2018, 33, 188-193.	2.2	16
1529	Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and metaâ€•analysis. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 282-290.	2.3	32
1530	Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation. Circulation, 2018, 137, 832-840.	1.6	158
1531	Role of cardiac electronic implantable device in the stratification and management of embolic risk of silent atrial fibrillation: are all atrial fibrillations created equal?. Expert Review of Cardiovascular Therapy, 2018, 16, 175-181.	1.5	6
1532	Novel oral anticoagulants in the preoperative period: a meta-analysis. Journal of Thrombosis and Thrombolysis, 2018, 45, 386-396.	2.1	6
1533	Arterial hypertension and atrial fibrillation. Journal of Cardiovascular Medicine, 2018, 19, 51-61.	1.5	4
1534	Clinical Trials for Atrial Fibrillationâ€”What Do We Know?. , 2018, , 630-642.		0

#	ARTICLE	IF	CITATIONS
1535	Left atrial function to identify patients with atrial fibrillation at high risk of stroke: new insights from a large registry. <i>European Heart Journal</i> , 2018, 39, 1416-1425.	2.2	85
1536	Regional variation in anticoagulation and clinical outcomes: scope for improvement. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018, 4, 152-154.	4.0	3
1537	Heart failure: a weak link in CHA ₂ DS ₂ -VASc. <i>ESC Heart Failure</i> , 2018, 5, 231-239.	3.1	8
1538	Real-Time Pathophysiologic Correlates of Left Atrial Appendage Thrombus in Patients Who Underwent Transesophageal-Guided Electrical Cardioversion for Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018, 121, 1540-1547.	1.6	12
1539	Left Atrial Appendage Occlusion, Shared Decision-Making, and Comprehensive Atrial Fibrillation Management. <i>Interventional Cardiology Clinics</i> , 2018, 7, 267-283.	0.4	0
1540	Novel oral anticoagulants in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 201-208.	2.0	5
1541	Anticoagulation in atrial fibrillation with heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 563-571.	3.9	17
1542	Temporal pattern/episode duration-based classification of atrial fibrillation as paroxysmal vs. persistent: is it time to develop a more integrated prognostic score to optimize management?. <i>Europace</i> , 2018, 20, f288-f298.	1.7	14
1543	Anticoagulant Use and Risk of Ischemic Stroke and Bleeding in Patients With Secondary Atrial Fibrillation Associated With Acute Coronary Syndromes, Acute Pulmonary Disease, or Sepsis. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 386-393.	3.2	36
1544	Surgery for Atrial Fibrillation and Other Supraventricular Tachycardias. , 2018, , 1295-1306.		0
1545	Nonpharmacological Management of Atrial Fibrillation in Patients at High Intracranial Hemorrhage Risk. <i>Stroke</i> , 2018, 49, 247-254.	2.0	28
1546	Atrial Appendage Thrombosis Risk Is Lower for Atrial Flutter Compared with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2018, 131, 442.e13-442.e17.	1.5	6
1547	Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2018, 3, 1174.	6.1	111
1548	Neural Network Detection of Atrial Fibrillation by Lorenz Plot Images of Interbeat Interval Variation. , 2018, , .		1
1549	Thrombosis in Atrial Fibrillation. , 2018, , 337-354.		0
1550	The cessation of oral anticoagulation following left atrial appendage surgery. <i>Future Cardiology</i> , 2018, 14, 407-415.	1.2	4
1551	Validation of Conventional Thromboembolic Risk Factors in a Korean Atrial Fibrillation Population—Suggestion for a Novel Scoring System, CHA ₂ DS ₂ -VAK. <i>Circulation Journal</i> , 2018, 82, 2970-2975.	1.6	12
1552	Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2018, 169, 517.	3.9	19

#	ARTICLE	IF	CITATIONS
1553	Anticoagulation for Atrial Fibrillation in Patients with End- Stage Kidney Disease. , 0, , .		0
1554	Ideal Blood Pressure in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 72, 1233-1245.	2.8	101
1555	Patientsâ€™ Priorities for Oral Anticoagulation Therapy in Non-valvular Atrial Fibrillation: a Multi-criteria Decision Analysis. American Journal of Cardiovascular Drugs, 2018, 18, 493-502.	2.2	14
1556	Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke. Expert Opinion on Pharmacotherapy, 2018, 19, 1597-1602.	1.8	15
1557	Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. Journal of the American Heart Association, 2018, 7, e008755.	3.7	21
1558	Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 59-68.	4.0	36
1559	Trend of Prevalence of Atrial Fibrillation and use of Oral Anticoagulation Therapy in Patients With Atrial Fibrillation in South Korea (2002â€“2013). Journal of Epidemiology, 2018, 28, 81-87.	2.4	17
1560	Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Europace, 2018, 20, 1565-1565ao.	1.7	186
1561	Optimum Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation and Undergoing Percutaneous Coronary Intervention. BioMed Research International, 2018, 2018, 1-10.	1.9	2
1562	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung and Circulation, 2018, 27, 1209-1266.	0.4	216
1563	Screening for Atrial Fibrillation With Electrocardiography. JAMA - Journal of the American Medical Association, 2018, 320, 485.	7.4	94
1564	Risk Factors. , 2018, , 17-34.		0
1565	Methods of Determining Prognosis. , 2018, , 213-230.		0
1566	Long-Term Prognosis after Transient Ischemic Attack and Stroke. , 2018, , 253-264.		1
1567	Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 73-82.	0.9	4
1568	Electronic physician notifications to improve guideline-based anticoagulation in atrial fibrillation: a randomized controlled trial. Journal of General Internal Medicine, 2018, 33, 2070-2077.	2.6	24
1569	Anticoagulation therapy in patients with stroke and atrial fibrillation: a registry-based study of acute stroke care in Surrey, UK. BMJ Open, 2018, 8, e022558.	1.9	17
1570	Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Nonâ€“Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation. Stroke, 2018, 49, 1464-1470.	2.0	32

#	ARTICLE	IF	CITATIONS
1571	Postoperative Anticoagulation After Neurologic Surgery. <i>Neurosurgery Clinics of North America</i> , 2018, 29, 575-583.	1.7	5
1572	Detrimental Effects of Insufficient Warfarin Therapy—A Warning Against Imprudent Use of Warfarin for Atrial Fibrillation Patients. <i>Circulation Journal</i> , 2018, 82, 1258-1259.	1.6	0
1573	Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2018, 12, 247-262.	2.1	15
1574	Greater nighttime blood pressure variability is associated with left atrial enlargement in atrial fibrillation patients with preserved ejection fraction. <i>Hypertension Research</i> , 2018, 41, 614-621.	2.7	3
1575	Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From AORBIT. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	12
1576	Methodologic Differences Across Studies of Patients With Atrial Fibrillation Lead to Varying Estimates of Stroke Risk. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	5
1577	Incidence and Risk Factors of Stroke or Systemic Embolism in Patients With Atrial Fibrillation and Heart Failure. The Fushimi AF Registry. <i>Circulation Journal</i> , 2018, 82, 1327-1335.	1.6	27
1578	Relationship between International Normalized Ratio and Outcomes in Modern Trials with Warfarin Controls. <i>Pharmacotherapy</i> , 2018, 38, 899-906.	2.6	9
1579	Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 398-406.	0.6	6
1581	Percutaneous devices for left atrial appendage occlusion: A contemporary review. <i>World Journal of Cardiology</i> , 2019, 11, 57-70.	1.5	25
1582	Use of simplified HAS-BLED score in patients with atrial fibrillation receiving warfarin. <i>Journal of Arrhythmia</i> , 2019, 35, 711-715.	1.2	3
1583	Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e006212.	2.2	37
1584	Cost of incorrect application of antithrombotic prophylaxis prior to invasive procedures. <i>BMC Health Services Research</i> , 2019, 19, 802.	2.2	2
1585	Risk of ischemic stroke and utility of CHA ₂ DS ₂ -VASc score in women and men with atrial fibrillation. <i>Clinical Cardiology</i> , 2019, 42, 1003-1009.	1.8	23
1586	Impact of the Duration and Degree of Hypertension and Body Weight on New-Onset Atrial Fibrillation. <i>Hypertension</i> , 2019, 74, e45-e51.	2.7	49
1587	Atrial Fibrillation Genetics Update: Toward Clinical Implementation. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 127.	2.4	26
1588	The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. <i>Cardiovascular Diabetology</i> , 2019, 18, 128.	6.8	57
1589	Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5-Year, Long-Term Data. <i>Journal of the American Heart Association</i> , 2019, 8, e011577.	3.7	32

#	ARTICLE	IF	CITATIONS
1590	Effect of direct oral anticoagulant for acute major cerebral artery occlusion in cardioembolic stroke/transient ischemic attack patients with non-valvular atrial fibrillation. Journal of the Neurological Sciences, 2019, 402, 162-166.	0.6	3
1591	Ethnic Differences in 90-Day Poststroke Medication Adherence. Stroke, 2019, 50, 1519-1524.	2.0	9
1592	Application of nonlinear methods to discriminate fractionated electrograms in paroxysmal versus persistent atrial fibrillation. Computer Methods and Programs in Biomedicine, 2019, 175, 163-178.	4.7	18
1593	Risk of stroke subsequent to infective endocarditis: A nationwide study. American Heart Journal, 2019, 212, 144-151.	2.7	7
1594	Effectiveness of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin for Preventing Further Cerebral Microbleeds in Acute Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation and At Least One Microbleed: CMB-NOW Multisite Pilot Trial. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 1918-1925.	1.6	10
1595	Stroke risk stratification in atrial fibrillation: a review of common risk factors. Journal of Community Hospital Internal Medicine Perspectives, 2019, 9, 113-120.	0.8	38
1596	Atrial fibrillation and stroke: a practical guide. Practical Neurology, 2019, 19, 208-224.	1.1	16
1597	Antithrombotic Treatment May Reduce Mortality Among New-Onset Atrial Fibrillation Patients with Gray-Zone Risk of Stroke. International Heart Journal, 2019, 60, 303-309.	1.0	3
1598	Antiplatelet Drugs in the Management of Venous Thromboembolism, Cardioembolism, Ventricular Assist Devices, and Pregnancy Complications. , 2019, , 1067-1077.		0
1599	Generalizing from the results of randomized studies of treatment: Can non-randomized studies be of help?. European Journal of Epidemiology, 2019, 34, 715-718.	5.7	10
1600	Stroke Risk Status, Anticoagulation Treatment, and Quality-of-Life in Chinese Patients with Atrial Fibrillation: China Registry of Atrial Fibrillation (CRAF). Cardiovascular Therapeutics, 2019, 2019, 1-10.	2.5	12
1601	A systematic review of cardiovascular responses associated with ambient black carbon and fine particulate matter. Environment International, 2019, 127, 305-316.	10.0	99
1602	“My watch kept on alarming all night about my heart rate”: diagnosis of asymptomatic atrial fibrillation with fast ventricular response in a patient with a recent TIA as the result of a smartwatch alarm. Oxford Medical Case Reports, 2019, 2019, omz014.	0.4	4
1603	Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism: A clinical review. Vascular Medicine, 2019, 24, 141-152.	1.5	7
1604	Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study. PLoS ONE, 2019, 14, e0211681.	2.5	22
1605	Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies. Journal of the American Heart Association, 2019, 8, e013525.	3.7	21
1606	Ischemic Stroke Risk in Patients With Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 74, 3050-3065.	2.8	65
1607	An overview of current and emerging devices for percutaneous left atrial appendage closure. Trends in Cardiovascular Medicine, 2019, 29, 228-236.	4.9	11

#	ARTICLE	IF	CITATIONS
1608	Meta-analysis of Stroke and Bleeding Risk in Patients with Various Atrial Fibrillation Patterns Receiving Oral Anticoagulants. American Journal of Cardiology, 2019, 123, 922-928.	1.6	12
1609	The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. International Journal of Clinical Practice, 2019, 73, e13285.	1.7	11
1610	Diagnosis and Management of Ischemic Stroke. Contemporary Cardiology, 2019, , 349-363.	0.1	1
1611	Risk stratification for stroke in atrial fibrillation: a critique. European Heart Journal, 2019, 40, 1294-1302.	2.2	37
1612	Risk Stratification in Atrial Fibrillation. , 2019, , 47-66.		0
1613	Atrial Fibrillation/flutter Hospitalizations among US Medicaid Recipients with and without Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 1359-1365.	2.0	12
1614	Intermittent vs continuous electrocardiogram event recording for detection of atrial fibrillationâ€”Compliance and ease of use in an ambulatory elderly population. Clinical Cardiology, 2020, 43, 355-362.	1.8	15
1615	Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?. Cardiovascular Diabetology, 2020, 19, 5.	6.8	29
1616	Quality of Warfarin Anticoagulation inÂIndigenous and Non-Indigenous Australians With Atrial Fibrillation. Heart Lung and Circulation, 2020, 29, 1122-1128.	0.4	4
1617	Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand. Thrombosis Research, 2020, 185, 63-71.	1.7	15
1618	Determinants of left atrial thrombus or spontaneous echo contrast in nonvalvular atrial fibrillation. Thrombosis Research, 2020, 195, 233-237.	1.7	11
1619	Gender medicine: Towards a gender-specific treatment of neuropsychiatric disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 175, 437-448.	1.8	6
1620	Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 405-414.	3.0	18
1621	Sex differences in atrial fibrillation. , 2020, , 533-541.		1
1622	Warfarin therapy in atrial fibrillation: assessment of patient knowledge of risks and benefits. Journal of Community Hospital Internal Medicine Perspectives, 2020, 10, 179-187.	0.8	3
1623	Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelinesâ€”Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e017024.	3.7	23
1624	<i>Annals</i> Clinical Decision Making: Translating Population Evidence to Individual Patients. Annals of Internal Medicine, 2020, 172, 610-616.	3.9	15
1625	What is the optimal blood pressure level for patients with atrial fibrillation treated with direct oral anticoagulants?. Journal of Hypertension, 2020, 38, 1820-1828.	0.5	5

#	ARTICLE	IF	CITATIONS
1626	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2020, 36, 1847-1948.	1.7	313
1627	Anticoagulant prescribing in patients with ischaemic stroke: what has changed over a decade?. Internal Medicine Journal, 2020, 50, 1274-1277.	0.8	0
1628	Atrial fibrillation and stroke prevention: state of the art—epidemiology and pathophysiology: new risk factors, concepts and controversies. European Heart Journal Supplements, 2020, 22, O1-O13.	0.1	12
1629	Stroke Prevention in Atrial Fibrillation. Circulation, 2020, 142, 2371-2388.	1.6	44
1630	Anticoagulation for Patients With Atrial Fibrillation and End-Stage Renal Disease on Dialysis: A National Survey. Canadian Journal of Cardiology, 2021, 37, 924-928.	1.7	6
1631	Structural heart intervention for prevention of embolic and hemorrhagic stroke: The new field of neurocardiology. Journal of Cardiology, 2020, 76, 227-235.	1.9	0
1632	Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation. Cerebrovascular Diseases Extra, 2020, 10, 44-49.	1.5	5
1633	Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: real-world data from the FANTASIA Registry. Annals of Medicine, 2020, 52, 300-309.	3.8	7
1634	The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years. Internal and Emergency Medicine, 2020, 15, 1183-1192.	2.0	25
1635	What should the C (—congestive heart failure—™) represent in the $CHA_2DS_2\text{-}VASc$ score?. European Journal of Heart Failure, 2020, 22, 1294-1297.	7.1	10
1636	Impact of Diabetes Mellitus on Stroke and Survival in Patients With Atrial Fibrillation. American Journal of Cardiology, 2020, 131, 33-39.	1.6	16
1637	Decision analysis and reinforcement learning in surgical decision-making. Surgery, 2020, 168, 253-266.	1.9	18
1638	Risks of Bleeding and Stroke Based on CHA ₂ DS ₂ -VASc Scores in Japanese Patients With Atrial Fibrillation: A Large-Scale Observational Study Using Real-World Data. Journal of the American Heart Association, 2020, 9, e014574.	3.7	16
1639	Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States. Clinical and Translational Science, 2020, 13, 352-361.	3.1	6
1640	Dabigatran for Japanese Patients with Atrial Fibrillation and Prior Stroke: A Subgroup Analysis of the J-Dabigatran Surveillance Program. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104717.	1.6	3
1641	Assessment of a Machine Learning Model Applied to Harmonized Electronic Health Record Data for the Prediction of Incident Atrial Fibrillation. JAMA Network Open, 2020, 3, e1919396.	5.9	76
1642	Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 131-140.	2.3	6
1643	A systematic review and external validation of stroke prediction models demonstrates poor performance in dialysis patients. Journal of Clinical Epidemiology, 2020, 123, 69-79.	5.0	20

#	ARTICLE	IF	CITATIONS
1644	Non-genetic risk factors for atrial fibrillation are equally important in both young and old age: A nationwide population-based study. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 666-676.	1.8	35
1645	Age threshold for anticoagulation in patients with atrial fibrillation: A Swedish nationwide observational study. <i>International Journal of Cardiology</i> , 2021, 326, 92-97.	1.7	1
1646	Diagnostic accuracy of smart gadgets/wearable devices in detecting atrial fibrillation: A systematic review and meta-analysis. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 4-16.	1.6	24
1647	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58 634 patients across four randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f40-f49.	3.0	13
1648	2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter. <i>Journal of the American College of Cardiology</i> , 2021, 77, 326-341.	2.8	19
1649	2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e000100.	2.2	15
1650	Frequency, Trends, and Outcomes of Cerebrovascular Events Associated With Atrial Fibrillation Hospitalizations. <i>American Journal of Cardiology</i> , 2021, 138, 53-60.	1.6	1
1651	Cardiovascular Medications. , 2021, , 597-642.		1
1652	Neurological complications of cardiovascular drugs. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 177, 319-344.	1.8	1
1654	Risk Stratification For and Use of DOAC Therapies for Stroke Prevention in Patient with Atrial Fibrillation. , 2021, , 93-119.		0
1655	Novel bleeding risk score for patients with atrial fibrillation on oral anticoagulants, including direct oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 931-940.	3.8	6
1656	Pre-Diabetes Increases Stroke Risk in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 875-884.	2.8	16
1657	Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function. <i>European Heart Journal</i> , 2021, 42, 1476-1485.	2.2	26
1658	Machine Learning Methodologies for Prediction of Rhythm-Control Strategy in Patients Diagnosed With Atrial Fibrillation: Observational, Retrospective, Case-Control Study. <i>JMIR Medical Informatics</i> , 2021, 9, e29225.	2.6	5
1659	Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: Perspectives on improving patient care. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 221-236.	1.5	2
1660	Atrial Fibrillation and Heart Failure. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 47-62.	1.7	19
1661	Comparative Analysis of Risk Stratification Scores in Atrial Fibrillation. <i>Current Pharmaceutical Design</i> , 2021, 27, 1298-1310.	1.9	1
1662	Screening and management of atrial fibrillation in primary care. <i>BMJ, The</i> , 2021, 373, n379.	6.0	9

#	ARTICLE	IF	CITATIONS
1663	Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease. <i>Seminars in Neurology</i> , 2021, 41, 365-387.	1.4	2
1664	Smoking Cessation after Diagnosis of New-Onset Atrial Fibrillation and the Risk of Stroke and Death. <i>Journal of Clinical Medicine</i> , 2021, 10, 2238.	2.4	13
1665	Impact of Fall Risk and Direct Oral Anticoagulant Treatment on Quality-Adjusted Life-Years in Older Adults with Atrial Fibrillation: A Markov Decision Analysis. <i>Drugs and Aging</i> , 2021, 38, 713-723.	2.7	8
1666	Pre-Stroke Statin Therapy Improves In-Hospital Prognosis Following Acute Ischemic Stroke Associated with Well-Controlled Nonvalvular Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2021, 10, 3036.	2.4	13
1667	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	2.2	2,517
1668	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	1.8	220
1669	Impact of sinus rhythm maintenance on major adverse cardiac and cerebrovascular events after catheter ablation of atrial fibrillation: insights from AF frontier ablation registry. <i>Heart and Vessels</i> , 2022, 37, 327-336.	1.2	5
1670	Rationale and design of a digital trial using smartphones to detect subclinical atrial fibrillation in a population at risk: The eHealth-based bavarian alternative detection of Atrial Fibrillation (eBRAVE-AF) trial. <i>American Heart Journal</i> , 2021, 241, 26-34.	2.7	6
1671	Cardiac Diseases. , 2022, , 477-487.e6.		1
1672	Cardiovascular Drugs and Hemostasis. , 2022, , 701-729.		1
1673	Secondary Prevention of Cardioembolic Stroke. , 2022, , 932-943.e4.		0
1674	Direct oral anticoagulants and the risk of osteoporotic fractures in patients with non-valvular atrial fibrillation. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110113.	2.7	3
1675	Neurologic complications of atrial fibrillation: Pharmacologic and interventional approaches to stroke prevention. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 177, 143-149.	1.8	1
1677	Cardiac Diagnostic Studies. , 0, , 188-213.		1
1678	Antithrombotic Treatment and Cardioversion of Patients with Atrial Fibrillation. , 2008, , 169-183.		1
1679	Integrative Approaches to Imaging. , 2008, , 349-362.		1
1681	Atrial Fibrillation and Stroke Prevention. , 2015, , 261-276.		1
1682	Toward an Automatic Left Atrium Localization Based on Shape Descriptors and Prior Knowledge. <i>Lecture Notes in Computer Science</i> , 2014, , 42-48.	1.3	2

#	ARTICLE	IF	CITATIONS
1683	Vaskuläre Erkrankungen. , 1999, , 954-1093.		1
1684	Klinischer Stellenwert gegenwärtiger Herzschrittmachertherapie. , 2000, , 129-149.		2
1685	Anticoagulation Therapy of Atrial Fibrillation in the Elderly. , 2003, , 329-334.		1
1686	The Level of Activity of the Hemostatic System, the Rate of Embolic Stroke, and Age: Is There a Correlation?. , 1995, , 437-442.		5
1687	Epidemiology and Risk Factor Management. , 1997, , 751-757.		5
1688	Nonlesional Spontaneous Intracerebral Hemorrhage. , 2011, , 3706-3729.		3
1689	Epidemiology of Stroke. , 2011, , 198-218.		2
1690	Fibrillation atriale : prévalence, facteurs de risque et mortalité dans une vaste population française suivie 15 ans. Bulletin De L'Academie Nationale De Medecine, 2007, 191, 791-805.	0.0	16
1691	Should patients with hypertension receive antithrombotic therapy?. Journal of Internal Medicine, 2001, 249, 205-214.	6.0	23
1692	Postoperative Stroke After Stopping Warfarin for Cutaneous Surgery. Dermatologic Surgery, 2000, 26, 785-789.	0.8	95
1693	Title is missing!. Dermatologic Surgery, 2001, 27, 91-92.	0.8	1
1694	Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation. European Heart Journal Supplements, 2020, 22, I13-I21.	0.1	23
1695	Diabetes Mellitus and Metabolic Syndrome. , 2009, , 465-496.		5
1696	Exercise Training for Patients With Chronic Atrial Fibrillation. Journal of Cardiopulmonary Rehabilitation and Prevention, 1996, 16, 193-196.	0.5	33
1698	How To Do It: Service provision and use of anticoagulants in atrial fibrillation. BMJ: British Medical Journal, 1995, 311, 558-560.	2.3	60
1699	How To Do It: Commentary: Caution needed in introducing warfarin treatment. BMJ: British Medical Journal, 1995, 311, 560-561.	2.3	8
1700	Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice. BMJ: British Medical Journal, 1996, 313, 1534-1534.	2.3	69
1701	Identification of patients with atrial fibrillation in general practice: a study of screening methods. BMJ: British Medical Journal, 1998, 317, 327-328.	2.3	67

#	ARTICLE	IF	CITATIONS
1702	Using anticoagulation or aspirin to prevent stroke. BMJ: British Medical Journal, 2000, 320, 1008-1008.	2.3	5
1703	Long term anticoagulation or antiplatelet treatment. BMJ: British Medical Journal, 2001, 323, 233-233.	2.3	5
1704	Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention. BMJ: British Medical Journal, 2008, 337, a840-a840.	2.3	3
1705	Implementation of antithrombotic management in atrial fibrillation. Postgraduate Medical Journal, 2000, 76, 783-786.	1.8	11
1706	Silent Cerebral Infarction in Patients With Nonrheumatic Atrial Fibrillation. Circulation, 1995, 92, 2178-2182.	1.6	215
1707	Management of Deep Vein Thrombosis and Pulmonary Embolism. Circulation, 1996, 93, 2212-2245.	1.6	553
1708	Management of Patients With Atrial Fibrillation. Circulation, 1996, 93, 1262-1277.	1.6	513
1709	Fibrin <scp>d</scp>-Dimer and Î²-Thromboglobulin as Markers of Thrombogenesis and Platelet Activation in Atrial Fibrillation. Circulation, 1996, 94, 425-431.	1.6	207
1710	Dual-Chamber Versus Ventricular Pacing. Circulation, 1996, 94, 578-583.	1.6	117
1711	Optimal Antithrombotic Therapy for Mechanical Prosthetic Heart Valves. Circulation, 1996, 94, 2055-2056.	1.6	8
1712	Incidence of and Risk Factors for Atrial Fibrillation in Older Adults. Circulation, 1997, 96, 2455-2461.	1.6	1,214
1713	High Concentration of Thrombomodulin in Plasma Is Associated With Hemorrhage. Circulation, 1997, 96, 2938-2943.	1.6	29
1714	Predictors of Major Vascular Events in Patients With a Transient Ischemic Attack or Minor Ischemic Stroke and With Nonrheumatic Atrial Fibrillation. Stroke, 1995, 26, 801-806.	2.0	85
1715	Oral Anticoagulants and Intracranial Hemorrhage. Stroke, 1995, 26, 1471-1477.	2.0	467
1716	Stroke Severity in Atrial Fibrillation. Stroke, 1996, 27, 1760-1764.	2.0	1,122
1717	Acute Stroke With Atrial Fibrillation. Stroke, 1996, 27, 1765-1769.	2.0	429
1718	Aspirin Wars. Stroke, 1996, 27, 585-587.	2.0	53
1719	US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke. Stroke, 1996, 27, 1473-1478.	2.0	16

#	ARTICLE	IF	CITATIONS
1720	Thromboembolism Prophylaxis in Chronic Atrial Fibrillation. Stroke, 1997, 28, 72-76.	2.0	93
1721	Warfarin Use Among Patients With Atrial Fibrillation. Stroke, 1997, 28, 2382-2389.	2.0	198
1722	Subdural Hematoma and Lupus Anticoagulants. Stroke, 1997, 28, 646-648.	2.0	7
1723	Relationship Between Prothrombin Activation Fragment F1.2 and International Normalized Ratio in Patients With Atrial Fibrillation. Stroke, 1997, 28, 1101-1106.	2.0	90
1725	Diurnal Variation in the Intensity of Anticoagulation in Atrial Fibrillation. Stroke, 2002, 33, 322-324.	2.0	6
1726	Thoroscopic Ablation with Appendage Ligation versus Medical Therapy for Stroke Prevention a Proof-of-Concept Randomized Trial. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2016, 11, 99-105.	0.9	3
1727	Brain Embolism. , 1999, , 35-185.		5
1729	The incidence of chronic subdural hematomas from 1990 to 2015 in a defined Finnish population. Journal of Neurosurgery, 2020, 132, 1147-1157.	1.6	86
1730	Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding. Yonsei Medical Journal, 2020, 61, 741.	2.2	22
1731	Evidence-based study on antithrombotic therapy in patients at risk of a stroke with paroxysmal atrial fibrillation. Experimental and Therapeutic Medicine, 2013, 6, 413-418.	1.8	3
1732	Moving Beyond Warfarin—Are We Ready?: A Review of the Efficacy and Safety of Novel Anticoagulant Agents Compared to Warfarin for the Management of Atrial Fibrillation in Older Adults. Journal of Gerontological Nursing, 2013, 39, 8-17.	0.6	4
1733	A comparison of two-dimensional and real-time 3D transoesophageal echocardiography and angiography for assessing the left atrial appendage anatomy for sizing a left atrial appendage occlusion system: impact of volume loading. EuroIntervention, 2017, 12, 2083-2091.	3.2	27
1734	CARDIAC RHYTHM AND ATRIAL TRANSPORT FUNCTION AFTER SURGICAL ABLATION OF ATRIAL FIBRILLATION USING CRYOENERGY: PREDICTORS AND EFFECTIVENESS OF THE PROCEDURE. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2010, 154, 55-68.	0.6	6
1735	Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke. Journal of Stroke, 2015, 17, 210.	3.2	7
1736	The burden of undertreatment and non-treatment among patients with non-valvular atrial fibrillation and elevated stroke risk: a systematic review. Current Medical Research and Opinion, 2022, 38, 7-18.	1.9	13
1737	Anticoagulation in Acute Neurological Disease. Seminars in Neurology, 2021, 41, 530-540.	1.4	0
1739	Pharmakologische Therapie von Vorhofflimmern/Vorhofflattern. , 2000, , 65-77.		0
1740	Herz-Kreislauf-Krankheiten. , 2000, , 25-67.		2

#	ARTICLE	IF	CITATIONS
1741	Antikoagulation â€” Indikation, DurchfÃ¼hrung, klinische Ergebnisse. , 2000, , 79-91.		0
1742	Epidemiologie, klinischer Verlauf und Prognose. , 2000, , 3-20.		0
1743	Anticoagulation. Diagnostic Pathology, 2000, , 691-715.	0.0	0
1744	Anticoagulation to prevent stroke in atrial fibrillation. BMJ: British Medical Journal, 2000, 321, 1156-1156.	2.3	1
1745	Cardioembolic Stroke. , 2001, , 123-135.		0
1746	Epidemiologie zerebrovaskulÃ¤rer Erkrankungen. , 2001, , 123-149.		0
1747	Regarding Postoperative Stroke after Warfarin for Cutaneous Surgery. Dermatologic Surgery, 2001, 27, 91-92.	0.8	0
1749	Cerebrovascular Complications of Cardiac Disorders. , 2001, , 375-380.		0
1750	New opportunities for stroke prevention and therapeutics: a hope from anti-inflammatory drugs?. , 2001,, , 3-10.		1
1751	Self-management of Oral Anticoagulants by Patients with Atrial Fibrillation: How Effective and Safe Is It?. , 2002, , 436-440.		0
1752	Atrial Defibrillators. Developments in Cardiovascular Medicine, 2002, , 63-76.	0.1	0
1753	è„³è¡€ç®¡éšœâ®³ã«ãšãšã„æš—è¡€æ“ç™,æ³•. Japanese Journal of Thrombosis and Hemostasis, 2002, 13, 141-150.o.1		1
1754	Antiplatelet Agents for Prevention of Thromboembolism in Atrial Fibrillation: When, Why, and Which One?. , 2002, , 422-435.		2
1755	Coronary artery surgery. Juntendõ, Igaku, 2003, 48, 458-465.	0.1	0
1757	Myocardial Damage and Cardiac Arrhythmias. , 2003, , 1199-1201.		0
1760	Anticoagulant Treatment. , 2003, , 212-216.		0
1761	Zerebrale DurchblutungsstÃ¶rungen. , 2003, , 1285-1299.		0
1762	Anticoagulant therapy. , 2003, , 157-165.		0

#	ARTICLE	IF	CITATIONS
1763	Warfarin Underuse for Nonvalvular Atrial Fibrillation: How to Adjust Our Aims?. , 2004, , 241-247.		0
1764	Management of Atrial Fibrillation: Is it Already Time to Update the Recent ACC/AHA/ESC Guidelines?. , 2004, , 127-133.		0
1766	Use of Chronic Anticoagulation in the Elderly: A Review of the Benefits and Risks. Developments in Cardiovascular Medicine, 2004, , 181-199.	0.1	0
1767	Cardiac Embolism. , 2004, , 187-198.		0
1768	Cardiac Monitoring in the Neurosciences Critical Care Unit. , 2004, , 137-150.		0
1769	Kardiologie. , 2004, , 313-356.		0
1770	Cerebrovascular Disease in the Elderly Hypertensive. , 2005, , 255-293.		0
1771	Advances in the Acute Treatment and Secondary Prevention of Stroke. , 2005, , 21-33.		0
1772	With what to treat which patient with recently symptomatic carotid stenosis?. Practical Neurology, 2005, 5, 68-83.	1.1	1
1773	Benefits of Endarterectomy for Recently Symptomatic Carotid Stenosis. Neurological Disease and Therapy, 2005, , 207-228.	0.0	0
1774	Epidemiology of Cerebrovascular Disease * *This work was supported in part by the National Institute of Neurological Disorders and Stroke Grant No. 5R01 NS17950 and the National Heart, Lung, and Blood Institute's Framingham Heart Study Contract No. N01-HC-25195.. , 2006, , 411-432.		0
1775	Is bij ouderen (65+) met atriumfibrillatie behandeling met anti-coagulantia geïndiceerd?. , 2006, , 159-160.		0
1781	Qu'attendre de l'Échocardiographie face à un accident embolique artériel ?. , 2008, , 327-352.		0
1783	THE PATIENT WITH PALPITATIONS. , 2008, , 209-253.		0
1784	Évaluation hémodynamique et du risque thrombo-embolique des patients en fibrillation auriculaire. , 2008, , 277-298.		0
1785	Ischemic Stroke and Transient Ischemic Attack: Long-Term Management and Secondary Prevention. , 2009, , 35-56.		0
1786	Intracerebral Hemorrhage: Long-Term Complications and Prevention. , 2009, , 69-79.		0
1787	あつぎ 泰成 先生の経歴と業績. Juntendo, Igaku, 2009, 55, 416-425.	0.1	0

#	ARTICLE	IF	CITATIONS
1788	Malattie cerebrovascolari dell'encefalo. , 2009, , 3-39.		0
1792	Diagnosis and Management of Ischemic Stroke. , 2011, , 373-390.		1
1793	Pharmacologic Management of Atrial Fibrillation and Flutter. , 2011, , 165-193.		0
1794	History of Supraventricular Tachycardia. , 2011, , 17-38.		0
1795	Anticoagulation in the Older Surgical Patient. , 2011, , 221-239.		0
1796	Precardioversion Transesophageal Echocardiography in Atrial Fibrillation. , 2011, , 158-163.		0
1797	CHADS2 Score is a Poor Predictor of Non-cerebral Acute Arterial Occlusion in Patients with Non-valvular Atrial Fibrillation. Annals of Vascular Diseases, 2011, 4, 110-114.	0.5	2
1798	Secondary Prevention of Cardioembolic Stroke. , 2011, , 1173-1191.		1
1799	Cardiac Diseases. , 2011, , 814-827.		1
1801	Echocardiography: Technology and Protocols. , 2012, , 71-81.		0
1805	Minimally Invasive Surgical Implantation of the Percutaneous Left Atrial Appendage Transcatheter Occlusion Device Initial Experience in a Canine Model. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2012, 7, 52-58.	0.9	0
1806	Implications of Atrial Fibrillation in Heart Failure Management. Contemporary Cardiology, 2012, , 237-252.	0.1	0
1807	Atrial fibrillation in diabetes: A cause for concern?. Journal of Diabetes Mellitus, 2012, 02, 378-385.	0.3	0
1811	Atrial Fibrillation. Modern Epidemiologic and Therapeutic Aspects. , 2012, , 427-438.		0
1816	Perspectives and Approach to Stroke Prevention and Therapy. , 2013, , 47-60.		0
1817	The Optimal Intensity of Warfarin Therapy in Japanese Patients with Atrial Fibrillation --A Report from the J-RHYTHM Registry-. Japanese Journal of Electrocardiology, 2013, 33, 25-31.	0.0	1
1818	Peri-device Implantation Anticoagulation Management: Evidence and Clinical Implications. , 2014, , 653-664.		0
1819	Epidemiology, Burden and Unmet Needs in Atrial Fibrillation. , 2014, , 1-22.		0

#	ARTICLE	IF	CITATIONS
1820	Detection and Management of Atrial Fibrillation in Patients with Stroke or TIA in Clinical Practice. , 2014, , 221-236.		0
1821	Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation. Journal of Health Economics and Outcomes Research, 2013, 1, 42-53.	1.2	0
1822	Antithrombotic Issues in Women. , 2014, , 321-357.		0
1823	Pharmacological Secondary Prevention of Ischemic Stroke. Brain & Neurorehabilitation, 2014, 7, 76.	1.0	2
1824	Atrial Fibrillation and Heart Failure in the Aging Population. , 2014, , 65-84.		0
1825	Surgery for Atrial Fibrillation and Other SVTs. , 2014, , 1295-1305.		0
1826	Emergent Reversal of Oral Anticoagulation: Review of Current Treatment Strategies. AACN Advanced Critical Care, 2014, 25, 5-12.	1.1	0
1827	Fibrilação Atrial e Acidente Vascular Cerebral. Revista Neurociencias, 2014, 22, 144-148.	0.0	0
1828	Stroke: progress at last?. Medical Journal of Australia, 1995, 163, 343-344.	1.7	0
1829	HEALTH MAINTENANCE AND PREVENTION IN THE ELDERLY. Primary Care - Clinics in Office Practice, 1995, 22, 697-711.	1.6	5
1830	Anticoagulation in Atrial Fibrillation: Is Aspirin Sufficient?. , 1996, , 216-220.		0
1833	Anticoagulants in Stroke Treatment. , 1997, , 716-728.		0
1834	Clinical Aspects of Stroke and Therapeutic Strategies. , 1997, , 43-66.		0
1835	Prophylaxe ischämischer Insulte. , 1998, , 1328-1333.		0
1836	Drug Prevention of Paroxysmal Atrial Fibrillation, When and How?. , 1998, , 40-44.		0
1838	Prevention of Thromboembolism in Atrial Fibrillation: When Antiplatelet Agents and When Anticoagulants?. , 1998, , 125-133.		0
1839	Conclusions and Questions from Large Trials of Anticoagulants in Patients with Atrial Fibrillation. Developments in Cardiovascular Medicine, 1998, , 43-48.	0.1	0
1840	Resource Utilization in Atrial Fibrillation. Developments in Cardiovascular Medicine, 1999, , 181-209.	0.1	0

#	ARTICLE	IF	CITATIONS
1841	Das Herz des alternden Menschen. , 1999, , 67-125.		0
1843	Cost-Effectiveness of Therapy in Nonatrial Fibrillation. Annals of Internal Medicine, 1999, 131, 979.	3.9	0
1845	Clinical Outcomes and Anticoagulant Intensity in Japanese Nonvalvular Atrial Fibrillation Patients ≥65 Years of Age with a CHADS₂ Score 0-1 and Taking Warfarin. Japanese Journal of Clinical Pharmacology and Therapeutics, 2015, 46, 191-197.	0.1	0
1846	Risk Factors for Stroke in Sulaimaniyah Iraqi Kurdistan Region-Iraq. International Journal of Clinical Medicine, 2016, 07, 639-651.	0.2	0
1847	The Link Between Hypertension and Stroke: Summary of Observational Epidemiological Studies. , 2016, , 17-37.		0
1848	Safe Strategies for Gradual Suspension and Reinstitution of Anticoagulation to Permit Elective Surgery. , 2016, , 297-307.		0
1849	Efficacy and Limitations of Warfarin and Novel Oral Anticoagulants with Atrial Fibrillation. Contemporary Cardiology, 2016, , 17-36.	0.1	0
1850	Recurrence of Stroke in Patients with AF Using NOACs. , 2017, , 11-23.		0
1851	Anticoagulants for Atrial Fibrillation. Cardiovascular Medicine, 2017, , 105-114.	0.0	0
1852	Implications of Atrial Fibrillation in Heart Failure Management. Contemporary Cardiology, 2017, , 269-284.	0.1	0
1853	OBSOLETE: Clinical Trials for Atrial Fibrillation - What do we know?. , 2018, , .		0
1854	Prim�rpr�vention und Sekund�rpr�vention des Hirninfarkts. Springer Reference Medizin, 2018, , 1-31.	0.0	0
1855	Prim�rpr�vention und Sekund�rpr�vention des Hirninfarkts. Springer Reference Medizin, 2019, , 1-31.	0.0	0
1856	Hypertension and atrial fibrillation: a complex problem requiring one comprehensive solution. Medic�na Pro Praxi, 2019, 16, 90-96.	0.0	0
1857	Thrombi outside the left atrial appendage: â€œsmall potatoesâ€?. EuroIntervention, 2019, 15, e216-e218.	3.2	0
1859	Anticoagulation in Cardiac Patients. , 2020, , 77-102.		0
1860	Ethnic Differences in Oral Antithrombotic Therapy. Korean Circulation Journal, 2020, 50, 645.	1.9	13
1861	Acceleration of opportunistic atrial fibrillation screening for elderly patients in routine primary care. PLoS ONE, 2020, 15, e0244240.	2.5	1

#	ARTICLE	IF	CITATIONS
1862	Pharmacologic Management of Atrial Fibrillation and Flutter. Contemporary Cardiology, 2020, , 359-407.	0.1	0
1863	Primärprävention und Sekundärprävention des Hirninfarkts. Springer Reference Medizin, 2020, , 883-913.	0.0	0
1864	Atrial fibrillation: all the elderly go hospitalized? A minireview. Journal of Gerontology and Geriatrics, 2020, 68, 47-52.	0.5	2
1865	VARIABILITY OF BLOOD PRESSURE IN COMORBIDITY OF ARTERIAL HYPERTENSION AND ATRIAL FIBRILLATION. Å½urnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, 2021, 19, 481-488.	0.1	0
1866	Long-term Efficacy of Combination Therapy with Anti-arrhythmic Agents and Pravastatin in Patients with Paroxysmal Atrial Fibrillation. Journal of Arrhythmia, 2007, 23, 124-130.	1.2	1
1867	Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors. Journal of Arrhythmia, 2009, 25, 81-88.	1.2	0
1868	Zulassungsstatus und damit verbundene medikolegale Aspekte. , 2005, , 152-154.		0
1870	Spezielle therapeutische Probleme im hÄrteren Alter. , 2005, , 98-122.		0
1871	Monitoring Chronic Oral Anticoagulant Therapy. , 1997, , 495-515.		0
1872	Hemorrhagic Complications. , 1997, , 519-544.		0
1873	Difference in the prevalence of intracardiac thrombus on the first presentation of atrial fibrillation versus flutter in the pediatric and congenital heart disease population. Journal of Cardiovascular Electrophysiology, 2020, 31, 3243-3250.	1.7	1
1874	Cost-effectiveness of antithrombotic agents for atrial fibrillation in older adults at risk for falls: a mathematical modelling study. CMAJ Open, 2020, 8, E706-E714.	2.4	4
1875	Stroke risk scores to predict hospitalization for acute decompensated heart failure in atrial fibrillation patients. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2020, 59, 73-82.	0.6	1
1876	2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. Journal of Arrhythmia, 2021, 37, 1389-1426.	1.2	38
1877	Pharmacological Management of Atrial Fibrillation: A Century of Expert Opinions in Cecil Textbook of Medicine. American Journal of Therapeutics, 2022, 29, e18-e25.	0.9	3
1878	Atrial Fibrillation and Hypertension: â€œQuo Vadisâ€ Current Hypertension Reviews, 2022, 18, 39-53.	0.9	5
1879	OUP accepted manuscript. Journal of Public Health, 2022, , .	1.8	0
1880	Screening for Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2022, 327, 368.	7.4	23

#	ARTICLE	IF	CITATIONS
1881	Controlled Level and Variability of Systolic Blood Pressure on the Risk of Thromboembolic Events in Atrial Fibrillation. SSRN Electronic Journal, 0, , .	0.4	0
1883	Two-year outcomes of UK patients newly diagnosed with atrial fibrillation: findings from the prospective observational cohort study GARFIELD-AF. British Journal of General Practice, 2022, 72, e693-e701.	1.4	3
1884	Artificial intelligence and atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2022, 33, 1932-1943.	1.7	10
1885	Stroke and/or transient ischemic attack prophylaxis from the perspective of an interventional cardiologist. Intervencni A Akutni Kardiologie, 2022, 21, 19-26.	0.0	0
1887	<scp>JCS</scp>/<scp>JHRS</scp> 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Journal of Arrhythmia, 2022, 38, 833-973.	1.2	8
1888	Atrial Fibrillation Screening: The Tools Are Ready, But Should We Do It?. Circulation, 2022, 145, 955-958.	1.6	3
1890	Relation of Hemoglobin A1C Levels to Risk of Ischemic Stroke and Mortality in Patients With Diabetes Mellitus and Atrial Fibrillation. American Journal of Cardiology, 2022, 172, 48-53.	1.6	4
1891	The management of anticoagulants in patients with atrial fibrillation and history of falls or risk of falls: protocol for a systematic review and meta-analysis. Systematic Reviews, 2022, 11, 63.	5.3	2
1892	Atrial fibrillation and stroke: A review and new insights. Trends in Cardiovascular Medicine, 2023, 33, 23-29.	4.9	18
1893	Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction. Open Heart, 2021, 8, e001726.	2.3	5
1894	GuÃa ESC 2021 sobre la prevenciÃn de la enfermedad cardiovascular en la prÃctica clÃnica. Revista Espanola De Cardiologia, 2022, 75, 429.e1-429.e104.	1.2	27
1896	What Caused This Transient or Persisting Ischaemic Event?. , 0, , 259-351.		1
1897	What is Evidence-Based Cardiology?. , 0, , 3-13.		0
1898	Atrial Fibrillation: Antithrombotic Therapy. , 0, , 548-555.		0
1899	Clinical Syndromesâ€”Brain. , 0, , 73-92.		0
1900	ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and Design of the GUARD-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day Patch-Based Continuous ECG Monitor. American Heart Journal, 2022, 249, 76-76.	2.7	3
1902	Anticoagulation management of post-cardiac surgery new-onset atrial fibrillation. Cleveland Clinic Journal of Medicine, 2022, 89, 329-335.	1.3	1
1904	Atrial Fibrillation and Stroke. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1905	ESC Working Group on e-Cardiology Position Paper: accuracy and reliability of electrocardiogram monitoring in the detection of atrial fibrillation in cryptogenic stroke patients. <i>European Heart Journal Digital Health</i> , 2022, 3, 341-358.	1.7	13
1906	How Would I Manage a 60-year-old Woman Presenting with Atrial Fibrillation?. <i>Journal of the Royal College of Physicians of Edinburgh</i> , The, 1999, 29, 301-306.	0.6	5
1907	Comprehensive comparison of stroke risk score performance: a systematic review and meta-analysis among 6 267 728 patients with atrial fibrillation. <i>Europace</i> , 2022, 24, 1739-1753.	1.7	12
1908	Postoperative cerebral infarction risk is related to lobectomy site in lung cancer: a retrospective cohort study of nationwide data in Japan. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001327.	3.0	1
1909	Controlled Level and Variability of Systolic Blood Pressure on the Risk of Thromboembolic Events in Atrial Fibrillation and Hypertension. <i>American Journal of Cardiology</i> , 2022, 180, 37-43.	1.6	0
1910	Screening for atrial fibrillation in the elderly: A network meta-analysis of randomized trials. <i>European Journal of Internal Medicine</i> , 2022, 105, 38-45.	2.2	8
1911	Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA ₂ DS ₂ -VASc Score ≥1: A Korean Multi-Center Cohort. <i>Yonsei Medical Journal</i> , 2022, 63, 892.	2.2	3
1912	Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants. <i>JAMA Network Open</i> , 2022, 5, e2229333.	5.9	3
1913	Efficacy and Safety of Anticoagulants in Patients with Atrial Fibrillation and History of Falls or Risk of Falls: A Systematic Review and Multilevel Meta-Analysis. <i>Drug Safety</i> , 2022, 45, 1349-1362.	3.2	5
1914	Improving guideline-based anticoagulation in atrial fibrillation: A systematic literature review of prospective trials. <i>Heart Rhythm</i> , 2022, , .	0.7	1
1915	Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study. <i>Circulation</i> , 2022, 146, 1415-1424.	1.6	76
1916	Hypertension management in patients with cardiovascular comorbidities. <i>European Heart Journal</i> , 2023, 44, 2066-2077.	2.2	24
1918	Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry. <i>Yonsei Medical Journal</i> , 2023, 64, 18.	2.2	4
1919	Arrhythmia Management in the Elderly. <i>Contemporary Cardiology</i> , 2023, , 193-235.	0.1	0
1920	Cardiovascular Drugs and Dental Considerations. <i>Journal of the California Dental Association</i> , 2000, 28, 519-529.	0.1	3
1921	Anticoagulation for Atrial Fibrillation: A Review of Current Literature and Views. <i>Cardiology in Review</i> , 2024, 32, 131-139.	1.4	4
1922	Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review. <i>Clinical Pharmacokinetics</i> , 2023, 62, 351-373.	3.5	5
1923	Choice and Timing of Antithrombotic After Ischemic Stroke, Intracerebral Hemorrhage or Cerebral Venous Thrombosis. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, .	1.4	0

#	ARTICLE	IF	CITATIONS
1924	Diagnosis and management of patients with narrow complex tachycardia: how well is your emergency department performing?. Canadian Journal of Emergency Medicine, 2023, 25, 257-258.	1.1	0
1925	Sex and hypertensive organ damage: stroke. Journal of Human Hypertension, 0, , .	2.2	1
1926	Atrial fibrillation in women. , 2023, , 645-654.		0
1927	ACUTE ADMISSIONS WITH ATRIAL FIBRILLATION IN A BRITISH MULTIRACIAL HOSPITAL POPULATION. International Journal of Clinical Practice, 1997, 51, 91-96.	1.7	40
1928	THE MEDICAL MANAGEMENT OF STROKE. International Journal of Clinical Practice, 1997, 51, 504-510.	1.7	2
1929	ANTIPLATELET DRUGS IN SECONDARY PREVENTION OF STROKE. International Journal of Clinical Practice, 1998, 52, 91-97.	1.7	8
1930	TRANSIENT ISCHAEMIC ATTACKS: EVALUATION AND MANAGEMENT. International Journal of Clinical Practice, 2000, 54, 432-436.	1.7	10
1931	OPEN ACCESS ECHOCARDIOGRAPHY: A PROSPECTIVE AUDIT OF REFERRAL PATTERNS FROM PRIMARY CARE. International Journal of Clinical Practice, 2003, 57, 136-139.	1.7	9
1932	ATRIAL FIBRILLATION, THROMBOEMBOLISM AND ANTITHROMBOTIC THERAPY. International Journal of Clinical Practice, 1999, 53, 110-117.	1.7	4
1933	Evaluation of Quantitative Decisionâ€Making for Rhythm Management of Atrial Fibrillation Using Tabular Qâ€Learning. Journal of the American Heart Association, 2023, 12, .	3.7	2
1934	Redefining the Roles of Aspirin Across the Spectrum of Cardiovascular Disease Prevention. Current Cardiology Reviews, 2023, 19, .	1.5	0
1935	Pathophysiology and treatment of adults with arrhythmias in the emergency department, part 1: Atrial arrhythmias. American Journal of Health-System Pharmacy, 2023, 80, 1039-1055.	1.0	0
1936	New pharmacotherapeutic options for oral anticoagulant treatment in atrial fibrillation patients aged 65 and older: factor Xla inhibitors and beyond. Expert Opinion on Pharmacotherapy, 2023, 24, 1335-1347.	1.8	0
1937	Principled estimation and evaluation of treatment effect heterogeneity: A case study application to dabigatran for patients with atrial fibrillation. Journal of Biomedical Informatics, 2023, 143, 104420.	4.3	0
1938	Optimising prediction of mortality, stroke, and major bleeding in patients with atrial fibrillation: external validation of the GARFIELD-AF model in UK primary care electronic records. British Journal of General Practice, 0, , BJGP.2023.0082.	1.4	0
1939	Comparison of Stroke Risk Scoring Systems in Patients with Non-Valvular Atrial Fibrillation. Advances in Clinical Medicine, 2023, 13, 9780-9788.	0.0	0
1940	Screening for undiagnosed atrial fibrillation using a single-lead electrocardiogram at primary care visits: patient uptake and practitioner perspectives from the VITAL-AF trial. , 2023, 24, .		1
1941	Percutaneous Left Atrial Appendage Closure Among Patients With Diabetes (Insights from a National) Tj ETQq1 1 0,784314 rgBT /Overl	1.6	0

#	ARTICLE	IF	CITATIONS
1942	Ischemic stroke risk factors not included in the CHADS-VASC score in patients with non-valvular atrial fibrillation. Arquivos De Neuro-Psiquiatria, 2023, 81, 712-719.	0.8	0
1945	Predictors and timeline of spontaneous conversion to normal sinus rhythm: A single center retrospective cohort study of patients with symptomatic atrial fibrillation. Indian Pacing and Electrophysiology Journal, 2023, , .	0.6	0
1946	Direct oral anticoagulants compared with other strategies in patients with atrial fibrillation and stroke or transient ischemic attack: Systematic review. Journal of the Formosan Medical Association, 2023, , .	1.7	0
1947	Magnesium for Atrial Fibrillation after Coronary Artery Bypass Graft Surgery: its Role in Aetiology and Prevention. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2000, 2, 260-268.	0.1	1
1949	Net clinical benefit of oral anticoagulants in Asian patients with atrial fibrillation based on a CHA2DS2-VASc score. BMC Cardiovascular Disorders, 2023, 23, .	1.7	0
1950	New-onset as opposed to established atrial fibrillation as a risk factor for incident stroke. Clinical Neurology and Neurosurgery, 2024, 236, 108106.	1.4	0
1952	Brain MRI microbleeds and risk of intracranial hemorrhage in atrial fibrillation patients: A Swedish case-control study. Journal of Stroke and Cerebrovascular Diseases, 2024, 33, 107629.	1.6	0
1953	Cardiac imaging correlates and predictors of stroke in patients with atrial fibrillation: a meta-analysis. Journal of Cardiovascular Medicine, 2024, 25, 280-293.	1.5	0